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CHAPTER 1 INTRODUCTION 
1.1 INTRODUCTION TO DIABETES AND INSULIN SIGNALING PATHWAY 
1.1.1 INTRODUCTION TO DIABETES 
Diabetes is a metabolic disorder characterized by high blood glucose. Accord-
ing to ‘Global diabetes report’ presented by World Health Organization in 2014, the 
total number of people with diabetes is 422 million1. Data collected by Center for Dis-
ease Control and Prevention show that 23.5 million people have diagnosed diabetes by 
2015 in United States of America itself. This accounts to about 7.5% of its population2. 
The number of diabetes cases has risen from 108 million in 1980 to 422 million in 2014 
globally1 and from 5.53 million in 1980 to 23.35 million in 2015 in United states2. This 
increase over the past few decades is alarming and requires immediate attention of the 
researchers, healthcare providers, and general public worldwide. There are many com-
plications associated with diabetes due to high blood glucose levels. Eventually, if not 
controlled, they can have impaired functioning of heart, kidneys, nerves, eyes and blood 
vessels1. The high blood glucose levels can lead to life threatening conditions like dia-
betic ketoacidosis, condition where high amounts of ketones are found in blood and 
urine, due to utilization of  fatty acids as a source of energy and hyperosmolar coma1. 
Diabetic retinopathy associated blindness accounts for 1% of the global blindness3. 
Analysis of ‘causes of vision loss from 1990-2010’ showed that 2.6% of the blindness 
and 1.9% of the visual impairment is caused due to diabetic retinopathy4. The risk of 
cardiovascular disease and stroke is higher in patients with high blood glucose5. Diabe-
tes can also lead to kidney failure6. End Stage Renal Disease (ESRD) is seen more often 
in patients with diabetes compared to normal population. Diabetes is responsible  for 
12-55% cases of the ESRD7.  Neuropathy (nerve damage) is another common effect 
and when combined with reduced blood flow can lead to other severe complications. 
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These combined effects increase the incidence of foot ulcers, infections, and can lead 
to limb amputations. The incidence of amputations is 10-20 times higher in patients 
with diabetes than those without8. Other complications of diabetes include periodontal 
disease, depression, erectile dysfuction, hearing loss, non-alcoholic fatty liver disease, 
pregnancy complications and more2. All these complications reduce the quality of life 
and they can lead to death as well. According to the WHO statistics, 1.5 million deaths 
were directly caused by diabetes globally in 20121. Their projections show that Diabe-
tes will be the 7th leading cause of death by 20309.  
There are two major types of diabetes: type I and type II.  Type II Diabetes 
accounts for 90-95% of all diabetic cases. Type I Diabetes is seen in children and young 
adults due to the lack of insulin production caused by the loss of pancreatic beta cells. 
This is also called insulin dependent diabetes mellitus. Type II Diabetes occurs in rela-
tively older people, which is the consequence of a combination of insulin resistance and 
relative insulin deficiency10.    
1.1.2 NORMAL GLUCOSE HOMEOSTASIS 
Majority of the cells in the body require glucose as a fuel. In the absorptive state 
after a meal, the blood glucose levels rise. To control the plasma glucose levels, insulin 
is released from pancreas. This hyperinsulinemia and hyperglycemia lead to the follow-
ing: 
1. Glucose uptake in the peripheral (muscle, adipocyte) and splanchnic (liver and 
gut) tissues 
2. Suppression of the glucose production by the liver and kidneys 
Majority of the insulin stimulated glucose disposal in the peripheral tissues takes 
place in the muscle (about 85%)11. 
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In post-absorptive state, after an 8-12 hour overnight fast, about 85% of the 
endogenous glucose production takes place in the liver and the rest in kidneys11. The 
glucose production in the liver is either by gluconeogenesis or glycogenolysis. During 
this phase, 50% of the glucose is utilized by the brain and another 25% is used by the 
liver and gastro intestinal tissues. The rest 25% is utilized in insulin dependent manner 
majorly in the muscle11.  
In this manner, many tissues contribute to maintain an optimum level of glucose 
in the body12 represented in figure 1.                
1.1.3 INSULIN PRODUCTION AND RELEASE IN PANCREAS 
Insulin is a hormone produced by the pancreatic beta cells in response to the 
rise in blood glucose levels. Translation of insulin mRNA leads to the production of 
110-aminoacid large sized pre-proinsulin whose amino terminal signal tag directs it to 
endoplasmic reticulum. In the endoplasmic reticulum, signal tag is cleaved to form pro-
insulin. This Pro-insulin then undergoes modifications such as formation of disulfide 
bonds and folding followed by its transport to the Golgi complex. In the golgi complex, 
pro-insulin is cleaved to form insulin and C peptide and are stored within the secretory 
granules13. 
When the blood glucose levels rise, this glucose enter the pancreatic cells 
through diffusion. Beta cells contain glucose sensors, one of them being Glucose trans-
porter 2 (GLUT2), that can transport glucose into the cells through facilitated diffusion. 
Glucose then undergoes glycolysis where it is converted to glucose 6 phosphate by 
glucokinase which then leads to formation of pyruvate, end product of glycolysis. Py-
ruvate is further oxidized in mitochondria to produce ATP through tricarboxylic acid 
cycle. This increased ATP: ADP ratio causes ATP dependent potassium channels to 
close. The increased positive charge inside the cell due to potassium leads to opening 
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of voltage dependent calcium channels and thereby influx of calcium ions. This facili-
tates release of insulin stored in the Golgi complex into the surrounding blood vessels. 
This is the first phase of insulin release, which is rapid. The second phase is prolonged 
where the insulin needs to be translated, modified and then released. This insulin re-
leased from the beta cell enters the blood stream and reaches other tissues where it 
performs specific actions.  
Glucose uptake in these insulin dependent tissues is facilitated through various 
glucose transporters present in the cell which upon insulin stimulation locate them-
selves at the plasma membrane. The translocation of glucose transporters occurs when 
insulin binds to the insulin receptors on the surface of the cell. Glucose that entered the 
cell is phosphorylated and then metabolized further depending on the tissue. The path-
way through which insulin enters the cells and regulates various cellular functions is 
regulated by numerous signaling molecules and is described further in detail below as 
insulin signaling pathway, also represented in Figure 2. 
1.1.4 INSULIN SIGNALING PATHWAYS 
Insulin is an anabolic hormone and thereby increases glucose uptake, synthesis 
of proteins, lipids and glycogen through activation of various pathways in skeletal mus-
cle cells12,14.  In the PI3K-dependent signaling pathway, insulin binds to tyrosine kinase 
insulin receptor present on the cell membrane. This insulin receptor is composed of two 
extracellular alpha subunits and two transmembrane beta subunits. Binding of the insu-
lin to the alpha subunits leads to conformational change induced activation of the re-
ceptor kinase activity in the beta subunits. This leads to the transphosphorylation of the 
beta subunits, further activating the kinase. This phosphorylation allows binding of 
other substrates. The various substrates for the insulin receptor include insulin receptor 
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substrate 1 (IRS1), APS (SHB2), Gab proteins, cbl and shc proteins. The phosphory-
lated tyrosines on these substrates allow them to bind to various downstream molecules, 
which include P85 subunit of the phosphatidylinositide 3 kinase (PI3K), Grb2, crk II, 
etc. The major pathway connecting actions of insulin and the IRS proteins is the PI3K 
and AKT signaling pathway. PI3K is a heterodimer with a regulatory and catalytic 
subunit. Binding of the regulatory subunit to the IRS proteins leads to the activation of 
catalytic subunit, which phosphorylates phosphatidylinositol 4,5-biphosphate (PIP2) to 
form phosphatidylinositol(3,4,5)-triphosphate (PIP3), a second messenger. To this 
membrane bound PIP3, PDK1(3-phosphoinositide-dependent protein kinase 1) binds 
and is activated. PDK1 then phosphorylates and activates AGC protein kinase family 
proteins, which are responsible for PI3K-PIP3 downstream effects. This AGC protein 
kinase family members include Akt/PKB, p70 ribosomal S6 kinase, serum and gluco-
corticoid induced protein kinase (SGK), and protein kinase C (PKC). Akt2 is the major 
isoform involved in the insulin metabolic actions. Akt is phosphorylated at Thr-308 by 
PDK-1 and at Ser-473 by mammalian target of rapamycin complex 2 (Mtorc2). Akt 
acts on substrates (TSC-2, FOXO, AS160, GSK3, PGC-1α) and leads to various phys-
iological functions including GLUT4 translocation to the plasma membrane and glu-
cose uptake, glycogen synthesis, and protein synthesis. Insulin also activates mitogen-
activated protein kinases (MAPK) to increase gene expression and differentiation 
through the Grb2-SOS-Ras-MAPK pathway. This pathway is activated inde-
pendently of the Akt pathway. The insulin receptor and IRS proteins bind to adaptor 
molecules like Grb2 and shc. Grb2 binds to Gab-1 with the carboxyterminal domain 
and to SOS with amino terminal domain. SOS is a Guanine nucleotide exchange factor, 
activates Ras-GDP to Ras-GTP.  Activated Ras interacts and activates a series of down-
6 
 
 
stream signaling molecules Raf-MEK1/2-ERK1/2. ERK is directly involved in regulat-
ing gene expression, cell proliferation or differentiation, cytoskeletal reorganization. 
Other insulin receptor substrates include APS (SHB2) and Cbl, which bind to proteins 
such as the Cbl-associated protein (CAP). Cbl-associated protein is involved in control 
of insulin-stimulated glucose uptake14-16. 
Insulin signaling is tightly regulated to control the physiological effects. There 
are several negative regulators of insulin signaling. They are important because the un-
controlled/abnormal activity in this regulation can lead to insulin resistance. The path-
way is inhibited by the activity of some protein phosphatases including tyrosine phos-
phatases, such as PTP1B, transmembrane phosphatases, such as LAR17, serine/threo-
nine phosphatases including PP118, PP2A19, PP2B20, and some members of PP2C21. It 
is also inhibited by lipid phosphatases such as PTEN22 and SHIP123. Other negative 
regulators include Grb24, Proteins of the suppressor of cytokine signaling (SOCS) fam-
ily25, Tribbles homolog 3 (Trb3)26, inositol phosphate (IP7)27. These negative regula-
tors are summarized in Figure 3. Phosphorylation on inhibitory serine/threonine sites 
on the insulin receptor can turn down the insulin signaling as well (Figure 4). This can 
be influenced by many factors such as hyperglycemia, fatty acids, cytokines, mitochon-
drial dysfunction, ER stress, increased cAMP concentration14. Insulin can also cause 
the inhibitory serine/threonine phosphorylation through activation of MAPK, JNK, 
IKK, Mtorc1/S6K14. 
1.1.5 PATHOGENESIS OF TYPE 2 DIABETES 
In Type 2 diabetes, glucose homeostasis is disrupted. The two major defects 
involved in the pathogenesis of type 2 diabetes are  
1. Abnormal insulin production/release 
2. Impaired sensitivity of tissue to insulin28 
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As 80% of the insulin dependent blood glucose clearance takes place in skeletal 
muscle, insulin resistance in skeletal muscle is one of the major drawback in Type II 
diabetes10.  
1.1.1.1 β-CELL FAILURE IN T2D 
Abnormalities in insulin secretion and release in β-cell are seen in type 2 diabe-
tes. To compensate the insulin resistance, β-cell produces large amounts of insulin in 
the early stages of T2D. It is observed that in the stages of impaired glucose toler-
ance(IGT), there is impaired first phase of insulin release. This prandial hyperglycemia 
is the characterisitic feature of IGT. However, with a normal prolonged second phase29, 
the hyperinsulinemia keeps the glucose under control or mildly impaired. As the disease 
progresses, the β-cell fails. Studies in human subjects have shown that β-cell mass is 
decreased in type 2 diabetes. This reduced mass is associated with cell death by apop-
tosis30. The mechanisms involved in β-cell failure involve glucotoxicity and lipotoxi-
city, a condition where the cells are exposed to high levels of glucose and fatty acids 
respectively for longer terms31. This can cause high burden on the mitochondria and 
ER in the β-cells which leads to increased ROS production and upregulated UPR re-
sponse respectively, which cause cell apoptosis. Research has shown many signaling 
molecules involved in the cell dysfunction. High glucose induced increased ca+2 levels 
in the cells is also shown to cause β-cell dysfunction32. Chronic exposure of cells to 
high glucose can lead to production of IL-1β which activates NFKB signaling, cell apop-
tosis, and β-cell dysfunction33. Hyperglycemia is known to cause glycation of intra or 
extracellular proteins and the Advanced Gycation End prodcuts (AGEs) that can cause 
cell damage. β-cells are vulnerable to oxidative stress, and under glucotoxic conditions, 
they can lead to activation of JNK and NFKB. Activated JNK phosphorylate IRS-1 at 
ser-30734, which attenuate the IRS-PI3K-AKT signaling, thereby increase in FOXO1 
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gene expression and decreased nuclear PDX-1, transcription factor important for β-cell 
survival35. mTOR signaling is important for cell growth and survival. Continuous acti-
vation of this pathway by glucose can lead to IRS2 phosphorylation and degradation, 
thereby cell apoptosis36. Lipotoxicity is shown to decrease glucose stimulated insulin 
secretion. In addition, there is reduced nuclear transclocation of PDX-1 (cell survival) 
, downregulated MafA expression (responsible for insulin expression), upregulated 
UCP237 (mitochondrial inner membrane protein uncoupling protein 2), activation of 
PLC-ε38 (lipid-induced protein kinase), variations in machinery required for insulin se-
cretion from its granules39, and detachment of insulin secretory granules from 
Ca2+channels40. 
1.1.1.2 MECHANISMS OF INSULIN RESISTANCE 
Many factors influence insulin sensitivity. Defects in any step along the insulin 
signaling pathway can cause insulin resistance. In addition, activation/abnormal func-
tion of the negative regulators of the pathway can also lead to this condition. Research 
over the years identified several causes for insulin resistance, which include genetic 
mutations, hyperglycemia, lipotoxicity, ER stress, and mitochondrial dysfunction14. 
Gene mutations in the IRS-1, PI3K, PTEN, AKT2, Trb3, and AS160 are linked to in-
sulin resistance as seen in diabetic patients. Chronic hyperglycemic condition is known 
to change insulin sensitivity through mechanisms of oxidative stress in tissues like mus-
cle, fat, and also reduce insulin secretion from beta cells. Accumulation of free fatty 
acids also leads to this metabolic dysfunction through activation of ser-307 IRS1 phos-
phorylation, JNK, IKK, PKC. Ceramides, a class of biologically-active sphingolipids 
act via activation of JNK, PKC, and by inhibiting Akt activation. Fatty acid Palmitate 
is shown to cause insulin resistance through induction of NF-κB signaling, cytokine 
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production, ER stress, and activation of JNK. Inflammatory cytokines also cause insulin 
resistance by various mechanisms. 
1.2 KINASES AND PHOSPHATASES 
Phosphorylation is one of the most important post translational modifications 
which regulates most signaling molecules in the cell. This process is carried out by 
kinases contrary to the phosphatases which carry out dephosphorylation. Of all the pro-
teins in the eukaryotic cell, one third portions undergo reversible phosphorylation41. In 
1950’s, Edmond Fischer and Edwin Krebs discovered the idea of reversible phosphor-
ylation using proteins isolated from rabbit skeletal muscle. They identified that this 
process required transfer of phosphate group from ATP to phosphorylase b to form 
phosphorylase a, a phosphoprotein using a ‘converting enzyme’42. However, the con-
cept of dephosphorylation was discovered about a decade earlier without the knowledge 
of phosphate group being its product until identified later by Drs.Krebs and Fischer. 
Phosphorylation and dephosphorylation are mostly carried out on amino acids contain-
ing OH group such as serine, threonine and tyrosine. Among these, serine undergoes 
almost 86.4% of the total phosphorylation followed by threonine (11.8%) and tyrosine 
(1.8%)43. Therefore 98% of the phosphorylation sites happen on serine/threonine43. Hu-
man genome sequence is expected to contain a total of 518 kinases with 90 Tyrosine 
and 428 Serine/Threonine kinases and about 130 total protein phosphatases with 107 
Tyrosine and about 30 Serine/Threonine phosphatases44. Protein Tyrosine Phospha-
tases are almost similar in number to tyrosine kinases. However, Protein serine/threo-
nine kinases are about 10fold higher than serine/threonine phosphatases. Combined, the 
number of genes coding kinases approximately 3 fold higher than that of phospha-
tases45. The large number of kinases is balanced through formation of holoenzyme com-
10 
 
 
plexes of phosphatases, generally composed of a catalytic subunit and one or more reg-
ulatory subunits. Each subunit has been shown to exist in various isoforms. These var-
ious subunit isoforms produce numerous possible combinations for each phosphatase 
and thereby match the kinases. The catalytic subunit itself is relatively non-specific and 
can dephosphorylate numerous substrates. Therefore, the interaction between the cata-
lytic subunit and regulatory subunits is required to regulate the specificity and activity 
of the phosphatases45. Phosphatases remove phosphate group via SN2 mechanism with 
water as a nucleophile46. Characterization of these phosphatases based on their substrate 
is as follows. 
i. Protein Tyrosine Phosphatases (PTP): remove the phosphate group from phos-
phorylated tyrosine residues. 
ii. Protein Serine/Threonine Phosphatases: remove the phosphate group from 
phosphorylated serine/threonine residues. This group is further classified into 
a.  Phospho Protein Phosphatase (PPP) which includes PP1, PP2A, PP2B, 
PP4, PP5, PP6, PP7. 
All the proteins in this group have a structurally conserved active site 
configuration, a catalytic water molecule and six conserved residues 
[two aspartate (D), one asparagine (N) and three histidine (H) residues] 
with two metal ions. 
b. Metal ion (Mg+2 and Mn+2) dependent phosphatase (PPM) which con-
tains PP2C. 
This family of proteins does not possess regulatory subunits to deter-
mine the substrate specificity. Instead they have conserved sequence 
motifs and additional domains. Both PPP and PPM class of proteins re-
quire metal ions to play catalytic role. 
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c. Aspartate bases based phosphatase comprising Fcp1 and Scp1. 
As the name indicates, these phosphatases use aspartate based catalysis. 
RNA polymerase II is the only substrate for this family of phosphatase. 
iii. Dual specificity protein serine/threonine/tyrosine phosphatase. 
iv.  Histidine phosphatase. 
v. Lipid phosphatase. 
As their names suggest, their substrates involve phosphorylated tyrosine, ser-
ine/threonine, serine/threonine/tyrosine, or histidine residues and lipids, respectively.  
1.3 PROTEIN PHOSPHATASE 2A (PP2A), REGULATION AND EFFECT OF 
INSULIN 
PP2A is a one of the major serine-threonine protein phosphatases that belongs 
to the phosphoprotein phosphatase family. This phosphatase constitutes for about 1% 
of the total protein in the cell47. It is a hetero-trimeric complex with a dimeric core 
enzyme (see Figure 5), composed of a 65kda A subunit (PP2Aa), a 55kda B regulatory 
subunit (PP2Ab), and a 36kda catalytic subunit C (PP2Ac). Subunits A and C form the 
dimeric core48. PP2A can exert its activity as a dimer (PP2Ad) or as a trimer complex
49. 
PP2Ac by itself can also act on substrates.  
1.3.1 SUBUNITS OF PP2A 
PP2Aa (A regulatory subunit) is ubiquitous and has two isoforms, alpha and 
beta, which are encoded by two different genes PPP2R1A and PPP2R1B. There is 86% 
similarity between these two isoforms. The dimer core, in most cases (90%), is com-
posed of A alpha isoform47. Both the isoforms are located in the cytoplasm. The struc-
ture of the A subunit is unveiled in 199950. It is composed of 15 non-identical repeats 
(HEAT sequence) containing 39 amino acids each. The repeats are arranged as two 
antiparallel alpha helices which are connected to each other by intra and inter repeat 
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loops forming a horse-shoe shape. B subunit binds to loops 1-10 whereas C subunit 
binds to loops 11-1551. Because of its flexibility, B subunits and other substrates can be 
incorporated easily47. PP2Aa guides PP2Ac in the interaction with PP2Ab and other 
substrates and regulates the specificity of PP2Ac52. 
PP2Ab (B regulatory subunit) regulates localization, activity and substrates for 
the complex. This regulatory subunit is encoded by 15 different genes which are tran-
scribed to a minimum of 26 transcripts and splice variants. They are expressed variably 
depending on the tissue type. They are classified into four families B (B55/PR55), B’ 
(B56/PR61), B‘’ (PR48/PR72/PR130), and B‘’’ (PR93/PR110). They require ATP and 
Mg+2 to be active. B has four different isoforms and has a tryptophan-aspartate repeat 
which helps in its identification. B’ has five isoforms which are all identical in the cen-
ter region but different in the C and N terminals. B’’ has three isoforms. Different regu-
latory subunits direct the holoenzyme to perform varied functions. For example, bind-
ing of B subunit to the PP2A complex prevents simian virus40 replication whereas 
binding of B’’ does the opposite. Not all subunits bind at the same region on the A 
subunit.  
PP2Ac (catalytic subunit) is in globular structure, ubiquitously expressed in al-
most all the tissues and is abundant in heart and brain. PP2Ac is conserved from eukar-
yotes to mammals, with 86% sequence match between yeast and humans. It is respon-
sible for the catalytic activity of the enzyme. PP2Ac has two isoforms, alpha and beta, 
which are 97% identical encoded by two different genes. Both are composed of 309 
amino acids and differ only by 8 amino acids at the N terminal. PP2Ac alpha is found 
mainly in plasma membrane whereas beta isoform is in cytoplasm and nucleus. PP2Ac 
alpha is more abundant than PP2Ac beta because of the high degree of mRNA transla-
tion53. Unique feature of PP2Ac is that C terminal tail is highly conserved 
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(304TPDYEL309). This tail binds to the A and B subunits of the complex. All the other 
phosphatases involved in PPP family cannot bind to A subunit even though they share 
sequence similarity with PP2Ac. This is because most of the amino acids required for 
specific interactions with A subunit are replaced46.  
All the subunits, their isoforms, tissue and subcellular distribution is summa-
rized in Table 1. 
1.3.2 REGULATION OF PP2A 
 Given the presence of large number of A, B and C subunit isoforms, various 
PP2A complexes are possible.  The combination of the A, B and C subunit isoforms 
affects the activity and specificity of PP2A complexes against a particular substrate. 
Binding and the presence of other regulators can also influence PP2A activity and spec-
ificity46,54. One such example is the binding of α4 protein. Binding of PP2A to α4 is 
important to stabilize PP2Ac in its inactive conformation. Besides stabilization, it also 
hinders ubiquitination site on PP2Ac thereby preventing its degradation55. Phospho ty-
rosyl phosphatase activator (PTPA) is also shown to be an important regulator. It acts 
by stabilizing PP2A in an active conformation, which facilitates acquirement of its Ser-
ine/Threonine phosphatase activity56. 
PP2A activity is also regulated by post-translational modifications on PP2Ac57. 
Several experiments in vivo as well as in vitro showed that phosphorylation on Tyr307 
on PP2Ac
57
 deactivates PP2Ac, by preventing its interaction with the regulatory subunit. 
Phosphorylation is also reported in a few PP2A regulatory subunits58, which altered 
their activity and also substrate specificity. In addition, PP2A undergoes carboxyl meth-
ylation on the carboxyl group of the C-terminal residue of Leu309. Leucine Carboxyl 
Methyl Transferase (LCMT), also known as PP2A-Methyl transferase (PPMT), is re-
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sponsible for methylation of PP2Ac, while PP2A Methyl Esterase (PPME) is responsi-
ble for PP2Ac de-methylation. Unlike phosphorylation, effect of methylation on activ-
ity is controversial. There are reports with an increase/decrease/no effect in the catalytic 
activity associated with carboxymethylation. It is however shown that PP2Ac methyl-
ation is required for binding of B subunit not the A/B’/B’’B’’’ subunits59,60. Recent stud-
ies have shown additional functions of PME-1 in addition to affecting the activity. It is 
shown to be important for maintaining normal PP2A levels by preventing it from pro-
teasome degradation61.  
1.3.3 INHIBITORS OF PP2A 
 I1
PP2A and I2
PP2A are two inhibitors which are found to inhibit PP2A through in 
vitro and in vivo experiments 57. Many small compounds found naturally inhibit PP2A. 
One of them being okadaic acid which is being used in laboratory practices. It also 
inhibits other phosphatases like PP1 but at relatively higher concentrations. Other com-
mercially available inhibitors include calyculin a, tautomycin, microcystins, can-
tharidin and endothall. Various inhibitors of PP2A, their specificity over other phos-
phatases and their origin is seen in Table 2.  
1.3.4 ROLE OF PP2A 
  PP2A is found to be involved in many cell signaling pathways, cell cycle reg-
ulation and various other pathways. Experiments conducted by employing phosphatase 
inhibitor okadaic acid showed that PP2A plays a role in cell cycle regulation (G2/M 
transition). Using Yeast, they presented the role of various B subunit analogues in cell 
cycle, stress response, cytoskeleton organization and morphogenesis. Experiments in 
drosophila showed the importance of PP2A in early embryogenesis and the changes in 
the tissue distribution during its development. Several viral antigens are found to inter-
act with PP2A and prevent the inhibitory role of PP2A in those signaling pathways and 
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promote cell proliferation. It is also shown in Xenopus eggs that it involves in initiation 
of DNA replication. Several studies showed the involvement of PP2A in termination of 
DNA replication, apoptosis, DNA damage response and heat shock response53. PP2A 
plays a role in numerous signaling pathways, including MAPK, mTOR, and Wnt sig-
naling pathways, that initiate the cell cycle.  
1.3.5 PP2A IN DIABETES 
  Our lab has shown that IRS1 interacts with PP2Ac using human skeletal mus-
cle biopsies. Further, its interaction is increased in obese insulin resistant nondiabetic 
controls and type 2 diabetic subjects when compared to lean controls62. Its interaction 
with IRS-1 also shown in murine HL-1 cardiomyocytes63. 
 There is evidence to indicate that insulin inactivates PP2A through in vitro and 
in vivo experiments. Also, published evidence shows interaction of PP2A with many 
signaling molecules, some of which are involved in insulin signaling pathway. Jian 
Chen et al showed that PP2A is phosphorylated in vitro by the tyrosine kinases which 
included insulin receptors. It is phosphorylated on Tyr307 and this inactivated PP2A57 . 
The effect of insulin on PP2A during myogenesis in rat L6 cells is shown by 
Srinivasan and Begum. They showed that insulin inactivated PP2A in the differentiated 
cells .They also showed that the phosphatase activity decreased relatively with the in-
creased concentrations of insulin and also the incubation time64. 
One of the effects of insulin in skeletal muscle cells is the glycogen synthesis 
through the INS/IRS-1/AKT pathway. Rosanna Cazzolli and associates showed that 
ceramide treatment of C2C12 skeletal myotubes reduced the glycogen synthesis 
through inhibition of phosphorylation on PKB upon insulin stimulation. Their results 
indicated that this inhibition is mediated through activated PP2A  via ceramide and 
thereby effecting the glycogen synthesis in the skeletal muscle cells65. 
16 
 
 
It is also shown that PP2A has a positive effect on the insulin signaling pathway 
by preventing the excessive serine phosphorylation on the IRS-1 which will otherwise 
negatively regulate the pathway. One such serine kinases is ribosomal protein P70 S6K-
1 which is an effector of mTOR. Madavia et al showed direct Interaction of PP2A with 
IRS-1 in cardiomyocytes protecting IRS-1 from excessive serine phosphorylation. They 
inferred from their results that PP2A interacts with IRS-1 via mTOR competing for 
serine residues on IRS-1 and thereby deciding the phosphorylation status of IRS-1. 
Many factors affect the association, one being the insulin stimulation63. 
One group has reported experiments on PP2Ac abundance in human skeletal 
muscle where they compared ten type II diabetics with ten lean controls. They showed 
that upon insulin stimulation, PP2Ac protein levels in control subjects reduced when 
compared to the basal levels but not in type II diabetics. They also showed correspond-
ing reduction in glucose disposal, glucose oxidation and increase in lipid oxidation66. 
Saturated fatty acids like palmitate negatively regulate insulin signaling path-
way by activating PP2A, which dephosphorylates Akt and ERK1/2. Opposite effect is 
seen with unsaturated fatty acids like oleic acid or linoleic acid67. 
Chronic exposure of pancreatic β-cells to high glucose (glucotoxicity) leads to 
metabolic dysfunction in these cells with reported beta cell death31. Experiments done 
by Arora., et al. showed that sustained activation of PP2Ac in insulin-secreting INS-1 
832/13 cells and normal rat islets under these hyperglycemic conditions. They also 
showed an increased PP2A activity under similar glucotoxic conditions with a corre-
sponding increase in carboxymethylation of PP2Ac68  
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1.4 INSULIN SENSITIVITY; PROTEIN INTERACTIONS AND MASS SPEC-
TROMETRY 
1.4.1 METHODS TO MEASURE INSULIN SENSITIVITY  
There are several methods to measure insulin sensitivity in humans. Hyperinsu-
linemic euglycemic clamp and insulin suppression test are used for direct measurement 
of insulin sensitivity whereas Oral glucose tolerance test and minimal model analysis 
of frequently sampled intravenous glucose tolerance test are considered for indirect 
measurement. There are several other Indices used for quick measurement of insulin 
sensitivity in cases where feasibility is an issue.69 
For settings where insulin sensitivity measurement and maintenance of steady 
state conditions is crucial, hyperinsulinemic euglycemic clamp should be the first 
choice. This technique is also mentioned as a gold standard to assess the action of in-
sulin in vivo70. The action of insulin on the body is measured by the rate of exogenous 
glucose infused to maintain a constant blood glucose concentration. Under conditions 
of hyperinsulinemia, most (>70%) of the infused glucose is used by skeletal muscle. 
This implies that the index measured during the clamp mainly reflects the skeletal mus-
cle sensitivity to insulin10. 
1.4.2 IMPORTANCE OF PROTEIN-PROTEIN INTERACTIONS 
Most of the proteins in vivo act in the form of complexes. Protein-protein inter-
actions play a very crucial role in various functions of the cell, such as gene transcrip-
tion, signal transduction71, cell cycle regulation, etc. Correct formation of these com-
plexes is important for the normal body function. Abnormalities in protein-protein in-
teractions cause aberrant cell signals and thereby cause diseases. Many protein com-
plexes have been targeted to treat diseases72. Studying the interactions will help us to 
find out the function of the particular target protein which is specifically useful in cases 
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of any unidentified protein interaction partners. It will also enable us to analyze the 
signaling pathways. Protein-protein Interactions have been classified as homo oligo-
meric /hetero oligomeric based on interaction surface; obligate/non obligate based on 
stability and transient/permanent depending on persistence73 
Protein-protein interactions may result in changes in 
1. Kinetic characteristics of the complexes  
2. Substrate channeling 
3. A new binding site on the complex for other effector molecules  
4. Substrate specificity  
5. Activity of the complex 
6. Downstream events  
Methods to determine protein-protein interactions. Biophysical methods de-
termine these interactions using the structural information of the proteins. These include 
X-ray crystallography, NMR Spectroscopy, fluorescence and atomic force microscopy. 
Direct high throughput methods include yeast two hybrid, affinity purification and mass 
spectrometry74,75,76. Indirect high throughput methods include gene co-expression and 
synthetic lethality. Computational predictions of the protein-protein interactions have 
also been reported74. Affinity purification coupled with mass spectrometry (AP-MS) is 
widely used for identification of interaction networks75. Affinity purification allows to 
enrich the target protein of interest and its co-interaction partners in a single step, and 
mass spectrometry offers supreme ability to identify proteins from a complex mixture 
in a high throughout fashion75,76.  
1.4.3 MASS SPECTROMETRY 
 Mass spectrometry is the most sensitive approach for global identification and 
quantification of proteins, protein-protein interactions, and protein post translational 
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modifications77.  The main components of a mass spectrometry instruments, a mass 
spectrometer, include an ion source, a mass analyzer, and a detector77: 
1. Ion source: a device to generate charged particles. Electrospray ionization 
(ESI) and matrix-assisted laser desorption ionization (MALDI) are two com-
monly used ion sources for proteomics studies77. 
2. Mass analyzer: a device to separate the ions based on their mass-to-charge 
ratio, m/z77.  Four common types of analyzers for the proteomic analysis include 
quadruple, Ion trap (quadruple ion trap, linear ion trap), time of flight, and or-
bitrap analyzers77. 
3. Detector: A detector is a device to record either the charge induced when an 
ion hits a surface or the current produced when an ion passes by 77. Two main 
detectors are electron multiplier (charge induced when ions hit a plate) and im-
age current detector (current produced when ions pass) 77. 
 As every wet lab experiment, proteomics studies begin with collecting starting 
material (e.g., tissue, body fluid, cell lysates, etc.) and followed by protein separation 
(e.g., affinity capture, electrophoresis, liquid chromatography, etc.).  Proteins are 
cleaved into peptides by enzymatic digestion. The most commonly used protease/en-
zyme for this purpose is trypsin due to its well-defined specificity, which hydrolyzes 
proteins at the carboxyl side (or "C-terminal side") of the amino acids lysine and argi-
nine.  Since one protein may generate many peptides after trypsin digestion, a tryptic 
digest of a complex mixture of proteins may contain thousands or even millions of 
peptides.  Therefore, the resulting peptides are further separated using a variety of tech-
niques (e.g. affinity capture, liquid chromatography, etc.).  The separated peptides are 
analyzed by mass spectrometry for peptide/protein identification and quantification. 
These steps are summarized in Figure 6.   
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In the present work, the proteomic approach developed in our laboratory78 was 
applied to investigate PP2Ac interaction partners in islet cells and human skeletal mus-
cle biopsies from human participants.  
1.5 SPECIFIC AIMS 
This project aims to by study the activity of PP2A and to determine the interac-
tion partners of PP2Ac in (i) clonal islet β-islet cells (INS-1 832/13) under basal and 
hyperglycemic conditions (ii) human skeletal muscle under basal and hyperinsulenemic 
conditions in in lean, obese/overweight non-diabetics and type II diabetics 
1.5.1 SPECIFIC AIM 1: INS-1 832/13 CELLS 
 Our aim is to determine the activity and interaction partners of pp2ac in β-islet 
cells under basal and hyperglycemic conditions. We hypothesized that chronic expo-
sure of insulin-secreting β cells to hyperglycemic conditions leads to increased interac-
tion of PP2Ac with its regulatory and scaffolding subunits resulting in its catalytic ac-
tivation with subsequent dephosphorylation and inactivation of key survival proteins. 
1.5.2 SPECIFIC AIM 2: HUMAN SKELETAL MUSCLE BIOPSY 
Here, our aim is to determine the activity, post translational modifications and 
interaction partners of pp2a in human skeletal muscle under basal and hyperinsulenemic 
conditions in lean, obese/overweight non-diabetics and type II diabetic subjects. PP2Ac 
activity is increased under hyperglycemic conditions and its regulation varies under this 
condition 
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CHAPTER 2 RESEARCH DESIGN AND METHODS 
2.1 REAGENTS 
Reagents are from these suppliers; protein A sepharose and iodoacetamide 
(Sigma, St Louis, MO); C18 ZipTip (Millipore, Billerica, MA). RPM1640 medium, 
normal fetal bovine serum (FBS) and penicillin-streptomycin-glutamine mixture (PSG) 
were purchased from Life Technologies. HPLC grade acetonitrile (ACN), trifluoroace-
tic acid (TFA) and formic acid (FA) were from Sigma. Sequence grade trypsin was 
from Promega. The normal mouse IgG (NIgG) and PP2Ac mouse monoclonal antibody 
(Cat. 05-421) were from Millipore.  
2.2 SPECIFIC AIM 1: INS-1 832/13 CELLS 
2.2.1 CELL CULTURE AND HIGH GLUCOSE TREATMENT 
INS-1 832/13 cells (provided by Dr.Aris Newgard) were grown in RPMI1640 
medium containing 2.5 mM glucose, 10% FBS and 1% PSG. In order to treat the cells 
with high glucose for 48 hours, same medium was supplemented with glucose to obtain 
a final concentration of 20 mM. Cells treated with low and high glucose were harvested 
after the treatment. The cells homogenized in lysis buffer containing 2mM EDTA, 
2mM EGTA, 20mM imidazole-HCl, pH 7.0 with protease inhibitors aprotinin, leupep-
tin, and PMSF. The cells are centrifuged at about 14000rpm for 15min followed by 
protein quantification using bradford method. 4 mg of protein was used for each sample 
and was first incubated with 30 µl of protein A beads conjugated to 4 µg of mouse 
NIgG for three hours. Treating with NIgG beads served as control to detect non-specific 
interactions. The supernatant from NIgG beads was incubated with 30 µl of protein A 
beads conjugated to 4 µl of anti-PP2Ac antibody overnight. Next day, both NIgG and 
PP2Ac beads were harvested. 
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2.2.2 PROTEOMICS SAMPLE PREPARATION AND ANALYSIS 
  NIgG and PP2Ac beads were washed the next day with PBS for three times. 
Then, the beads were treated with 30 µl of 2 x SDS buffer comprising 50 mM DTT at 
95oC for 5 min. subsequently, the samples are treated with iodoacetamide (IAA) fo-
rabout 30min. The eluates were resolved on 4-15% SDS-PAGE. Five slices were ex-
cised from each lane (one sample) followed by in-gel trypsin digestion, peptide purifi-
cation and HPLC-ESI-MS/MS. The analysis is done on an LTQ Orbitrap Elite as de-
scribed78-80. Maxquant is used for the Peptide/protein identification and quantifica-
tion81. The different steps involved are shown in Figure 7. 
2.2.3 STATISTICAL ANALYSIS  
Proteins are obtained from Maxquant with peak areas for each which is utilized 
for analysis (Figure 8). Proteins with atleast two unique peptides are considered for 
analysis. For it to be categorized as PP2Ac interaction partner, a protein has to meet the 
following criteria: 1) should be identified with label-free quantification PAs in more 
than half of the PP2Ac immunoprecipitates (4 IPs); and 2) should have an enrichment 
ratio (PP2Ac/NIgG) greater than 10, or should not be identified in any of the eight NIgG 
samples. The calculation of enrichment ratio is explained later in 2.3.5. The proteins 
which pass the above criteria are considered as potential interaction partners. Further 
identification of glucose responsive interaction partners (low glucose vs high glucose, 
n=4) from these PP2A interaction partners, is done as follows: 1) they should have fold 
change >0.05 of normalized peak areas; 3) and have significantly altered normalized 
peak areas (P <0.05 calculated by independent t-test).  
Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA),a bi-
oinformatics analysis software package82-84 is used for pathway analysis on both inter-
action partners as well as glucose-responsive PP2Ac interaction partners. The software 
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contains chemical, biological interactions, and functional annotations formed by man-
ual curation of the scientific literature85,86. 
2.2.4 VALIDATION THROUGH WESTERN BLOT ANALYSIS 
To Validate a glucose responsive interaction partner, western blot technique is 
used. INS-1 832/13 cells were treated with low (2.5 mM) and high (25 mM) glucose 
for 24 hours followed by collecting cell lysates and protein concentration estimation 
using the bradford assay. Samples were then treated with SDS sample buffer and re-
solved on 10% SDS-PAGE. The gel is then transferred onto nitrocellulose membranes 
(Bio-Rad), and analyzed by Western blotting (WB) with the specific antibodies. en-
hanced chemiluminescence kit87-89 is used to detect the protein complexes further. 
2.3 SPECIFIC AIM 2: HUMAN SKELETAL MUSCLE BIOPSIES 
2.3.1 SUBJECTS 
A total of 24 participants including 8 lean, 8 overweight/obese non-diabetic and 
8 type 2 diabetic volunteers were recruited and took part in the study at the Clinical 
Research Center at Wayne State University. Written consent was attained from all par-
ticipants and the study was explained in detail including the indirect benefits and risks.  
No one had any significant medical problems except for type 2 diabetic participants 
who have type 2 diabetes, and none engaged in any heavy exercise, and they were di-
rected to stop all kinds of exercise for at least 2 days prior to the study. Institutional 
Review Board of Wayne State University approved this protocol. 
2.3.2 HYPERINSULINEMIC-EUGLYCEMIC CLAMP WITH MUSCLE BIOP-
SIES 
 A hyperinsulinemic-euglycemic clamp was used to assess insulin sensitivity 
and expose skeletal muscle to insulin in vivo, as previously described78.  Followed by a 
ten hour overnight fast, the study began at approximately 08:30 hours (time -60 min). 
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Two catheters were placed, one in an antecubital vein, maintained throughout the study 
for infusions of insulin and glucose. The second in a vein in the contra lateral arm, 
which was covered with a heating pad (60°C). The purpose of heating pad is to arteri-
alize the venous blood being collected. Blood samples were collected for determination 
of plasma glucose concentrations. At approximately 09:00 hours (time −30 min), under 
local anesthesia, a percutaneous needle biopsy of the vastus lateralis muscle was per-
formed. These biopsy samples were blotted free of blood, cleaned of connective tissue 
and fat (~30 sec), and then frozen in liquid nitrogen. At 09:30 hours (time 0 min), con-
tinuous human insulin (Humulin R; Eli Lilly, Indianapolis, IN) infusion was begun at 
a rate of 80 mU m-2 minute-1, and continued for 120 min. Plasma glucose was measured 
at 5-min intervals throughout the clamp.  Euglycemia was maintained at 90 mg/dl by 
variable infusion of 20% d-glucose.  Another biopsy is taken at 11:30 hours (time 120 
minutes) in the contralateral leg.   
Plasma insulin concentration was calculated using the ALPCO Insulin ELISA 
Jumbo (Alpco Diagnostics, Salem, NH). 
2.3.3 OUTLINE 
Clinical and proteomics studies were carried out similar to those describe78, 
which reported the discovery of new IRS1 interaction partners in human skeletal mus-
cle. The main difference was that PP2Ac Co-immunoprecipitation was used to enrich 
PP2Ac interaction partners in the present work instead of IRS1 Co-immunoprecipita-
tion used in the publication.    
As illustrated in Figure 11, the approach we used included extensive clinical 
and proteomics data acquisition and data analysis. We first recruited subjects which 
was followed by comprehensive tests to screen them for eligibility. This is followed by 
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hyperinsulinemic-euglycemic clamp, procedure to measure insulin sensitivity and mus-
cle biopsies are collected. The proteomics study was performed in the following order: 
biopsy homogenization; immunoprecipitation of the “bait” protein (PP2Ac), at the en-
dogenous level; followed by one dimensional SDS-PAGE to separate co-interaction 
proteins; in-gel trypsin digestion to generate peptide fragments; and HPLC-ESI-
MS/MS analysis to identify co-immunoprecipitating proteins. Multiple biological com-
parisons and immunoprecipitation of NIgG (as non-specific control) were used for false 
positive minimization.  Extensive literature searches as well as bioinformatics were 
used to integrate clinical and proteomics data and to identify pathways and functional 
categories in which identified PP2Ac interaction partners were involved.  
2.3.4 PROTEOMIC SAMPLE PREPARATION 
 Biopsies were homogenized and processed as described78,79,90 . The lysate pro-
teins were precleared with NIgG followed by PP2AC immunoprecipitation. The co-
immunoprecipitates were resolved on one dimensional SDS-PAGE, which is followed 
by in-gel trypsin digestion, peptide enrichment, and HPLC-ESI-MS/MS analysis using 
a LTQ-Orbitrap Elite as described78. Peptides/protein identification and quantification 
were performed using the MaxQuant software. It is one of the most prevalent quantita-
tive proteomics software81. Using this, peak areas for each protein were obtained by 
selecting the option for label-free quantification (LFQ). Only those proteins with a min-
imum of 2 unique peptides and with false discovery rate (FDR) at 0.01 were considered. 
In total, 2057 proteins were identified in the 48 muscle biopsies using HPLC-ESI-
MS/MS. 
To be considered as a PP2Ac interaction partner, a protein has to additionally 
pass these following criteria: 1). with an enrichment ratio >10; 2). Identified with LFQ 
26 
 
 
peak area (PA) in more than half of the PP2Ac IP (i.e. >24 biopsies used). The enrich-
ment ratio was calculated as follows: 1st, PA for a protein identified in a gel lane was 
normalized against the sum of the peak areas for all proteins identified in the same gel 
lane to obtain normalized ratio for individual protein, Norm:i, 
Norm: 𝑖 =
PA𝑖
∑ PA𝑖n1
   
Then, the average of normalized ratio for each protein in the PP2Ac co-immuno-
precipitates, Average_Norm:i_IRS1, as well as the average of normalized ratio for the 
same protein in the NIgG co-immunoprecipitates, Average_Norm:i_NIgG, were ob-
tained. Finally, Average_Norm:i_PP2Ac was divided by Average_Norm:i_NIgG, 
which gives the enrichment ratio for each protein.  
Enrichment_Ratio: 𝑖 =
Average_Norm: 𝑖_PP2Ac
Average_Norm: 𝑖_NIgG
  
Proteins exclusively detected in the PP2Ac immunoprecipitates were identified 
as PP2Ac interaction partners as we used NIgG as a control. Nevertheless, this will give 
rise to false negatives since our high sensitivity method would identified trace amounts 
of a protein non-specifically absorbed on the NIgG beads. However, if a protein is true 
component of the PP2Ac complex, higher peak area will be assigned to this protein in 
the PP2Ac sample than in the NIgG sample.  
 To determine the relative quantities of PP2Ac interaction partners in human 
skeletal muscle biopsies among lean controls, obese insulin resistant non-diabetic con-
trols, and type 2 diabetic participants, the PA for each protein identified in a specific 
biopsy was normalized against the PA for PP2Ac identified in the same biopsy, which 
results in Norm:j.  
Norm: 𝑗 =
PA𝑗
PA_PP2Ac
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The normalization strategy is widely used in proteomics studies involving pro-
tein-protein interactions91, and uses similar concept as in western blotting, where the 
signal for an interaction protein is normalized against that for the protein serving as the 
“bait.” The normalized peak area for each PP2Ac interaction partner, Norm:j, was con-
verted to log2 form and compared within the group to assess effects of insulin or  across 
the 3 groups to determine effects of obese insulin resistance and type 2 diabetes on 
protein-protein interactions involving PP2Ac.  
2.3.5 STATISTICAL ANALYSIS FOR PP2A             
To be considered as a PP2Ac interaction partner, a protein has to further satisfy 
the following criteria: 1) the protein is identified with label-free quantification PAs in 
more than 4 of the PP2Ac immunoprecipitates (IPs); and 2) those proteins have an en-
richment ratio larger than 10, or not identified in all of the eight NIgG control samples. 
The calculation of enrichment ratio was described in our previous publication81. To be 
considered as glucose responsive PP2Ac interaction partners, has to: 1) be an identified 
PP2Ac interaction partner; 2) has >1.5fold change of normalized peak areas (low glu-
cose vs high glucose, n=4); 3) and has significantly changed normalized peak areas (P 
<0.05 assessed by independent t-test). Although a large number of proteins were as-
signed in at least one of 48 biopsies that were studied, various filters narrowed the num-
ber of proteins that were used in comparisons among groups as described above.  This 
approach is diagrammed in Figure 12.  To assess the effects of insulin within a group, 
statistical significance was calculated by paired t tests.  For across group comparisons, 
statistical significance was assessed using ANOVA with post hoc independent t tests.  
Differences were considered statistically significant at p<0.01. 
Pathway analysis on PP2Ac interaction partners was performed using Ingenuity 
Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA), which is widely used 
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and contain biological and chemical interactions and functional annotations created by 
manual curation of the scientific literature84.  A pathway was considered significantly 
enriched if the p-value for that pathway was less than 0.01 and contained at least 4 
identified PP2Ac partners.   
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CHAPTER 3 RESULTS 
3.1 SPECIFIC AIM 1: DETERMINE THE INTERACTION PARTNERS OF 
PP2AC IN β-ISLET CELLS UNDER BASAL AND HYPERGLYCEMIC CON-
DITIONS 
3.1.1 PP2AC INTERACTION PARTNERS IN INS-1 832/13 CELLS 
All these results are published in92. Using the proteomics approach developed 
in our lab78, a total of 1131 proteins with FDR at 0.01 were identified from PP2Ac 
coimmunoprecipitations which have a minimum of 2 unique peptides. Among the 1131 
proteins, 606 proteins had enrichment ratio larger than 10. Out of these 606 proteins, 
514 proteins were identified with a peak area (PA) in more than half (e.g., >4 out of 8) 
PP2Ac coimmunoprecipitates. These 514 proteins are considered as potential interac-
tion partners of PP2Ac listed in Table 5. These 514 proteins are then compared with the 
PP2A interactions obtained from BioGRID3.2 database, which came upto 38 proteins 
(Table 7). Thus, excluding 38 previously known PP2A partners, 476 proteins from this 
study were considered novel PP2Ac interaction partners. The previously reported 
PP2Ac interaction partners include the α and β isoforms of PP2A 65 kDa regulatory 
subunit A, α and δ isoforms of PP2A 55 kDa regulatory subunit B (PPP2R2A and 
PPP2R2D), the α isoform of PP2A 72/130 kDa regulatory subunit B (PPP2R3A), and 
the γ isoform of PP2 56 kDa regulatory subunit B (PPP2R5C). Most of these 38 inter-
action partners were identified in human cells. These known partners are symbolic to 
the effectiveness of our proteomic approach. However, most of these proteins were first 
identified in rat β-cells through our study. Among the 476 novel PP2Ac interaction 
partners, there were more than 15 different kinases, such as dual specificity mitogen-
activated protein kinase kinase 2 (MAP2K2), mitogen-activated protein kinase 1 
(MAPK1), CRA_a isoform of LIM motif-containing protein kinase 1 (LIMK1), and 
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calcium/calmodulin-dependent protein kinase type 1 (CAMK1). There were some pro-
tein phosphatases (regulatory/catalytic subunits) as well. Examples include serine/ thre-
onine-protein phosphatase 4 regulatory subunit 1 (PPP4R1), serine/threonine-protein 
phosphatase 6 catalytic subunit (PPP6C), protein phosphatase 1 regulatory subunit 12A 
(PPP1R12A), and the α isoform of protein phosphatase 3 catalytic subunit (PPP3CA). 
We also identified insulin-degrading enzyme (IDE), UDP-glucose:glycoprotein gluco-
syltransferase 1 (UGGT1) and voltage-dependent anion-selective channel protein 1 
(VDAC1) as PP2A partners. There were a number of ribosomal proteins, translation 
initiation factors as well as Ras related proteins identified in the current study.  
3.1.2 GLUCOSE RESPONSIVE PP2AC INTERACTION PARTNERS 
Out of the 514 PP2Ac interaction partners, 265 are identified with fold change 
greater than 1.5 (i.e., 1.5fold increase) or less than 0.67 (i.e., 1.5fold decrease) by com-
paring high low glucose treated samples. Among these 265, 89 proteins showed a sig-
nificant change in response to the high glucose treatment (P < 0.05). These 89 PP2Ac 
partners were considered as glucose responsive interaction partners. All these 89 part-
ners are mentioned in Table 6. Among them, seven proteins are known to interact with 
PP2Ac previously in other cell models. They include regulatory subunits of PP2A such 
as PPP2R1B93-97 and PPP2R2A10-12,35,43.  The interaction of PPP2R1B and PPP2R2A 
with PP2Ac was increased by 1.83 and 2.32 folds, respectively in response to high glu-
cose treatment. The other three PP2Ac partners, sarcolemmal membrane-associated 
protein (SLMAP)94, cortactin binding protein 2 (CTTNBP2)95, and Ints5 protein98, also 
presented an increased interaction with PP2Ac with fold change 4.95, 11.03 and 2.47, 
respectively. Conversely, protein phosphatase 1B (PPM1B)99, a known PP2Ac partner, 
displayed a decreased interaction with PP2Ac ( 0.27 fold change ) in response to the 
high glucose treatment. Out of the thirteen PP2Ac interaction partners with a fold 
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change higher than 5 or lower than 0.2 (P < 0.01) in response to high glucose treatment, 
only protein peripherin presented a reduced association with PP2Ac (0.19fold change), 
while others showed an increase in association with PP2Ac. For example, association 
of CRA_a isoform of LIM motif-containing protein kinase 1 (LIMK1), LIM domain-
containing protein 1 (LIMD1) increased 9.85 fold and 12.94 fold, respectively with 
PP2Ac.  
3.1.3 GLUCOSE RESPONSIVE PP2AC INTERACTION PARTNERS RE-
LATED TO INSULIN SECRETION  
Ingenuity Pathway Analysis of the 514 PP2Ac interaction partners showed 59 
significantly enriched pathways (with a minimum of four interaction partners in a spe-
cific pathway and P < 0.01; Table 8). Most of the pathways are related to AMPK sig-
naling, cytoskeleton dynamics, and protein synthesis and degradation. On the other 
hand, very few glucose responsive PP2Ac partners were recognized in these pathways 
including PPP2R2A, PPP2R1B, ARPC4, LIMK1 and RhoA. Through this IPA analy-
sis, we did not find any enrichment in the insulin secretion pathway. We further did a 
manual literature search for the proteins involved in insulin secretion. Through this 
methos, we identified several proteins involved in insulin secretion and other related 
cellular functions. RHOA, PLA2G6, APPL1, EIF2C2, PFKFB2 and RAB10 have been 
shown to regulate insulin secretion (Figure 9). Protein CIAPIN1 and PPP4R1 are pro-
mote anti-apoptosis, thus retaining islet survival and function. We identified few pro-
teins involved in vesicle trafficking that include VPS52, VPS37A, TSG101, RAB5C, 
RAB10 and EEA1. There were few components of ribosomes such as RPL9, RPL4, 
RPL30, RPL18A and MRPL35. All these ribosomal components were found with in-
creased PP2Ac association in response to high glucose treatment. LIMD1, VGLL4, 
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STAT6, PHF5A, DDX17, NCOR1, ILF3, HIST1H1C and TRIP11 are all involved in 
regulation of transcription. 
3.1.4 EXPERIMENTAL VALIDATION OF PPP2R1B AS A GLUCOSE RE-
SPONSIVE PP2AC INTERACTION PARTNER 
 PPP2R1B, β isoform of PP2A A subunit was validated by co-IP and western 
blot. It was identified as a glucose responsive PP2Ac interaction partner. INS-1 832/13 
cells were incubated with low (2.5 mM) and high glucose (25 mM). Through western 
blot, we showed an increased association of PPP2R1B with (1.57 fold) under glu-
cotoxic/high glucose condition (n = 4, P < 0.05) (shown in Figure 10). These findings 
are consistent with our proteomics results where there was 1.83fold change in response 
to high glucose treatment (n = 4, P < 0.05). Furthermore, we quantified abundance of 
this PPP2R1B, normalized to β-actin level. This presented only 1.13-fold change in 
high glucose over the basal conditions (P > 0.05). However, when PPP2R1B is normal-
ized with levels of PP2Ac PPP2R1B/PP2Ac, a significantly increase is seen upon high 
glucose treatment (n = 4, 1.47 folds, P < 0.01). 
3.2 SPECIFIC AIM 2: DETERMINE INTERACTION PARTNERS OF PP2A IN 
HUMAN SKELETAL MUSCLE UNDER BASAL AND HYPERINSULENEMIC 
CONDITIONS IN LEAN, OBESE/OVERWEIGHT NON-DIABETICS AND 
TYPE 2 DIABETIC SUBJECTS.  
3.2.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM 
LEAN, OVERWEIGHT/OBESE, AND TYPE 2 DIABETIC HUMAN PARTICI-
PANTS  
Clinical characteristics of all the 24 human subjects (8 lean, 8 obese/overweight, 
and 8 type 2 diabetic) is listed in Table 3 and Table 4.  
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 PP2Acα and PP2Acβ were detected in PP2Ac immunoprecipitates from all 48 
biopsies used for the study. After performing statistical analysis as mentioned in the 
Figure 12, 211 proteins met the criteria for classification as PP2Ac interaction partners. 
These 211 partners may interact with PP2Ac directly or indirectly. 
Table 9 lists the 211 PP2Ac interaction partners with their enrichment ratio. 
PP2A interaction partners were pooled from various databases including BioGrid, 
SPIKE, IntAct, and STRING. By comparing these partners from databases with the 211 
partners identified in our study (human skeletal muscle), 21 were found in common 
(Table 11). Further comparison with 514 partners previously identified in beta cells (in 
our study) yielded 38 proteins (listed in Table 12) while 9 out of these 38 are redundant. 
Altogether, a total of 50 partners are previously identified while 161 were novel. The 
50 known PP2Ac interaction partners included AMPK, CAV1, CCDC6, CCT2, 
CCT6A, CUL1, IGBP1, PPME1, PPP2R1A, PPP2R2A, PPP2R3A, PPP2R5D, PPP4C, 
PSMC6, PSMD1, RAC1, SOD1, STRN, STRN3, TIPRL, USP7 from the databases and 
AKR1B1, APPL1, ARCN1, ASNA1, NTPCR, CAND1, CCDC6, DARS, EIF2B1, 
FAHD1, FLNA, GFPT1, GSN, IDH3B, IGBP1, MYH14, NAP1L4, PDIA6, PPME1, 
PPP2R1A, PPP2R2A, PPP2R3A, PPP4C, PPP4R2, PSMC2, PSMC3, PSMD12, 
PSMD13, PSMD14, RAB1B, RAC1, RPS15A, RPS25, S100A11, STRN, TALDO1, 
TSN, TUBB2A from the beta cells ( the ones in bold italics are redundant). 
Ingenuity pathway analysis on the 211 PP2Ac interaction partners and PP2Ac 
suggested various pathways significantly enriched compared to the whole genome 
background, such as IRS, Mtor, and MAPK signaling.  Two of the significantly en-
riched pathway, IRS and mTOR signaling, are illustrated in Figure 13 and Figure 14 
respectively. 
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We also performed network analysis using Ingenuity pathway analysis for the 
211 PP2Ac interaction partners and PP2Ac to illustrate how these partners can be in-
terrelated. Figure 15 shows the network with the highest score and highest number of 
interaction partners identified in this study.  
3.2.2 PARTNERS WITH SIGNIFICANT DIFFERENCE AMONG LEAN CON-
TROL, OBESE/OVERWEIGHT CONTROL, AND TYPE 2 DIABETIC 
GROUPS 
As mentioned in the Figure 12, by comparing the normalized peak areas of the 
211 proteins, 69 interaction partners exhibited significant difference among the three 
groups. All the 69 partners are listed in Table 10. 
Upon insulin stimulation, in lean control group, 4 proteins showed significant 
difference which included ACO1, IRP1, PPME1, and PPP4R2 whereas insulin stimu-
lation in obese control significantly changed CCDC6 and LUM and in type 2 diabetic 
group, it seemed to significantly change one protein, ACOT9.  
63 proteins showed a significant change in obese/overweight insulin resistant 
controls when compared with lean controls while 37 proteins exhibited a significant 
change in type 2 diabetics compared to lean controls. When the 63 proteins between 
lean and obese, 37 proteins between lean and T2D are compared, 32 proteins are in 
common i.e., they are seen with a change in both type 2 diabetics and obese group when 
compared to lean. When type 2 diabetic group is compared to obese non-diabetic insulin 
resistant group, 47 proteins presented with a significant change. These partners showed 
either a significant increase or decrease. Out of 63 proteins difference between lean and 
obese/overweight, interaction of only PDE4D and SCPEP1 is increased in obese/over-
weight compared to lean while the rest presented with an increase. CCT2, COPS2, 
PDE4D, ACO1/IRP1, CA1, GSTM3, BLVRB showed an increased interaction in T2D 
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compared lean among 37 proteins different between these two groups. 43 out of 47 
significant proteins between T2D and obese had an increased interaction with PP2A in 
T2D while the remaining four, EIF2B1, LAP3, LUM, and SCPEP1 exhibited a de-
crease. For easy access and understanding, all the 69 proteins are divided per their func-
tion and are color coded based on their difference between groups in Figure 16A and 
Figure 16B. One protein can show difference between groups in more than one case 
(for example, AKT2 protein show difference between lean and obese group, lean and 
type 2 diabetic group; hence you can see AKT2 coded in two different colors). It is to 
be noted that one protein can be involved in more than one function mentioned but, to 
simplify, a protein is grouped only under one function.  
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CHAPTER 4 DISCUSSION 
4.1 SPECIFIC AIM 1: DETERMINE THE INTERACTION PARTNERS OF 
PP2AC IN HUMAN Β-ISLET CELLS UNDER BASAL AND HYPERGLYCE-
MIC CONDITIONS  
4.1.1 PP2AC INTERACTION WITH SIGNALING PROTEINS IMPORTANT 
FOR PHYSIOLOGICAL INSULIN SECRETION 
We discovered several PP2Ac interactions that have been involved in islet func-
tion and insulin secretion. They include proteins involved in protein sorting and traf-
ficking, SRP72 and GGA2, and vesicle trafficking (VPS52, VPS37A, Rab10, Rab5C 
etc.). They also include small G proteins Rac1, Rho A, Rab5c. These findings suggest 
a close interaction between these signaling proteins and PP2Ac. These small G-proteins 
(Rac1, Cdc42, Rho A and Rab) play a pivotal role in glucose stimulated insulin secre-
tion100,101. They also play an important role to traffic insulin stored vesicles to the cell 
membrane and  cytoskeletal remodeling to allow fusion of these secretory granules with 
the plasma membrane in order for insulin secretion100,101. 
We identified an important interaction, PP2Ac with LIMK1 because LIMK1 is 
a serine/threonine-protein kinase which plays a vital role in the regulation of dynamics 
of actin filament at the cell membrane. Activation of  kinases like ROCK1, PAK1 and 
PAK4 cause phosphorylation and activation of LIMK1, which then phosphorylates and 
thereby inactivates the actin binding/depolymerizing factors102,103. This inactivation of 
the depolymerizing factors result in the prevention of breakdown of F-actin and thereby 
actin cytoskeleton stabilization. Besides, LIMK1 has shown to regulate quite a few ac-
tin-dependent biological processes including cell cycle progression, cell motility, and 
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cell differentiation104. This finding has huge significance considering that a glucose re-
sponsive PP2Ac partner is involved in vesicle trafficking and actin cytoskeletal remod-
eling, essential for glucose stimulated insulin secretion. 
An othe important interaction partner to be noted is the immunogloblin-binding 
protein [Igbp1]. Igbp1, also known as α4,  is a non-canonical adaptor subunit of PP2A60. 
In addition to binding to its regulatory subunits, PP2Ac is also shown to interact with 
other substrates, including α4 that regulate its localization, abundance, and activity. In 
this case, α4 is known to involve in PP2A biogenesis, stability and activation60,105. 
PP2AC-IGBP1 complex protects the catalytic subunit from proteasomal degradation106. 
Other such regulators are found later in this study. α4 is also shown to interact with 
other phosphatases like PP4 and PP6105. It is worthwhile to note that we also identified 
PP4 as an interacting partner of PP2Ac.  This is the first evidence for regulation of 
protein phosphatase 4 in beta cells its involvement in the induction of defects in nuclear 
lamin processing stimulated by cytokines107.  
4.1.2 PP2AC INTERACTION WITH KEY PROTEINS THAT REGULATE 
CELL DYSFUNCTION AND APOPTOSIS 
We also identified protein methyl esterase-1 as an interaction partner. As dis-
cussed earlier, PP2Ac undergoes methylation at the carboxyterminal leucine (Leu-309) 
residue. As already mentioned, PP2A activity is increased under glucotoxic conditions 
with corresponding increase in C-terminal methylation of PP2Ac68. LCMT-1/leucine 
carboxy methyl tranferase, involved in transferring methyl onto leucine -309 of PP2Ac. 
siRNA-mediated knockdown of LCMT-1 significantly decreased the carboxylmethyl-
ation of PP2Ac and hyperactivation of PP2A under high glucose/glucotoxic conditions. 
This implies that the carboxylmethylation leads to a sustained activation of PP2A89,108. 
However, potential regulatory roles of PME-1 in islet function are yet to be defined.  
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We also noted another key protein with a significant increase [~3.6 fold] in the 
interaction with PP2Ac, PPP4R1, a regulatory subunit of PP4. High levels of expression 
of protein phosphatase 4 catalytic subunit (PP4c) in the nuclear fraction is found in β-
cells107. Additionally, exposing β-cells to IL-1β, a proinflammatory cytokine, lead to a 
marked increase in nitric oxide release with a corresponding decrease in carboxyl-
methylation of PP4C. IP studies indicated a potential interaction of PP4c with nuclear 
lamin-B, a vital regulatory protein important in the nuclear envelope assembly107. 
We also identified a significant [2.3-fold] increase in the interaction between 
PP2Ac and its regulatory subunit, B55α. Yan et al presented involvement of a B55α-
containing PP2A holoenzyme in the dephosphorylation of FOXO1 in islet β-cells under 
H2O2-induced oxidative stress conditions
109. They also reported increased expression 
of B55α subunits in islets obtained from db/db mouse, a diabetic mouse kodel109. Sig-
nificant increase in the abundance of B55α subunit under hyperglycemic conditions in 
INS-1 832/13 cells has been reported recently109. 
4.2 SPECIFIC AIM 2: DETERMINE INTERACTION PARTNERS OF PP2A IN 
HUMAN SKELETAL MUSCLE UNDER BASAL AND HYPERINSULENEMIC 
CONDITIONS IN LEAN, OBESE/OVERWEIGHT NON-DIABETICS AND 
TYPE 2 DIABETIC SUBJECTS 
4.2.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE  
 Using the proteomics approach for protein-protein interactions developed in 
our laboratory78, we have identified 211 PP2Ac interaction partners in skeletal muscle 
from 8 lean, 8 overweight/obese, and 8 human participants, which represents the largest 
PP2Ac interaction network in humans to date.  Among them, 50 were known PP2Ac 
interaction partners while 161 were novel (Table 9).   
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4.2.2 KNOWN PARTNERS 
Among these 50 PP2Ac interaction partners are some regulatory and a scaffold 
subunit of PP2A. They include PPP2R1A, ‘A’ subunit alpha isoform, PPP2R2A, ‘B’ 
subunit alpha isoform, PPP2R3A, B’’ subunit alpha isoform, PPP2R5D, B’ subunit delta 
isoform, STRN, B’’’ subunit alpha isoform, and STRN3, B’’’ subunit beta isoform. It is 
also known to bind to catalytic subunit of protein phosphatase 4 (PPP4C)110. Other im-
portant known partners include PPME1 and IGBP1. PPME1 is protein methylesterase, 
which catalyzes the demethylation of PP2A on leucine309. As mentioned in the intro-
duction, regulation of PP2A through methylation is controversial. However, PPME-1 
is shown to protect PP2A from degradation61 and so does IGBP1. It is also known as 
alpha4, binds to catalytic subunit thereby stabilizing and preventing it from the degra-
dation105.  
Caveolin-1 is a scaffolding protein which is found in most cell types as a prime 
component of the caveolae plasma membranes. This protein is involved in promoting 
cell cycle progression. Protein expression of Insulin Receptor Substrate (IRS)-1 is re-
duced in caveolin knock out cells111. In addition, our lab has shown interaction of IRS1 
with CAV1 in human skeletal muscle biopsies112. It’s interaction with PP2A is also 
shown in human prostate cancer cells where cav-1 acts as a positive regulator in the 
Akt signaling pathway via inhibition of PP1 and PP2A113. Mechanism of inhibition 
involves binding of cav-1 to the catalytic subunits of both PP1 and PP2A (have a con-
sensus cav-1 binding motif). Thus, the lowered activities of PP1 and PP2A lead to in-
creased phosphorylation levels of their specific substrates like PDK1, Akt, and 
ERK1/2113.  
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Coiled-coil domain containing 6 (CCDC6) translates to a protein that is ubiqui-
tously expressed and its gene re-arrangements is seen in many malignancies114. Its in-
teraction with PP2Ac is seen in high throughput experiments as an attempt to under-
stand phosphatase interactions using human cell lines110,115. 
Protein levels are regulated in many ways. Various cell signals regulate the 
translation of proteins through mRNA. In this process of translation, proteins have to 
synthesized, folded, and localized specifically. In contrast, protein degradation can oc-
cur through proteasome machinery where unneeded/misfolded proteins are tagged with 
ubiquitin and are degraded through E1, E2, and E3 enzymes. PP2A is known to interact 
with molecules involved in these processes. Here, we identified few such proteins like 
CCCT2, CCT61, CUL-1, PSMC6, PSMD1, and USP7. CCT2 and CCT6A are chaper-
one proteins. All the proteins after translation require proper folding to achieve the ter-
tiary structure. The function of these chaperones is to correct the partially folded or 
misfolded proteins which otherwise can aggregate to form lethal complexes using ATP 
as source of energy116.  Cullin-1 protein is a core component of a E-3 Ubiquitin protein 
ligase complex, Cullin-RING ubiquitin ligases (CRLs), involved in the ubiquitination 
of proteins in cell cycle and signal transduction. It’s interaction with PP2A is seen while 
elucidating the structure of the cullin-RING ubiquitin ligase (CRL) network using hu-
man 293T cell lines117. PSMC6 and PSMD1 are subunits of a proteasome complex ma-
chinery. This machinery degrades proteins tagged with ubiquitin. Interaction of PP2A 
with PSMC6, PSMD1 and superoxide dismutase-1 is identified using high throughput 
quantitative tandem mass spectrometry93 in human HeLa S3 and HEK 293 cells. Ubiq-
uitin specific peptidase 7 (USP7) deubiquitinates proteins, including p53, FOXO4, 
MDM2, PTEN and others, thereby controlling important cellular functions such as cell 
proliferation, apoptosis, and signal transduction118. Using two-dimensional SDS-PAGE 
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analysis and other proteomics-based experiments, USP7 is shown to interact with PP2A 
along with other substrates in HeLa cells118  
Small G-protein Rac1 is known to involve in insulin signaling pathway. It is 
also shown to play a role in actin cytoskeleton remodeling and insulin-stimulated 
GLUT4 translocation in L6 myotubes119,120.  In addition, experiments on rat and human 
muscle indicated the activation of Rac1 after exercise and its role in contraction induced 
glucose uptake121. Using western blot, PP2A is shown to bind to c-terminus of Rac1 in 
cell culture models122.  
Target of rapamycin (TOR) is a serine/threonine protein kinase which belongs 
to the phosphatidylinositol kinase-related kinase family, plays key roles in cellular pro-
cesses such as proliferation and cell growth. Yeast ortholog of TOR signaling pathway 
regulator (TIPRL), Tip41 is shown to negatively regulate TOR signaling123 In an at-
tempt to study the role of TIPRL in TOR signaling, it was found that TIPRL facilitates 
TOR signaling via its association with PP2Ac in human cell lines in contrast to the 
findings in yeast123. We found TIPRL as PP2A partner in muscle. 
AMPK is a protein kinase, composed of alpha beta and gamma subunits, and is 
activated in response to altered energy levels in the cell. Higher ATP levels reduce the 
activity of AMPK. When the AMP levels rise, ATP is exchanged for AMP and activates 
AMPK. Isoforms identified here are PRKAG1 (gamma 1) and PRKAB2 (beta 2). 
PRKAG1 is ubiquitously expressed whereas PRKAB2 is found abundant in skeletal 
muscle cells. It is known to have important role in skeletal muscle insulin sensitivity124. 
In skeletal muscle, activation of AMPK will cause fatty acid and glucose oxidation. It 
also plays a role in activation of GLUT4 transporters, for uptake of glucose and in gly-
cogen metabolism125. PP2A has been shown to be able to dephosphorylate AMPK126 
Activation of AMPK is achieved by phosphorylation of AMPK at various serine and 
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threonine sites. Its binding to PP2Ac may change the phosphorylation status of this 
kinase and thereby its activation or inactivation. Since de novo AMP synthesis will 
activate AMPK, experiments were conducted using rat hepatocytes to see if altering the 
activity of enzymes involved in purine biosynthesis will improve insulin sensitivity. 
They found that abundant adenosuccinate lyase (ADSL) can lead to increased AMP 
production, thereby AMPK activation and improved insulin sensitivity127. Both ADSL 
and AMPK are found as PP2Ac interaction partners in our study. 
4.2.3 PROTEINS INVOLVED IN INSULIN RECEPTOR AND mTOR SIGNAL-
ING 
Binding of insulin to the insulin receptor on the cell membrane leads activates 
a cascade of signaling molecules. The pathways activated are PI3K-AKT signaling 
pathway and Grb2-SOS-Ras-MAPK pathway. These result in various physiological 
functions such as GLUT4 translocation to the plasma membrane, glucose uptake, gly-
cogen synthesis, and protein synthesis12,14. Here we see seven molecules associated 
with Insulin signaling pathway as PP2A interaction partners. These include AKT2, eu-
karyotic translation initiation factor 2B subunit alpha (ELF2B1), MAP2K1/MEK1, pro-
tein phosphatase 1 regulatory subunit 7, AMPK subunit gamma isoform (PRKAG1), 
protein tyrosine phosphatase, non-receptor type 11, and Ras. Akt2 isoform is found to 
be crucial for insulin action in vivo128. PP2A is shown to negatively regulate Akt2 in 
fibroblast cells129.  PP2A hyperactivation associated with insulin resistance in response 
to saturated fatty acids like ceramide is seen with an associated Akt deactivation130. 
However, experiments on liver hepatocytes in vitro and in vivo showed that PP2A ac-
tivity is essential for insulin-stimulated glycogen storage131. This is supported by our 
data where its interaction is significantly decreased in obese insulin resistant non-dia-
betic control basal and insulin stimulated biopsies when compared to lean control bas 
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and insulin stimulated biopsy respectively. Similar pattern is seen with type 2 diabetic 
group. Interaction is significantly decreased in type 2 diabetic basal and insulin stimu-
lated biopsies when compared to lean control basal and insulin stimulated biopsies re-
spectively. PP2A might play a protective role in terms of its interaction with Akt2 in a 
normal lean person while this interaction may be disrupted in cases of obese insulin 
resistance and type 2 diabetes. PTPN11, also known as SHP2, encodes a protein tyro-
sine phosphatase containing SHP binding domain. It is shown to bind with a variety of 
intermediate signaling molecules such as Grb2, p85 subunit of PI3 kinase, IRS-1, and 
Gab1 and 2. Being a protein tyrosine phosphatase, SHP-2 is believed to act by 
dephosphorylating these molecules, thereby lessening the signal132. PP2A, being a 
phosphatase itself can be regulated through phosphorylation and dephosphorylation on 
its Tyr307 site. This interaction between PTPN11 and PP2A is a novel. Further, its 
interaction is significantly decreased in obese insulin stimulated biopsy when compared 
to lean insulin stimulated biopsy. eukaryotic translation initiation factor 2B subunit al-
pha (ELF2B1), as the name indicates is involved in protein synthesis. Elf2B is regulated 
through phosphorylation. GSK3 inhibits the activity of elf2B by phosphorylating it un-
der basal conditions. Upon insulin stimulation, GSK3 is inactivated by Akt which leads 
to elf2B dephosphorylation and activation, thereby increasing protein synthesis133. 
PP2A is shown to interact with elf2B in our study. In addition, its interaction is 1) de-
creased in obese basal and insulin stimulated biopsy compared to basal and insulin 
stimulated biopsy in lean respectively, 2) decreased in type 2 diabetic basal and insulin 
stimulated biopsy when compared to obese basal and insulin stimulated biopsy respec-
tively and 3) decreased in type 2 diabetic insulin stimulated biopsy compared to lean 
insulin stimulated biopsy. PP2A is also seen to interact with regulatory subunit of pro-
tein phosphatase 1. PP1 is known to dephosphorylate and activate glycogen synthase, 
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promoting glycogen synthesis. Insulin is shown to activate PP1 in L6 rat skeletal muscle 
cells134. Its interaction with PP2A among three groups varied significantly specifically 
between type 2 diabetic, obese and obese, lean groups. Interaction is decreased in  
1) obese bas and insulin stimulated biopsy when compared to lean basal and 
insulin stimulated biopsy and 2) type 2 diabetic basal and insulin stimulated biopsy 
when compared to obese basal and insulin stimulated biopsy correspondingly. Through 
the Grb2-SOS-Ras-MAPK pathway, Insulin activates mitogen-activated protein ki-
nases (MAPK) to increase gene expression and differentiation. Activation of Insulin 
receptor and IRS proteins activates signaling cascade that promotes activation of Ras-
GDP to Ras-GTP.  Activated Ras interacts and activates a series of downstream signal-
ing molecules Raf-MEK1/2-ERK1/2. ERK is directly involved in regulating gene ex-
pression, cell proliferation or differentiation, cytoskeletal reorganization. Ras and 
MAP2K1/MEK1 are identified as PP2A interaction partners. Nevertheless, these two 
molecules did not show any significant difference among groups. 
mTOR pathway has great impact on the cell growth and metabolism. It regulates 
protein biosynthesis, lipid synthesis, mitochondrial biogenesis and metabolism. Previ-
ous reports show that PP2A is down regulated by mTOR, and degradation of IRS1 by 
mTOR is achieved through inhibition of PP2A135. Growth factors like insulin stimulate 
mTOR by increased phosphorylation of TSC2 protein by kinases like PKB, ERK1/2 
and RSK1. This TSC2 phosphorylation leads to inactivation of TSC1/2 and there by 
activation of mTOR. AMPK is activated in response to low energy levels. This acti-
vated AMPK phosphorylates and reduce the activity of TSC2 and thereby reduce 
mTOR activation136. RSK1 and AMPK regulate the mTOR pathway through phosphor-
ylation and dephosphorylation. In the present work, we detected many PP2A interaction 
partners involved in the mTORpathway. These include small G proteins Ras and Rac, 
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transcription factors elf3 and elf4A, PRKAG1 (gamma 1) and PRKAB2 (beta 2) subu-
nits of AMPK, Ribosomal protein S6 kinase alpha-1, and ribosomal protein S15A that 
regulate protein synthesis. 
4.2.4 INTERACTION PARTNERS WITH SIGNIFICANT CHANGES IN 
THEIR INTERACTION TO PP2AC IN SKELETAL MUSCLE IN LEAN, 
OVERWEIGHT/OBESE, AND TYPE 2 DIABETIC HUMAN PARTICIPANTS 
Upon insulin stimulation, in lean control group, 4 proteins showed significant 
difference which included ACO1/IRP1- Cytoplasmic aconitate hydratase, protein meth-
ylesterease-1, and PPP4R2. Aconitate hydratase is an enzyme involved in tricarboxylic 
acid cycle. Besides, it acts as an iron-sulfur protein, maintaining levels of iron inside 
the cell. PPME-1, serves two functions, demethylates PP2Ac and helps maintain levels 
of PP2A. PPP4R2 is a regulatory subunit of protein phosphatase 4. All the three pro-
teins, protein methylesterase-1, PP4 regulatory subunit, and aconitate hydratase dis-
played a decreased interaction with PP2Ac upon insulin stimulation.  
Insulin stimulation in obese control significantly changed CCDC6 and LUM. 
CCDC6 is a well-known tumor suppressor and its chromosomal re-arrangement is seen 
in thyroid papillary carcinoma. It is a known PP2Ac interaction partner identified in 
HeLa and other human cell lines110,115 using different proteomic approaches. Here, we 
saw an increased interaction of PP2Ac with CCDC6 upon insulin stimulation in 
obese/overweight insulin resistant non-diabetic group. LUM encodes for protein Lumi-
can, which belongs to the family of comparatively small leucine-rich proteoglycans. 
Proteoglycans are a major component in the extracellular matrix of many tissues. This 
is a major proteoglycan found in cornea but high levels of expression of this protein is 
found in skeletal muscle137. It binds to collagen fibrils in the tissue spaces, thus regu-
lating collagen fibril organization in addition to corneal transparency, epithelial cell 
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migration, apoptosis, tissue repair, angiogenesis and cell growth138. Interaction of lumi-
can with PP2Ac is decreased upon insulin stimulation in obese subjects. The signifi-
cance of this interactions is yet to be elucidated. 
In type 2 diabetic group, upon insulin stimulation, only one protein showed sig-
nificant change, ACOT9. Acyl-CoA thioesterase 9 is a mitochondrial protein which 
catalyzes hydrolysis of acyl-CoAs to form coenzyme A and free fatty acid. It is well 
documented that mitochondrial dysfunction and free fatty acid induce skeletal muscle 
insulin resistance139. The major pathway for oxidation of fatty acids is the mitochon-
drial fatty acid oxidation (β-oxidation), producing majority of ATP required for the 
cells where Coenzyme A (CoA) is an important co-factor140. Hence, this enzyme is one 
of the factors that regulate levels of coenzyme A. It is interesting to observe that the 
interaction of PP2Ac with ACOT9 is decreased significantly upon insulin stimulation 
given the fact that insulin decreases fatty acid oxidation in the skeletal muscle.  
4.2.5 PARTNERS WITH SIGNIFICANT CHANGE BETWEEN TYPE 2 DIA-
BETIC AND LEAN SUBJECTS 
37 proteins exhibited a significant change in type 2 diabetics compared to lean 
controls out of which seven proteins showed an increased interaction and rest with a 
decreased interaction in type 2 diabetic compared to lean. The seven proteins included 
BLVRB, CCT2, COPS2, PDE4D, ACO1/IRP1, CA1, GSTM3 which are explained in 
detail below. While CCT2, COPS2, and PDE4D are seen with a difference in both basal 
and insulin stimulated biopsies, change in BLVRB is seen only in basal and change in 
ACO1/IRP1, CA1, GSTM3 are seen in only insulin stimulated biopsies. Out of these 
37, 25 proteins showed a difference in basal biopsies and 32 in insulin stimulated biop-
sies with 20 in common. Akt2 is one among them. As discussed earlier, Akt2 is an 
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important signaling molecule in insulin signaling pathway in skeletal muscle. The de-
creased interaction of Akt2 with PP2A in T2D biopsies compared to lean is an im-
portant observation. PP2A might positively regulate Akt2 considering that decreased 
interaction is seen in type 2 diabetics where insulin signaling is impaired. Nevertheless, 
further studies are required to conclude this.  
Protein synthesis and degradation  
Here, we found many proteins involved in protein synthesis as well as is degra-
dation. STAT proteins, as mentioned above, are transcription factors that regulate pro-
tein synthesis. Transcription factors STAT3 andSTAT5 show a significant difference 
between lean and T2D. In inactive state, STAT’s exist as cytosolic proteins in an un-
phosphorylated state. Stimulation by cytokine or growth factors induce tyrosine phos-
phorylation of STATs and its translocation to the nucleus. In addition to tyrosine phos-
phorylation, all STAT’s including STAT3 and STAT5, are regulated by serine phos-
phorylation (PP2A being a serine/threonine phosphatase). This serine phosphorylation 
is facilitated by several serine/threonine kinases including, but not restricted to, ERK, 
p38, JNK, mTOR, CaMKII, IKKε, and PKCδ141. We also saw gamma subunit of cal-
cium/calmodulin-dependent protein kinase type II (CAMK2G) as PP2A interaction 
partner. It is noteworthy that both STAT proteins and CaMK-II subunit gamma showed 
a decreased interaction in type 2 diabetic (basal and insulin stimulated). These STAT 
proteins in addition to eukaryotic translation initiation factor 2B subunit al-
pha(EIF2B1), glycyl-tRNA synthetase (GARS), and C-terminal-binding protein 1 
(CTBP1) regulate protein synthesis at the transcription and translation level. All of them 
showed a decreased interaction in T2D. C-terminal-binding protein 1 is a transcriptional 
repressor involved in physiological and pathological functions like apoptosis (antago-
nist) and tumorigenesis (suppress tumor suppressor genes)142. CTBP1 dimerizes with a 
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second closely related gene, CTBP2. It is shown in human hepatic cell line that CTBP2 
over-expression improved insulin sensitivity by augmenting phosphorylation of (AKT) 
and glycogen synthase kinase 3β (GSK3β)143. It also showed to reverse the effects of 
palmitate on ROS level, gluconeogenesis, lipid accumulation, and hepatic glucose up-
take143. In other human tumor cell lines, under hypoxia conditions, overexpression of 
CtBP2 resulted in reduction of PTEN levels with corresponding increase in the levels 
of PI3K and pAkt144. Though such role in skeletal muscle is not shown, it will be inter-
esting to study the role of this protein in skeletal muscle and the function of pp2a-CtBP1 
interaction in insulin resistance and type 2 diabetes. Protein levels can also be regulated 
post-translation. In this context, we see T-complex protein 1 subunit beta (CCT2) and 
proteasome activator subunit 2(PSME2) as PP2A partners. T-complex protein 1 subunit 
beta, a chaperone protein, as mentioned earlier, corrects the partially folded or mis-
folded proteins116 showed an increased interaction in T2D whereas proteasome activa-
tor subunit 2 presented with an decreased interaction. PSME-2 is involved in the deg-
radation of proteins through ubiquitin-proteasome system.  
Protein modifications  
We also saw proteins associated with protein modifications. ADP ribosylation 
is a post translational modification, where a ADP-ribosyl group is transferred onto pro-
tein from nicotinamide adenine dinucleotide (NAD+)145. This reversible modification is 
involved in many cellular processes such as apoptosis, DNA damage repair, cell prolif-
eration, gene transcription and others. The transfer of ADP-ribosly group is aided by 
group of enzymes called ADP-ribosyl transferase145. Here, we have found arginine spe-
cific ribosyl transferase (ART3) as PP2A interaction partner, with a reduced interaction 
in T2D. Sumoylation is another post translational modification that regulates protein 
structure and intracellular localization through addition of small protein SUMO. 
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SUMO-activating enzyme subunit 2 (UBA2) is found in our study, with a decreased 
interaction in T2D. This protein forms a heterodimer with another protein SME-1 that 
acts as a SUMO-activating enzyme146. Ubiquitination is also an important PTM which 
leads to protein degradation through proteasome complex. COP9 signalosome complex 
subunit 2 (COPS2), subunit of the COP9 signalosome complex, is involved in the ubiq-
uitin-proteasome pathway through regulation of a E3ubiquitin -protein ligase complex 
family, culin-RING ubiquitin ligase (CRLs). One of CRLs include cullin-RING-based 
SCF (SKP1-CUL1-F-box protein), which mediate the ubiquitination of proteins in-
volved in cell cycle progression, signal transduction and transcription. These complexes 
require neddylation, the attachment of a ubiquitin-like NEDD8 molecule, for its func-
tion and this neddylation process is closely regulated by the COP9 signalosome147,148. 
Cullin-1 is a known interaction partner of PP2A. CUL-1 and COP9 interact with each 
other shown through various high throughput and low throughput experiments117,149-151. 
Here, we found both COP9 and CUL-1 as PP2A interactions in our study. However, 
Cullin-1 (CUL1) showed no significant difference between groups while COP9 is pre-
sented with an increased interaction in T2D. Other protein involved in protein modifi-
cation is leucine aminopeptidase (LAP3), an exopeptidase, catalyzes the hydrolysis of 
leucine residues from the amino-terminus of protein. Its interaction with PP2A is de-
creased significantly in T2D. Being an exopeptidase, changes in LAP abundance and/or 
its activation result can alter a protein activation. 
Membrane proteins 
Insulin stimulation leads to a rapid actin filament reorganization that corre-
sponds with recruitment PI 3-kinase subunits and glucose transporter proteins to regions 
of reorganized actin in culture muscle cells152-154. Initiation of these effects of insulin 
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requires an intact actin cytoskeleton and activation of PI 3-kinase152-154. It is my specu-
lation that these changes might alter the proteins involved in cell membrane organiza-
tion and also the proteins to which they are connected to in the extracellular matrix.  
Extracellular matrix is made of proteoglycans and fibrous proteins, including colla-
gen, elastin, fibronectin, and laminin155. The  extracellular matrix is linked to the cell 
via transmembrane cell adhesion proteins that connect the matrix to the cell's cytoskel-
eton155. The principal cell adhesion proteins are the integrins that act as cell surface 
receptors. Fermitin family homolog 2 (FERMT2) is scaffolding protein that enhances 
this integrin activation. While the integrins are connected to extracellular matrix 
through their extracellular domains, their intracellular domains are anchored to the actin 
filaments via intracellular anchor proteins, filamin, talin, actinin, and vinculin155. In our 
study, we saw proteins Lumican (LUM), a proteoglycan, Fermitin (FERMT2), and fil-
amin A (FLNA) as interactors of PP2A with a decreased interaction in T2D. Besides, 
Fermitin is also shown to be a key protein required for muscle differentiation156. During 
development and regeneration, for the growth of skeletal muscles, muscle precursor 
cells (or satellite cells) proliferate, known as myoblasts, and consequently differentiate 
into myofibers156. Another interesting protein involved in the actin cytoskeleton organ-
ization, cellular adhesion is the Ras GTPase-activating-like protein (IQGAP1)157.  It is 
also known to regulate MAPK and Wnt/β-catenin signaling pathways. IQGAP1 is a 
downstream effector of Rac and Cdc42, small GTPases that regulate actin assembly157. 
As mentioned above, integrin family of cell surface receptors mediate cell adhesion by 
anchoring to actin assembly. This cell adhesive function of integrins is regulated by its 
phosphorylation or dephosphorylation modulated by Ca2+/calmodulin-dependent pro-
tein kinase II (CaMK) or protein phosphatase 2A158. In human mammillary epithelial 
cells, β1 integrin is immunoprecipitated with Rac and vice versa159. Given the role of 
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IQGAP in actin assembly, further studies showed that IQGAP1 and PP2A coimmuno-
precipitated with Rac and β1 integrin159. Combining the results, formation of a quater-
nary complex that consists of IQGAP1, PP2A, Rac, and β1 integrin is possible159. Ad-
ditional experiments were conducted to show that PP2A functions by recruitment of 
IQGAP1 to Rac-β1 integrin159. Subsequently, by stimulating human mammillary epi-
thelial cells with Epidermal Growth Factor (EGF), they presented a mechanism to ex-
plain the regulation by PP2A: activated PP2A promotes IQGAP1 recruitment to β1 in-
tegrin-Rac under basal conditions but activation by a growth factor causes dissociation 
of IQGAP1 from β1 integrin-Rac through activation of CaMKII and formation of 
PP2A-IQGAP1-CaMKII complex160. EGF stimulation is thus shown to abolish the 
PP2A function160.  IQGAP1 can also directly recruit and sequentially activate B-Raf, 
Mek1/2(MAPK1/2) and Erk1/2 as a part of MAPK signaling pathway161. Its direct in-
teraction with MAP2K1 is shown162. It is also shown to interact directly with β-catenin 
under basal conditions (as part of degradation complex along with axin, GSK3, CK1α, 
and APC)  and after activation, β-catenin is rescued from degradation through IQGAP1-
PP2A-mediated dephosphorylation with its subsequent nuclear translocation and spe-
cific gene transcriptions161. It is very significant to note that we showed interaction of 
PP2A with IQGAP1, MAP2K1, Rac 1, and CAM2KG in our study. IQGAP1 is seen 
with a decreased interaction in T2D while MAP2K1, Rac1 or CAM2KG exhibited no 
significant difference.  
Other proteins 
ATP synthase subunit S (ATP5S) is one of the subunits of the catalytic core of 
ATP synthase enzyme. This enzyme catalyzes the formation of ATP from ADP in the 
mitochondria163. Experiments were conducted on human skeletal muscle comparing the 
abundance and phosphorylation of ATP synthase between basal and insulin stimulated 
52 
 
 
biopsies of lean, obese and T2D. The amount of ATP synthase in basal biopsies is found 
to be decreased in obese and T2D compared to lean. They found abnormal phosphory-
lation sites in obese and T2D164. In our study, we saw a decreased interaction of PP2Ac 
with ATP5S in type 2 diabetic insulin stimulated biopsy compared to lean insulin stim-
ulated biopsy. The interaction in basal biopsies of T2D also dampened but it’s not sig-
nificant (p=0.05). 
cAMP-specific 3,5-cyclic phosphodiesterase 4D (PDE4D), involved in hydrol-
ysis of cAMP is seen as a PP2A partner with increased interaction in T2D. PDE4D 
regulates cAMP levels in the cell which is an important second messenger that regulates 
various cellular processes. In skeletal muscle, acute cAMP signaling has been impli-
cated in regulation of muscle contraction, glycogenolysis, and sarcoplasmic calcium 
dynamics165. In adipocytes, cAMP effects lipid metabolism through cAMP dependent 
protein kinase (PKA)112. It is known that activation of cells by insulin inhibits lipolysis. 
Insulin mediates this process through activation of phosphodiesterases thereby reduc-
tion in cAMP levels and reduced PKA activity112.  
SAM domain and HD domain-containing protein 1 (SAMHD1) plays a role in 
regulation of the innate immune response, upregulated in response to viral infection and 
may be involved in mediation of tumor necrosis factor-alpha proinflammatory re-
sponses. Its interaction with PP2A is decreased in T2D. The exact role of this interac-
tion or this protein in skeletal muscle and diabetes is unknown and yet to be explored.  
4.2.6 PARTNERS WITH SIGNIFICANT CHANGE BETWEEN OBESE AND 
LEAN  
63 proteins showed a significant change in obese/overweight insulin resistant 
controls when compared with lean controls. Among these 63, 59 showed a significant 
difference between lean basal and obese basal biopsies whereas 56 proteins showed a 
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significant difference between lean insulin stimulated and obese insulin stimulated bi-
opsies with an overlap of about 50 proteins. Among these 63, only two proteins showed 
an increased interaction with PP2A while the rest showed a decrease. The two proteins 
are PDE4D and SCPEP1. The difference in PDE4D is seen in both basal and insulin 
stimulated biopsies but SCPEP1 presented with an increase only in basal biopsy.  
Protein synthesis and degradation 
Among these 50 are the proteins involved in proteasome complex machinery. 
These include proteasome 26S subunit, ATPase 2 (PSMC2), proteasome 26S subunit, 
ATPase 3 (PSMC3), proteasome 26S subunit, non-ATPase 1(PSMD1), proteasome 26S 
subunit, non-ATPase 11(PSMD11), proteasome 26S subunit, non-ATPase 
12(PSMD12), proteasome 26S subunit, non-ATPase 13(PSMD13), proteasome 26S 
subunit, non-ATPase 14(PSMD14), and proteasome activator subunit 2(PSME2). It is 
worthwile to note that the interactions of all these proteins with PP2Ac is decreased in 
obese group compared to lean (both basal and insulin stimulated biopsies).  
chaperonin containing TCP1 subunit 2(CCT2) and chaperonin containing TCP1 
subunit 6A(CCT6A) are chaperone proteins. These chaperones correct the partially 
folded or misfolded proteins using ATP as source of energy116. 
Ribosomal Protein S25 (RPS25), eukaryotic translation initiation factor 2B sub-
unit alpha(EIF2B1), eukaryotic translation initiation factor 3 subunit M (EIF3M), 
glycyl-tRNA synthetase (GARS), valyl-tRNA synthetase (VARS), and STAT3 are in-
volved in protein synthesis and their interaction with PP2Ac is decreased as well (in 
obese). STAT3 is a transcription factor which upon activation by cytokines or growth 
factors will promote transcription of appropriate genes. It was reported that phosphor-
ylated STAT3 amounts are increased by two-fold in overweight T2D compared to over-
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weight controls. STAT3 is also shown to contribute to insulin resistance in various tis-
sues like liver and smooth muscle166. In our study its interaction with PP2Ac is de-
creased in both basal and insulin stimulated biopsies of obese insulin resistant group 
when compared to the corresponding lean biopsies. 
Mitochondrial proteins 
Among these are mitochondrial proteins which include acyl-CoA dehydrogen-
ase (ACADS & ACADM), acyl-CoA thioesterase 9(ACOT9), glycyl-tRNA synthe-
tase(GARS), hydroxysteroid 17-beta dehydrogenase 8(HSD17B8), and superoxide dis-
mutase 1, soluble(SOD1). Among these Acycl dehydrogenase and hydroxysteroid 17-
beta dehydrogenase 8 are involved in fatty acid metabolism.  
Membrane proteins 
Extracellular proteins like fermitin family homolog 2 (FERMT2), filamin A 
(FLNA), and lumican (LUM) (explained in 4.2.6) also show significant change in their 
interactions. Both showed decreased interaction in obese subjects (both basal and insu-
lin stimulated biopsies). 
Other proteins 
Other important proteins that showed significant change between obese and lean 
are AKT2 (involved in insulin signaling), PPME1 (demethylation of PP2Ac), CAV1 
(caveolae plasma membrane protein), CCDC6. All these proteins are explained in 4.2.2 
and show a decreased interaction in obese.   
Arginine specific ribosyl transferase (ART3; involved in post translational mod-
ification145), leucine aminopeptidase (LAP3; an exopeptidase that catalyzes the hydrol-
ysis of leucine residues from the amino-terminus of protein), SUMO-activating enzyme 
subunit 2 (UBA2; involved in sumoylation, a  post translational modification), cAMP-
specific 3,5-cyclic phosphodiesterase 4D (PDE4D; regulates cAMP levels in the cell 
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which is an important second messenger that regulates various cellular processes). All 
these proteins are explained in detail in 4.2.5. Interaction of ART3, LAP3, and UBA2 
with PP2A is decreased in obese whereas interaction of PDE4D is increased. 
Aldo-keto reductase family 7 member A2 (AKR7A2; catalyze redox transfor-
mations of various substrates including glucose), X-ray repair cross complementing 5 
(XRCC5; involved in DNA damage repair), and dipeptidyl peptidase 9 (DPP9; post-
proline dipeptidyl peptidase that cleaves dipeptides) are seen with a decreased interac-
tion and are explained later in 4.2.7. 
PP2Ac also seems to bind to protein phosphatase 1 regulatory subunit 7 
(PPP1R7) and protein phosphatase 4 regulatory subunit 2 (PPP4R2) with a decreased 
interaction.   
4.2.7 PARTNERS WITH SIGNIFICANT CHANGE BETWEEN TYPE 2 DIA-
BETIC AND OBESE  
47 proteins presented with a significant change when type 2 diabetic group is 
compared to obese non-diabetic insulin resistant group. Among 47, 33 proteins are seen 
with a change in basal biopsies while 40 in insulin stimulated biopsies with 26 shared. 
Among these 47 proteins, only four proteins showed a decreased interaction in T2D 
while the rest presented with an increased interaction. These four include translation 
initiation factor eIF-2B subunit alpha (EIF2B1), cytosol aminopeptidase (LAP3), lumi-
can (LUM), and serine carboxypeptidase 1 (SCPEP1). While the change in interaction 
with ElF2B1 and LAP3 are seen in only basal biopsies, LUM and SCPEP1 are seen in 
both basal and insulin stimulated biopsies.   
PP2A regulatory subunit A alpha isoform (PPP2R1A) is the only PP2A subunit 
that showed significant difference among groups and it is only seen to change between 
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T2D and obese groups. Its interaction with PP2Ac is increased in type 2 diabetes sub-
jects compared to obese/overweight in basal and insulin stimulated biopsies corre-
spondingly. 
Protein degradation and synthesis  
When compared between obese and T2D, we saw some proteins involved in 
protein synthesis and degradation as PP2A partners with significant change between 
those groups. They include, proteins involved in proteasome complex machinery, pro-
teasome 26S subunit, ATPase 2 (PSMC2), proteasome 26S subunit, non-ATPase 
1(PSMD1), proteasome 26S subunit, proteasome 26S subunit, non-ATPase 
14(PSMD14). In addition to proteasome complexes, we also identified COP9 signal-
osome complex subunit 2 (COPS2), subunit of the COP9 signalosome complex, in-
volved in the ubiquitin-proteasome pathways. All of them showed an increased inter-
action in T2D. glycyl-tRNA synthetase(GARS) and valyl-tRNA synthetase (VARS) 
are involved in protein synthesis which also exhibited increased interaction in T2D.  
ATP-dependent Clp protease ATP-binding subunit (CLPX), chaperonin con-
taining TCP1 subunit 2(CCT2) and chaperonin containing TCP1 subunit 6A(CCT6A) 
are chaperone proteins. CLPX is involved in mitochondrial unfolded protein response 
( UPRmt). It identifies any unfolded proteins, utilizes cycles of ATP hydrolysis to dis-
rupt its innate structure, and translocates the unfolded protein into ClpP protease for 
irreversible proteolysis167. Experiments were conducted on in vitro muscle cells to de-
termine the role of ClpP knock down on mitochondrial function and cellular changes168. 
In addition to the reduced UPRmt, dampened mitochondrial respiration, increased pro-
duction of reactive oxygen species, and transformed mitochondrial morphology at the 
level of mitochondria besides the other changes were observed168. At the cellular level, 
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translation inhibition, impaired myoblast differentiation, and cell proliferation were de-
tected168. Since CLPX is directly associated with this protease machinery, it would be 
interesting to know the role of CLPX in the muscle. Because its association with PP2A 
in T2D is increased compared to obese, it might play a prominent role in the metabolic 
dysfunction associated with type 2 diabetes. It is also important to note that mitochon-
drial dysfunction is associated with T2D.  
Protein modifications 
Proteins involved in protein modifications are as follows: Dipeptidyl peptidase 
9(DPP9) belongs to the family of serine peptidases, dipeptidyl peptidase IV. DPP9 acts 
as a post-proline dipeptidyl peptidase that cleaves Xaa-Pro (Xaa is any amino acid 
except proline) dipeptides from the N-terminus of proteins169. It is highly expressed in 
skeletal muscle170 but its role in skeletal muscle or diabetes is unknown. It would be 
interesting to learn because DPP4 (other protein that belongs to this dipeptidyl pepti-
dase IV family) inhibitors are used to treat type 2 diabetes171. Substrates of DPP4 in-
clude glucagon-like-peptides 1 (GLP-1) and glucose-dependent insulinotropic peptide 
(GIP)13169. These two proteins promote almost 60% of postprandial insulin secre-
tion172. DPP4 inhibition thereby extends the activity of GLP and GIP with improved 
insulin secretion and blood glucose regulation. Another protein involved in protein 
modification is the serine carboxypeptidase 1(SCPEP1), that can break the peptide bond 
at c-terminal residues of proteins. SCPEP1 showed a decreased interaction with PP2Ac 
in T2D.  
Metabolic processes 
Proteins involved in various metabolic processes like pentose phosphate path-
way, polyol pathway, and anti-oxidant mechanisms are seen as PP2A partners and with 
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a change between obese and T2D. Glucose is converted to glucose-6-phosphate in gly-
colysis. This glucose-6-phosphate, undergoes pentose phosphate pathway besides citric 
acid acid cycle and electron transport chain. Pentose phosphate pathway yields NADPH 
(maintain glutathione at a reduced state) and pentoses (precursor for synthesis of DNA 
nucleotides). Transaldolase 1 (TALDO1) is an enzyme involved in this pentose phos-
phate pathway and is seen as a partner of PP2A with increased interaction in T2D. We 
saw TALDO1 as PP2A partner in beta cells as well92. 
Aldo-keto reductase family 1 member B (AKR1B1) and aldo-keto reductase 
family 7 member A2 (AKR7A2) belong to aldo-reductase family, catalyze redox trans-
formations of various substrates including glucose173. The role of AKR1B1 (aldose re-
ductase) in hyperglycemia associated injury is widely studied174-177 considering the fact 
that it catalyzes the reduction of glucose to sorbitol in a NADPH + H+ dependent man-
ner. Glucose, in addition to glycolysis is also metabolized through polyol pathway. The 
polyol pathway involves conversion to glucose to sorbitol by aldose reductase and sub-
sequent conversion to fructose by sorbitol dehydrogenase. Under hyperglycemic con-
ditions associated with diabetes, the high amounts of the glucose are converted to sor-
bitol. In some tissues like retina, nerve cells, and kidney, which lack enzyme sorbitol 
dehydrogenase, sorbitol gets accumulated. This accumulation of sorbitol is shown to be 
responsible for diabetic complications like retinopathy177, neuropathy174,176, and others. 
Though skeletal muscle has the enzyme sorbitol dehydrogenase, use of aldose reductase 
inhibitors is shown to improve contractile function in skeletal muscle of diabetic rats178. 
We are the first to show an interaction of PP2Ac with AKR1B1 and its increased inter-
action in type 2 diabetes compared to obese/overweight. We also identified this protein 
in beta cells however with no change under hyperglycemic conditions. Other aldo-keto 
reductase, AKR7A2, is a aflatoxin reductase which is mainly involved in conversion of 
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succinic semialdehyde (SSA) to γ-hydroxybutyrate (GHB)173. However, its role in skel-
etal muscle is not known.  
Oxidative damage in the cells is caused by imbalance between production of 
reactive oxygen species and the capacity of the cell to neutralize these. This antioxidant 
mechanisms include enzymes such as superoxide dismutase and glutathione S-transfer-
ase among others. Here, in our study we saw superoxide dismutase 1 (SOD1) and glu-
tathione S-transferase mu 3 (GSTM3) as PP2A partners with an increased interaction 
in T2D.  Superoxide dismutase 1 (SOD1), converts superoxide anions to hydrogen per-
oxide and oxygen, reducing reactive oxygen species in the cell. This is mainly found in 
the cytoplasm of the cell. Studies have shown that deletion of SOD1 gene in mice led 
to significant, age-dependent loss of muscle mass which was specific to skeletal mus-
cle179. These mice also presented with high amounts of oxidative damage in skeletal 
muscle, particularly in older animals179. However, knockout of SOD from only skeletal 
muscle showed no significant changes in the muscle mass or reactive oxygen species 
(ROS) production180. But, there was enhanced Akt-mTOR signaling and increased 
number of muscle fibers with centrally located nuclei in skeletal muscle, which suggests 
elevated regenerative pathways or muscle weakness180. This is important because it is 
clearly indicated that in patients with diabetes, oxidative stress (due to high glucose 
concentrations) is evident and that some complications of diabetes involve oxidative 
stress among other reasons181. Reciprocally, oxidative stress is also shown to be one of 
the causes of insulin resistance in type 2 diabetes181. Macromolecules such as molecules 
of extracellular matrix, lipoproteins and deoxyribonucleic acid are also damaged by 
free radicals in diabetes mellitus181. To counteract this damage to cell membrane pro-
teins, especially lipids, Glutathione is present in the cells. glutathione S-transferase 
functions by conjugating glutathione to detoxify these compounds182. Further studying  
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the role of these antioxidant enzymes, glutathione S-transferase mu 3 (GSTM3) and  
Superoxide dismutase 1 (SOD1) in association with PP2A in skeletal muscle might be 
significant considering their importance in diabetes.  
Other proteins 
Other proteins involved in other important cellular processes are also seen 
which are as follows: 
We saw increased interaction of PP2A with X-ray repair cross complementing 
5 (XRCC5), a 80-kilodalton subunit of the Ku heterodimer protein ( ATP-dependant 
DNA helicase II ) which is involved in DNA damage repair183.  
Interaction of Lumican (LUM), a proteoglycan (component in the extracellular 
matrix; explained in 4.2.6), is decreased in T2D. 
cAMP-specific 3,5-cyclic phosphodiesterase 4D (PDE4D), involved in hydrol-
ysis of cAMP is seen with increased interaction in T2D. PDE4D regulates cAMP lev-
els165 (explained in 4.2.6). 
4.3 SUMMARY AND FUTURE DIRECTIONS 
PP2A is one of the important serine/threonine phosphatase involved in many 
cellular functions. It’s localization and function is regulated by different ways. They 
include, binding of different regulatory B subunits, post translational modifications, and 
binding to different substrates. The activity of PP2A is altered in glucotoxic conditions 
in beta cells and it is also shown to be effected by insulin in skeletal muscle cells thus 
playing a vital role in diabetes. Considering its complex regulation and its prime role in 
diabetes, we studied the interactions of PP2A in beta islet cells and skeletal muscle, 
tissues that significantly contribute to glucose metabolism. Using high throughput pro-
teomics approach, we identified 516 interaction partners of PP2Ac in INS-1 832/13 
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beta cells and 211 interactions in human skeletal muscle biopsies. In beta cells, 89 pro-
teins showed a significant change in interaction with PP2Ac under hyperglycemic con-
ditions. Similarly, 69 proteins showed a significant difference in interacting with PP2Ac 
when compared among lean, obese/overweight and type 2 diabetic group. To be more 
precise, 63 proteins presented a significant change between obese/overweight and lean 
group, 37 proteins between type 2 diabetics and lean, and 47 proteins between type 2 
diabetic and obese group. This is the largest PP2Ac interactome till date. These inter-
actions helped us understand the role and regulation of PP2A in beta cells and skeletal 
muscle. In addition, the 37 proteins that showed a significant difference between lean 
and type 2 diabetic human skeletal muscle biopsies further advances our understanding 
of the role of PP2A in type 2 diabetes in humans. Similarly, analyzing 89 glucose stim-
ulated interactions unveiled on the function of PP2A in insulin secretion and produc-
tion. In depth analysis of the the altered interactions can provide with a target to correct 
either hyperglycemia induced beta cell death or metabolic dysfunctions in type 2 dia-
betes. 
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FIGURES
 
Figure 1. Glucose homeostasis involving major tissues12  
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Figure 2. Insulin signaling pathway showing the signaling molecules involved and 
various effects seen16 
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Figure 3. Negative regulators of insulin signaling pathway14 
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Figure 4. Insulin signaling regulation by inhibitory serine/threonine phosphoryla-
tion14  
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Figure 5. Diagrammatic representation of heterotrimeric PP2A complex 
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Figure 6.  Main steps in mass spectrometry-based proteomics studies 
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Figure 7. Cell culture, proteomics data acquisition, and data analysis 
 
 
 
 
 
 
 
 
 
 
 
INS cells, n=4 Low Glucose Vs High glucose 
4mg protein lysate 
NIgG  Co-IP & PP2Ac Co-IP 
HPLC-ESI-MS/MS 
LTQ-Orbitrap Elite 
MaxQuant: Protein identification & quantification 
Ingenuity Pathway Analysis 
1D-SDS-PAGE 
Trypsin in-gel digestion 
Proteins identified with minimum 2 unique peptides with FDR at 0.01 in at least 
one PP2Ac IP?       
(1131 proteins) 
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Figure 8. Proteomic data analysis (INS-1 832/13 CELLS) 
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Figure 9. Summary of glucose-responsive PP2Ac interaction partners. In response 
to high glucose treatment, the proteins with increased PP2Ac association are high-
lighted in red, and the ones with decreased association are highlighted in green 
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Figure 10. Experimental validation of PPP2R1B as a glucose responsive PP2Ac 
interaction partner 
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Figure 11. Clinical and proteomics data acquisition and data analysis 
 
 
 
 
Subject recruitment 
(e.g., advertisement, phone screening, scheduling, etc.) 
Comprehensive screening tests 
(e.g., OGTT, blood chemistry, BMI, ECG, etc.) 
In-patient clinical testing 
(e.g., muscle biopsies, hyperinsulinemic-euglycemic clamp) 
Muscle biopsies from lean (n=8), overweight/obese (n=8), type 
2 diabetic (n=8): Basal & 2h; 48 biopsies 
 1.5-3mg protein lysate 
NIgG Co-IP & PP2Ac Co-IP 
HPLC-ESI-MS/MS 
LTQ-Orbitrap Elite 
MaxQuant: Protein identification & quantification 
Ingenuity: Pathway & network analysis 
1D-SDS-PAGE 
Trypsin in-gel digestion 
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Figure 12. Proteomic data analysis (Human skeletal muscle) 
 
 
 
 
 
 
Proteins identified with minimum 2 unique peptides with FDR at 0.01 in at 
least one PP2Ac IP after excluding common contaminants? (2240 proteins, 
excluding PPP2CA/B)  
Identified with LFQ peak area (PA) in more than half (e.g., > 8 out of 
16) PP2Ac IP samples? 
(820 proteins, excluding PPP2CA/B) 
Enrichment ratio for each protein determined.  Enrichment ra-
tio for a protein > 10 (PP2Ac vs NIgG IP)? 
(211 proteins, PP2Ac interaction partners)  
Normalized PA for PP2Ac interaction partners determined 
P<0.01 by ANOVA? 
(69 PP2Ac interaction partners with a significant change among the 3 
groups) 
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Figure 13.  The significantly enriched pathway, Insulin Receptor signaling, for the 
211 PP2Ac interaction partners and PP2Ac in human skeletal muscle. PP2Ac in-
teraction partners were highlighted in purple; partners with increased interaction 
between groups was indicated in green; PP2A was highlighted in yellow 
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Figure 
14.  The significantly enriched pathway, mTOR signaling, for the 211 PP2Ac in-
teraction partners and PP2Ac in human skeletal muscle. PP2Ac interaction part-
ners were highlighted in purple; partners with increased interaction between 
groups was indicated in green; partners with increased interaction between one 
group set and decreased in other group set was indicated in blue; PP2A was high-
lighted in yellow 
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Figure 15. Network pathway obtained from Ingenuity Pathway Analysis. Pathway 
obtained using 70 molecules per network and the one assigned with highest score 
is taken; shows 45 interaction partners in human skeletal muscle; target protein 
PP2Ac (in yellow) and its interaction partners (in purple) 
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Figure 16A. 69 proteins PP2Ac partners in human skeletal muscle with significant 
change among different groups (color coded)  
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Figure 16B. 69 proteins PP2Ac partners in human skeletal muscle with significant 
change among different groups (color coded) 
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TABLES 
Table 1. Various isoforms of PP2A subunits, their cellular and sub-cellular distri-
bution45. HE: high expression 
Subunit Gene Iso-
form 
Other name Normal tissue 
distribution 
Subcellular 
distribution 
Scaffold (A) PPP2R1A Α PR65α, 
PP2A-Aα 
Ubiquitously ex-
pressed and 
highly expressed 
in ovary (oogene-
sis) 
Cytosol 
  PPP2R1B Β PR65β, PP2A-
Aβ 
Ubiquitously ex-
pressed and 
highly expressed 
in ovary (oogene-
sis) 
Cytosol 
Catalytic (C) PPP2CA Α PP2Acα Brain and heart 
(HE). Present in 
skeletal muscle66 
Cytoplasm 
and nucleus 
  PPP2CB Β PP2Acβ Brain and heart 
(HE) 
Cytoplasm 
and nucleus 
Regulatory 
(B) 
PPP2R2A Α PR55α, 
PP2ABα 
Widely distrib-
uted in all tissues  
Membranes, 
cytoplasm, 
microtubules 
nucleus. 
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Golgi com-
plex, endo-
plasmic retic-
ulum and 
neurofila-
ments 
  PPP2R2B Β PR55β, 
PP2ABβ 
Brain and testis 
(HE) 
Cytosol 
  PPP2R2C Γ PR55γ, 
PP2ABγ 
Brain (SE)  Mainly in 
Cytoskeletal 
fraction 
  PPP2R2D Δ PR55δ, 
PP2ABδ 
Wide spread dis-
tribution in tis-
sues, Testis (HE) 
Cytosol 
Regulatory 
(B′) 
PPP2R5A Α PR56/61α, 
PP2AB′α 
Cardiac tissues 
and skeletal mus-
cles184 (HE) 
Cytoplasm 
  PPP2R5B Β PR56/61β, 
PP2AB′β 
Brain (HE) Cytoplasm 
  PPP2R5C Γ1, 2,3 PR56/61γ, 
PP2AB′γ 
Cardiac tissues 
and skeletal mus-
cles185 (HE) 
Cytoplasm 
and nucleus 
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  PPP2R5D Δ PR56/61δ, 
PP2AB′δ 
Primarily exist in 
brain 
Cytoplasm, 
nucleus, mi-
tochondria, 
microsomes 
  PPP2R5E Ε PR56/61ε, 
PP2AB′ε 
Primarily exist in 
brain  
Cytoplasm 
Regulatory 
(B″) 
PPP2R3A Α PR130, B″α1 Brain (HE), heart, 
lung, kidney and 
muscle186 
Centrosome 
and Golgi 
complex 
  PPP2R3A Α PR72, B″α2 Heart (HE) and 
skeletal muscle186 
Cytosol and 
nucleus 
  PPP2R3B Β PR70, PR48, 
B″β 
Placenta  Nucleus 
  PPP2R3C Γ G5PR, G4-1 During develop-
mental process 
expressed in fetal 
brain 
Nucleus 
  PPP2R3D Δ PR59, B″δ Cardiac tissue, 
kidney and lungs  
Nucleus 
Regulatory 
(B″′) 
STRN   Striatin, 
PR110 
Brain  Membrane 
and cyto-
plasm 
  STRN3   SG2NA Neurons  Nucleus 
  PPP2R4   PTPA, PR53 Widely expressed Cytosol, nu-
cleus 
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Table 2. Various inhibitors of PP2A including their sources and specificity to dif-
ferent phosphatases _ENREF_4141. 
Inhibitor Source Inhibitory        potency 
Okadaic acid Dinoflagellates PP2A ∼ PP4 > PP1 ∼ 
PP5 >>> PP2B∗ 
Dinophysistoxin-1 Dinoflagellates PP2A > PP1 >>> PP2B 
Microcystins Cyanobacteria PP2A ∼ PP1 >>> PP2B 
Nodularins/Motuporin Cyanobacteria PP2A ∼ PP1 >>> PP2B 
Calyculin A Isolated from marine sponges PP2A > PP1 >>> PP2B 
Tautomycin Streptomyces spiroventricilla-
tus 
PP1 > PP2A >>> PP2B 
Cantharidin Blister beetles PP2A > PP1 >>> PP2B 
Endothall Synthetic compound PP2A > PP1 >>> PP2B 
Fostriecin Streptomyces pul-
veraceussubsp. Fostreus 
PP2A ∼ PP4∗ 
TF-23A Isolated from marine red alga PP2A 
Cytostatin Streptomyces sp. MJ654-NF4 PP2A 
I1
PP2A Cellular inhibitor PP2A 
I2
PP2A (SET, PHAP-II, 
TAF-1β) 
Cellular inhibitor PP2A 
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Table 3. Clinical characteristics for the 8 lean, 8 overweight/obese, and 8 type 2 
diabetic participants in the PP2Ac interaction partner study. Results were shown 
as mean ± SEM.   
GROUP ID Gender BMI 
at 
V2 
Age 2h 
OGTT 
M value 
mg/kgBW/mi
n  average of 
last 30 m 
HBA1
c 
Fasting 
plasma 
glucose  
(mmol/l)     
OC/OW 106PAT M 27.5 37.0 141.5 7.7 5.6 89.0 
OC/OW 237MW
S 
M 29.5 36.0 81.5 6.9 5.7 105.0 
OC/OW 281TEJ F 29.2 42.0 91.0 4.6 5.4 90.4 
OC/OW 274GRD M 26.7 40.0 141.0 4.0 5.5 90.1 
OC/OW 115D-G F 36.7 48.0 132.0 3.9 5.4 90.0 
OC/OW 199JMA F 33.1 29.0 109.5 5.5 5.2 77.8 
OC/OW 330GDS F 35.7 57.0 113.5 5.4 6.0 86.7 
OC/OW 354JMG M 32.5 47.0 111.5 8.0 5.3 108.0 
LC 217MCB M 22.7 30.0 97.7 7.4 5.4 84.4 
LC 242DDR M 24.7 28.0 128.0 9.0 4.7 87.7 
LC 341S-D M 25.0 59.0 87.8 6.6 5.6 92.4 
LC 407NJZ F 24.0 30.0 126.5 13.0 5.4 91.2 
LC 418KMN F 23.6 26.0 134.5 9.6 5.2 91.1 
LC 482D-S F 23.1 65.0 114.0 10.0 5.3 93.2 
LC 506E-J M 24.5 44.0 102.0 13.1 5.4 90.9 
LC 360JMS F 24.2 33.0 95.1 15.4 4.7 83.6 
T2D 292TJ F 25.4 59.0 NA 6.5 9.0 201.2 
T2D 423I_C M 34.8 37.0 NA 0.5 7.3 143.0 
T2D 640 YAN M 32.5 49.0 NA 3.6 6.9 134.6 
T2D 699N-M F 36.2 19.0 NA 2.5 0.0 113.6 
T2D 304-Rb F 28.0 57.0 NA 2.0 7.6 153.0 
T2D 337NMS F 32.3 41.0 NA 6.1 10.6 83.6 
T2D 359-EBK M 39.1 44.0 NA 2.0 6.4 100.6 
T2D 322BRM F 29.2 51.0 NA 5.0 6.5 165.6 
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Table 4. Clinical characteristics for the 8 lean, 8 overweight/obese, and 8 type 2 
diabetic participants in the PP2Ac interaction partner study. Results were shown 
as mean ± SEM.   
 
LC OC/OW T2D 
Gender (M/F) (4/4) (4/4) (3/5) 
Age (years) 39.3±5.32 42.0 ± 3.0 44.6±4.5 
BMI (kg/m2) 23.9±0.26(<25) 31.3 ± 1.3 (>25) 32.1±1.5 
2h OGTT Glucose 
(mg/dl) 
110.6±5.78 115.2 ± 7.8 (<140) N/A 
HBA1c (%) 5.2±0.1 5.5 ± 0.1 (<5.7) 6.7±1.0(>6.5) 
Fasting plasma glucose 
(mg/dl) 
89.3±1.20 92.1 ± 3.5 (<100) 136.8±13.3(>126) 
M-value (mg/kg/min) 10.5±1.0 5.8 ± 0.6 3.5±0.7 
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Table 5. The 516 proteins identified as interaction partners in INS-1 832/13 cells. 
Gene name Protein 
ID 
Protein 
name 
MW 
[kDa
] 
Se-
quence 
length 
Number of 
unique 
peptides 
detected in 
the PP2Ac 
IP 
Enrich-
ment ra-
tio 
Acta2 P62738 Actin, aortic 
smooth mus-
cle  
42.00
9 
377 2 Infinitea 
Actr2 Q5M7
U6 
Actin-re-
lated protein 
2  
44.73
3 
394 3 Infinite 
Actr3 F1LRA
3 
Actin-re-
lated protein 
3  
47.28
5 
418 2 Infinite 
Add3 Q62847 Gamma-ad-
ducin  
78.80
3 
705 2 Infinite 
Ahcy P10760 Adenosylho-
mocystein-
ase  
47.53
8 
432 3 Infinite 
Ahcyl2 D3ZW
L6 
Adenosylho-
mocystein-
ase  
66.49
8 
613 2 Infinite 
Aimp2 Q32PX
2 
Aminoacyl 
tRNA syn-
thase com-
plex-inter-
acting multi-
functional 
protein 2  
35.44
2 
320 3 12.2 
Aip Q5FW
Y5 
AH recep-
tor-interact-
ing protein  
37.59
8 
330 10 Infinite 
Akap10 F1LNB
3 
Protein 
Akap10  
73.77
3 
662 4 Infinite 
Akr1b1 P07943 Aldose re-
ductase  
35.79
7 
316 2 Infinite 
Aldoa G3V90
0 
Fructose-
bisphos-
phate al-
dolase  
45.08
6 
418 3 Infinite 
Amz2 F1LPX
7 
Archae-
metzincin-2  
41.70
3 
362 5 Infinite 
Ankhd1 E9PTK
9 
Protein 
Ankhd1  
269.2
6 
2540 2 Infinite 
Ankle2 Q7TP6
5 
Ankyrin re-
peat and 
LEM do-
106.4
4 
964 31 Infinite 
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main-con-
taining pro-
tein 2  
Anks1a D4AC1
2 
Ankyrin re-
peat and 
SAM do-
main con-
taining 1 
(Predicted)  
122.1 1125 16 12.4 
Anxa1 D3ZVZ
4 
Annexin  43.59
2 
385 7 Infinite 
Anxa4 P55260 Annexin A4  35.84
8 
319 2 Infinite 
Api5 B1WC4
9 
Api5 protein  56.78
4 
504 9 Infinite 
Apip D3ZUI
1 
APAF1 in-
teracting 
protein (Pre-
dicted), iso-
form CRA_a  
27.05
3 
241 8 Infinite 
Appl1 D3ZW
A8 
Protein 
Appl1  
79.36
3 
707 3 Infinite 
Arcn1 Q66H8
0 
Coatomer 
subunit delta  
57.19
9 
511 2 Infinite 
Arfip1 D3ZNX
6 
Arfaptin-1  38.32
2 
341 4 Infinite 
Arfip2 Q6AY6
5 
Arfaptin-2  37.77
2 
341 3 Infinite 
Arg1 P07824 Arginase-1  34.97
3 
323 2 Infinite 
Arhgap1 D3ZLP
8 
Protein 
Arhgap1  
54.60
6 
478 5 Infinite 
Arhgef11 D3ZZE
7 
Rho guanine 
nucleotide 
exchange 
factor 11  
173.0
4 
1565 3 Infinite 
Arhgef7 F1LNB
0 
Rho guanine 
nucleotide 
exchange 
factor 7  
97.16
5 
862 4 Infinite 
Arl6 D3ZIB
8 
Protein Arl6  21.78
6 
193 2 Infinite 
Armcx3 Q5XID
7 
Armadillo 
repeat-con-
taining X-
linked pro-
tein 3  
42.55
2 
379 3 Infinite 
Arpc4 B2RZ7
2 
Actin related 
protein 2/3 
complex, 
subunit 4 
(Predicted), 
isoform 
CRA_a  
19.66
7 
168 2 Infinite 
87 
 
 
Asap2 F1M7E
9 
Protein 
Asap2 
(Fragment)  
107.5
2 
967 2 Infinite 
Ascc3 F1LPQ
2 
Activating 
signal coin-
tegrator 1 
complex 
subunit 3  
250.2
2 
2197 3 Infinite 
Asna1 D3ZD9
8 
Protein 
Asna1  
38.99
3 
350 3 Infinite 
Atox1 Q9WU
C4 
Copper 
transport 
protein 
ATOX1  
7.292
4 
68 3 Infinite 
Atp5a1 F1LP05 ATP syn-
thase subunit 
alpha  
59.81
2 
553 4 Infinite 
Atp5b G3V6D
3 
ATP syn-
thase subunit 
beta  
56.34
4 
529 8 20.0 
Atp6v1a D4A13
3 
Protein 
Atp6v1a  
68.26
4 
617 3 Infinite 
Atp6v1h D3ZW9
6 
Protein 
Atp6v1h  
55.86
8 
483 2 Infinite 
Atxn10 Q9ER2
4 
Ataxin-10  53.72
6 
475 13 43.0 
Atxn2 F1M04
9 
Protein 
Atxn2 (Frag-
ment)  
103.9
8 
966 6 Infinite 
Bax G3V8T
9 
Apoptosis 
regulator 
BAX  
21.44
4 
192 3 Infinite 
Blmh A1A5L
1 
Bleomycin 
hydrolase  
52.45
1 
455 3 Infinite 
Btaf1 F1LW1
6 
Protein 
Btaf1 (Frag-
ment)  
207.1
2 
1848 2 Infinite 
Calm2 D4A5H
3 
Uncharac-
terized pro-
tein  
16.82
7 
149 2 Infinite 
Calr P18418 Calreticulin  47.99
5 
416 3 Infinite 
Camk1 Q63450 Calcium/cal-
modulin-de-
pendent pro-
tein kinase 
type 1  
41.63
8 
374 2 Infinite 
Camk2b F1LNI8 Calcium/cal-
modulin-de-
pendent pro-
tein kinase 
type II subu-
nit beta  
65.03
4 
589 11 Infinite 
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Cand1 P97536 Cullin-asso-
ciated 
NEDD8-dis-
sociated pro-
tein 1  
136.3
6 
1230 8 Infinite 
Cand2 G3V7E
8 
Cullin-asso-
ciated 
NEDD8-dis-
sociated pro-
tein 2  
139.7
2 
1273 6 Infinite 
Capn1 F1LS29 Calpain-1 
catalytic 
subunit  
82.09
9 
713 2 Infinite 
Capza1 F8WFI
5 
F-actin-cap-
ping protein 
subunit al-
pha-1  
33.19
7 
289 3 Infinite 
Capza2 Q3T1K
5 
F-actin-cap-
ping protein 
subunit al-
pha-2  
32.96
7 
286 2 Infinite 
Cat P04762 Catalase  59.75
6 
527 3 Infinite 
Cbr3 B2GV7
2 
Carbonyl re-
ductase 3  
30.84
1 
277 3 Infinite 
Cc2d1a F1LQC
6 
Coiled-coil 
and C2 do-
main-con-
taining pro-
tein 1A  
103.7
1 
942 3 Infinite 
Ccdc6 D4AEK
9 
Protein 
Ccdc6  
52.97
3 
470 38 Infinite 
Ccdc88a D3ZYD
7 
Protein 
Ccdc88a  
215.8
6 
1874 4 Infinite 
Ccdc88b D3ZSB
7 
Ribosomal 
protein S6 
kinase  
85.30
7 
771 3 Infinite 
Cdc14a E9PSZ
9 
Protein 
Cdc14a  
66.90
2 
597 2 226.9 
Cdc16 Q4V88
4 
CDC16 cell 
division cy-
cle 16 homo-
log (S. cere-
visiae)  
71.36 620 2 Infinite 
Cdc42bpg D3Z83
7 
Protein 
Cdc42bpg  
172.4
2 
1552 11 14.8 
Cdk2 D3ZJC
8 
Cyclin-de-
pendent ki-
nase 2  
39.03
4 
346 2 Infinite 
Cdk5 Q03114 Cyclin-de-
pendent ki-
nase 5  
33.25
4 
292 4 Infinite 
Celf1 G3V7F
9 
CUG triplet 
repeat, RNA 
55.14
2 
513 4 Infinite 
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binding pro-
tein 1, iso-
form CRA_a  
Cep290 D4A5F
2 
Protein 
Cep290  
289.6
8 
2479 2 Infinite 
Cfl1 F1M51
0 
Cofilin-1 
(Fragment)  
24.45
7 
226 8 Infinite 
Ciapin1 Q5XID
1 
Anamorsin  33.04
1 
309 4 Infinite 
Ckap5 F1M94
9 
Protein 
Ckap5 
(Fragment)  
196.8
3 
1778 24 22.8 
Ckb P07335 Creatine ki-
nase B-type  
42.72
5 
381 6 Infinite 
Cltb P08082 Clathrin 
light chain B  
25.11
7 
229 2 Infinite 
Cmpk1 Q4KM
73 
UMP-CMP 
kinase  
22.16
9 
196 3 Infinite 
Cnbp P62634 Cellular nu-
cleic acid-
binding pro-
tein  
19.46
3 
177 22 12.6 
Cndp2 Q6Q0N
1 
Cytosolic 
non-specific 
dipeptidase  
52.69
3 
475 3 Infinite 
Cnot3 D3ZXE
8 
Protein 
Cnot3  
81.88 751 2 Infinite 
Cnot4 F1MA
D6 
Protein 
Cnot4  
78.21
1 
713 3 Infinite 
Cnot6l F1M64
2 
Protein 
Cnot6l 
(Fragment)  
62.73
5 
553 4 Infinite 
Copb1 P23514 Coatomer 
subunit beta  
107.0
1 
953 3 Infinite 
Copb2 O35142 Coatomer 
subunit beta  
102.5
5 
905 2 Infinite 
Copg1 Q4AEF
8 
Coatomer 
subunit 
gamma-1  
97.61
3 
874 7 Infinite 
Cpped1 Q66H7
1 
Calcineurin-
like phos-
phoesterase 
domain-con-
taining pro-
tein 1  
35.26 312 2 Infinite 
Crip1 P63255 Cysteine-
rich protein 
1  
8.549
7 
77 3 Infinite 
Crip2 P36201 Cysteine-
rich protein 
2  
22.69
6 
208 4 Infinite 
Crkl Q5U2U
2 
Crk-like pro-
tein  
33.86
5 
303 5 Infinite 
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Csnk1a1 D3ZRE
3 
Casein ki-
nase I iso-
form alpha  
41.93
3 
365 3 Infinite 
Csrp1 P47875 Cysteine and 
glycine-rich 
protein 1  
20.61
3 
193 9 Infinite 
Csrp2 G3V9V
9 
Cysteine and 
glycine-rich 
protein 2, 
isoform 
CRA_b  
20.92
6 
193 10 31.6 
Cstb P01041 Cystatin-B  11.19
6 
98 2 Infinite 
Ctnna1 Q5U30
2 
Catenin 
(Cadherin 
associated 
protein), al-
pha 1  
100.2
4 
908 4 Infinite 
Cttnbp2 Q2IBD
4 
Cortactin 
binding pro-
tein 2  
178.7
7 
1649 7 Infinite 
Cttnbp2nl D4A8X
8 
CTTNBP2 
N-terminal 
like (Pre-
dicted), iso-
form CRA_a  
70.07
6 
638 32 Infinite 
Cwf19l1 D3Z86
3 
CWF19-like 
1, cell cycle 
control (S. 
pombe) 
(Predicted)  
60.37
7 
537 3 Infinite 
Cyld Q66H6
2 
Ubiquitin 
carboxyl-
terminal hy-
drolase 
CYLD  
106.7
1 
953 2 Infinite 
Dars P15178 Aspartate--
tRNA ligase, 
cytoplasmic  
57.12
6 
501 7 Infinite 
Dctn2 Q6AY
H5 
Dynactin 
subunit 2  
44.14
7 
402 4 Infinite 
Ddx17 E9PT29 Protein 
Ddx17  
72.82
7 
651 2 Infinite 
Ddx41 B2RYL
8 
DEAD 
(Asp-Glu-
Ala-Asp) 
box poly-
peptide 41  
69.79
8 
622 2 Infinite 
Ddx5 Q6AYI
1 
DEAD 
(Asp-Glu-
Ala-Asp) 
box poly-
peptide 5  
69.23
8 
615 6 Infinite 
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Ddx6 D3ZD7
3 
Protein 
RGD156456
0  
54.24
4 
483 6 Infinite 
Dhx38 D4A32
1 
Protein 
Dhx38  
140.5
4 
1228 23 Infinite 
Dnaja1 P63036 DnaJ homo-
log subfam-
ily A mem-
ber 1  
44.86
8 
397 8 13.7 
Dnaja2 O35824 DnaJ homo-
log subfam-
ily A mem-
ber 2  
45.76
5 
412 5 Infinite 
Dnm1 D3ZNS
3 
Dynamin-1  97.49
7 
866 2 Infinite 
Dstn Q7M0E
3 
Destrin  18.53
3 
165 10 Infinite 
Dtd1 B0K01
4 
Dtd1 protein  23.39
4 
209 2 Infinite 
Dync1h1 P38650 Cytoplasmic 
dynein 1 
heavy chain 
1  
532.2
5 
4644 3 Infinite 
Dync1li2 Q62698 Cytoplasmic 
dynein 1 
light inter-
mediate 
chain 2  
54.74
4 
497 3 Infinite 
Dynlrb1 P62628 Dynein light 
chain road-
block-type 1  
10.99 96 2 Infinite 
Dyrk1a Q63470 Dual speci-
ficity tyro-
sine-phos-
phorylation-
regulated ki-
nase 1A  
85.54 763 2 Infinite 
Edc4 Q3ZAV
8 
Enhancer of 
mRNA-
decapping 
protein 4  
152.5
9 
1407 10 Infinite 
Eea1 F1LUA
1 
Protein Eea1 
(Fragment)  
161.1 1411 20 Infinite 
Eef1a2 P62632 Elongation 
factor 1-al-
pha 2  
50.45
4 
463 5 56.5 
Eftud2 F1LM6
6 
Protein Ef-
tud2  
109.4
8 
972 2 Infinite 
Eif2b1 Q64270 Translation 
initiation 
factor eIF-
2B subunit 
alpha  
33.67
8 
305 2 Infinite 
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Eif2b4 Q63186 Translation 
initiation 
factor eIF-
2B subunit 
delta  
57.80
9 
524 3 Infinite 
Eif2c2 Q9QZ8
1 
Protein argo-
naute-2  
97.31
7 
860 5 Infinite 
Eif3d Q6AY
K8 
Eukaryotic 
translation 
initiation 
factor 3 sub-
unit D  
63.98
8 
548 2 Infinite 
Eif3g Q5RK0
9 
Eukaryotic 
translation 
initiation 
factor 3 sub-
unit G  
35.65
1 
320 5 Infinite 
Eif4g1 D3ZU1
3 
Protein 
Eif4g1  
175.7 1598 4 Infinite 
Eif5a Q3T1J1 Eukaryotic 
translation 
initiation 
factor 5A-1  
16.83
2 
154 4 Infinite 
Eif6 Q3KR
D8 
Eukaryotic 
translation 
initiation 
factor 6  
26.57
1 
245 2 Infinite 
Erlin2 B5DEH
2 
Erlin-2  37.71 339 2 Infinite 
Erp29 G8JLQ
4 
Endoplas-
mic reticu-
lum resident 
protein 29 
(Fragment)  
28.67
4 
261 2 Infinite 
Ewsr1 F1MA6
0 
Protein 
Ewsr1  
68.74
2 
661 3 Infinite 
Exoc2 F1LMB
9 
Uncharac-
terized pro-
tein  
104.0
2 
924 2 Infinite 
Exoc3 Q62825 Exocyst 
complex 
component 3  
86.49
6 
755 2 Infinite 
Exoc6 O54923 Exocyst 
complex 
component 6  
93.17
7 
804 2 Infinite 
Fahd1 F1M7U
1 
Acylpy-
ruvase 
FAHD1, mi-
tochondrial 
(Fragment)  
24.58
1 
222 2 Infinite 
Fam40a G3V8E
2 
Protein 
Fam40a  
95.60
9 
837 26 Infinite 
Fam83h D3ZRK
0 
Protein 
Fam83h  
131.1
6 
1209 2 Infinite 
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Fam98a Q5FW
T1 
Protein 
FAM98A  
55.07 515 2 Infinite 
Fblim1 D3Z8E
7 
Filamin 
binding LIM 
protein 1, 
isoform 
CRA_a  
41.47
9 
376 5 Infinite 
Fbxl15 D4ABB
4 
F-box/LRR-
repeat pro-
tein 15  
33.17
9 
300 2 Infinite 
Fbxo7 Q68FS
3 
F-box only 
protein 7  
57.56 522 2 Infinite 
Fgfr1op Q4V7C
1 
FGFR1 on-
cogene part-
ner  
43.01
1 
399 3 Infinite 
Fgfr1op2 Q6TA2
5 
FGFR1 on-
cogene part-
ner 2 homo-
log  
29.37
4 
253 11 Infinite 
Fhdc1 D3ZL8
3 
Protein 
Fhdc1  
125.6 1148 3 Infinite 
Fhl2 O35115 Four and a 
half LIM do-
mains pro-
tein 2  
32.08
6 
279 6 Infinite 
Filip1 Q8K4T
4 
Filamin-A-
interacting 
protein 1  
137.7
5 
1212 11 Infinite 
Flna C0JPT7 Filamin al-
pha  
280.4
9 
2639 16 Infinite 
Fn3krp B2RYN
1 
Fructosa-
mine-3-ki-
nase-related 
protein  
34.16
9 
309 10 61.5 
Fubp3 G3V82
9 
Protein 
Fubp3  
61.43
6 
569 6 Infinite 
Fus Q5PQK
2 
Fusion, de-
rived from 
t(12;16) ma-
lignant lipo-
sarcoma 
(Human)  
52.67
3 
518 2 Infinite 
Fxr1 Q5XI81 Fragile X 
mental retar-
dation syn-
drome-re-
lated protein 
1  
63.94
7 
568 2 Infinite 
Fxr2 F1M3Y
6 
Protein Fxr2 
(Fragment)  
70.64
5 
654 24 42.6 
Fzd7 D4AD
M3 
Protein Fzd7  48.67
7 
434 2 Infinite 
Ganab D4A0
W9 
Protein Ga-
nab  
106.9 944 4 Infinite 
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Gapvd1 D4A02
2 
Protein 
Gapvd1  
162.7
6 
1463 3 Infinite 
Gart G3V91
8 
Phosphori-
bosyl-
glycinamide 
formyltrans-
ferase, iso-
form CRA_a  
107.5
8 
1010 2 Infinite 
Gbf1 F1M8X
9 
Protein Gbf1 
(Fragment)  
200.3
7 
1807 6 11.9 
Gcn1l1 F1LRI5 Protein 
Gcn1l1 
(Fragment)  
293.1
7 
2672 45 356.3 
Gemin5 D3ZGD
0 
Uncharac-
terized pro-
tein  
167.1 1501 3 Infinite 
Gfpt1 D3ZZH
8 
Glucosa-
mine--fruc-
tose-6-phos-
phate ami-
notransfer-
ase [isomer-
izing] 1  
78.91
8 
699 6 15.4 
Gga1 F1LPF4 Protein 
Gga1  
70.00
8 
635 2 Infinite 
Gga2 G3V8F
7 
Golgi asso-
ciated, 
gamma 
adaptin ear 
containing, 
ARF binding 
protein 2, 
isoform 
66.21
4 
604 5 Infinite 
Git1 Q9Z27
2 
ARF 
GTPase-ac-
tivating pro-
tein GIT1  
85.23 770 5 Infinite 
Glod4 Q5I0D1 Glyoxalase 
domain-con-
taining pro-
tein 4  
33.26
7 
298 4 Infinite 
Gmds Q3MH
S7 
GDP-man-
nose 4, 6-de-
hydratase  
42.09
4 
372 4 Infinite 
Gmps F1LS80 GMP syn-
thase [gluta-
mine-hydro-
lyzing]  
77.76
2 
699 3 Infinite 
Golga1 D4A6K
4 
Golgi auto-
antigen, gol-
gin subfam-
ily a, 1 (Pre-
dicted)  
87.38
4 
758 2 Infinite 
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Gpd1 O35077 Glycerol-3-
phosphate 
dehydrogen-
ase 
[NAD(+)], 
cytoplasmic  
37.45
2 
349 6 Infinite 
Gprasp2 D4A54
2 
Protein 
Gprasp2  
92.93
6 
827 3 Infinite 
Gpsm1 G3V8F
6 
G-protein 
signalling 
modulator 1 
(AGS3-like, 
C. elegans), 
isoform 
CRA_b  
78.23
5 
705 2 Infinite 
Gsdma D4A2V
1 
Protein 
Gsdma  
50.78
7 
454 3 Infinite 
Gsn F8WFK
3 
Gelsolin  86.28
5 
781 2 Infinite 
Gstz1 P57113 Maleylaceto
acetate iso-
merase  
23.96
1 
216 4 Infinite 
Hadha Q64428 Trifunc-
tional en-
zyme subu-
nit alpha, 
mitochon-
drial  
82.66
4 
763 2 Infinite 
Hal P21213 Histidine 
ammonia-ly-
ase  
72.28
3 
657 5 Infinite 
Hcn1 Q9JKB
0 
Potas-
sium/sodium 
hyperpolari-
zation-acti-
vated cyclic 
nucleotide-
gated chan-
nel 1 
102.4
2 
910 2 Infinite 
Hist1h1c P15865 Histone 
H1.4  
21.98
7 
219 4 Infinite 
Hist1h2ail D3ZJ08 Histone H3  15.38
8 
136 2 Infinite 
Hist2h2aa3 P02262 Histone 
H2A type 1  
14.07
7 
130 4 Infinite 
Hmmr D4A2
M9 
Hyaluronan 
mediated 
motility re-
ceptor 
(RHAMM) 
82.93
5 
715 3 Infinite 
Hnrnpa2b1 A7VJC
2 
Heterogene-
ous nuclear 
37.47
7 
353 8 Infinite 
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ribonucleo-
proteins 
A2/B1  
Hnrnpf Q794E
4 
Heterogene-
ous nuclear 
ribonucleo-
protein F  
45.72
9 
415 2 Infinite 
Hnrnpl F1LPP9 Protein 
Hnrnpl  
67.90
2 
623 2 Infinite 
Hnrnpul2 D4ABT
8 
Protein 
Hnrnpul2  
84.85
8 
745 2 Infinite 
Hspa4l B4F772 Heat shock 
70 kDa pro-
tein 4L  
94.22 838 5 Infinite 
Hspb1 G3V91
3 
Heat shock 
27kDa pro-
tein 1  
22.80
7 
206 2 Infinite 
Hsph1 Q66HA
8 
Heat shock 
protein 105 
kDa  
96.41
7 
858 8 Infinite 
Ica1 Q63054 Islet cell au-
toantigen 1  
54.66
2 
480 2 Infinite 
Ide P35559 Insulin-de-
grading en-
zyme  
117.7
1 
1019 4 Infinite 
Idh3B Q68FX
0 
Isocitrate de-
hydrogenase 
[NAD] sub-
unit beta, 
mitochon-
drial  
42.35
3 
385 2 Infinite 
Igbp1 O08836 Immuno-
globulin-
binding pro-
tein 1  
39.13
5 
340 22 Infinite 
Ilf3 F1LNJ4 Interleukin 
enhancer-
binding fac-
tor 3  
98.07
9 
915 4 Infinite 
Ilk Q99J82 Integrin-
linked pro-
tein kinase  
51.37
3 
452 3 Infinite 
Ints10 E9PTE
0 
Protein 
Ints10  
82.13
5 
710 12 Infinite 
Ints12 Q68FR
3 
Integrator 
complex 
subunit 12  
48.47
7 
461 5 Infinite 
Ints3 D3ZUT
9 
Protein Ints3  117.8
9 
1041 18 Infinite 
Ints4 D3ZZQ
6 
Protein Ints4  108.2
5 
964 17 21.6 
Ints5 D3ZT
W1 
Protein Ints5  108.4 1019 9 Infinite 
97 
 
 
Ints7 D4ADS
6 
Protein Ints7  106.9
1 
967 20 Infinite 
Ipo4 D3ZQZ
8 
Protein Ipo4  90.52
7 
817 2 Infinite 
Irf2bpl Q5EIC
4 
Interferon 
regulatory 
factor 2-
binding pro-
tein-like  
81.49
5 
783 6 Infinite 
Itpk1 D3ZQ
M7 
Protein Itpk1  46.20
4 
421 2 Infinite 
Kab D3ZET
9 
Protein Kab  174.9
9 
1588 4 Infinite 
Kalrn P97924
-4 
Isoform 4 of 
Kalirin  
337.5
7 
2968 2 Infinite 
Kti12 Q5I0L7 Protein 
KTI12 hom-
olog  
38.35
7 
350 2 Infinite 
Lancl1 Q9QX6
9 
LanC-like 
protein 1  
45.23
9 
399 2 Infinite 
Larp1 F1M06
2 
Protein 
Larp1 (Frag-
ment)  
116.2
1 
1024 7 Infinite 
Lgals2 Q9Z14
4 
Galectin-2  14.73
2 
130 2 Infinite 
Lig1 Q9JHY
8 
DNA ligase 
1  
102.4
8 
918 14 48.3 
Limch1 F1M39
2 
Protein 
Limch1 
(Fragment)  
110.1
1 
979 3 Infinite 
Limd1 B5DEH
0 
LIM do-
main-con-
taining pro-
tein 1  
71.39
2 
663 3 Infinite 
Limk1 G3V66
3 
LIM motif-
containing 
protein ki-
nase 1, iso-
form CRA_a  
72.60
7 
647 4 Infinite 
Lin7c Q792I0 Protein lin-7 
homolog C  
21.83
4 
197 2 Infinite 
Lmna P48679 Prelamin-
A/C  
74.32
3 
665 28 16.2 
LOC100359593 Q6PD
W1 
40S riboso-
mal protein 
S12  
14.51
5 
132 7 Infinite 
LOC100359636 D3ZRV
7 
Protein 
LOC100359
636  
12.49 110 4 Infinite 
LOC100360491 D3ZR
M9 
60S riboso-
mal protein 
L13  
24.20
2 
211 9 Infinite 
LOC100360722 F1LW3
3 
Protein 
LOC100360
29.71
6 
270 2 Infinite 
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722 (Frag-
ment)  
LOC100361025 D3Z9I6 Heterogene-
ous nuclear 
ribonucleo-
proteins me-
thyltransfer-
ase-like 2 
42.43
5 
371 2 Infinite 
LOC100361517 D3ZIU
2 
Protein 
RGD130559
3  
13.34
6 
122 2 Infinite 
LOC100361915 F1M4I4 Uncharac-
terized pro-
tein (Frag-
ment)  
73.37
6 
663 2 Infinite 
LOC100362366 D3ZFA
8 
Protein 
LOC100364
909  
15.46
8 
135 12 Infinite 
LOC100362464 F1LR6
5 
Cold shock 
domain-con-
taining pro-
tein E1  
88.88
2 
798 4 Infinite 
LOC100364240 D4A0X
3 
Lysophos-
phatidylcho-
line acyl-
transferase 
2B  
103.5
9 
967 3 Infinite 
LOC100365869 G3V6
W6 
Protein 
LOC100365
869  
45.79
6 
403 2 Infinite 
LOC100365889 F1M8D
7 
Protein 
LOC100365
889 (Frag-
ment)  
90.00
3 
806 2 Infinite 
LOC100365889 D3ZIT7 Protein 
LOC100365
889  
83.78
4 
750 14 Infinite 
LOC500726 D4A1G
8 
Uncharac-
terized pro-
tein  
171.6
9 
1575 11 Infinite 
LOC681718 F1MA2
9 
Protein 
LOC681718  
24.90
8 
215 3 Infinite 
LOC686548 D3ZE6
3 
Protein 
LOC679748  
12.60
5 
115 2 Infinite 
LOC687994 D3ZC8
2 
Protein 
LOC687994  
75.43
5 
689 12 16.9 
LOC688393 D3ZK
M5 
Protein 
LOC688393  
41.56
3 
373 2 Infinite 
LOC689899 D3ZTH
8 
Uncharac-
terized pro-
tein  
17.75
3 
156 4 Infinite 
LOC690416 D3ZQ6
2 
Uncharac-
terized pro-
tein  
65.58
7 
600 2 Infinite 
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LOC690728 D4ABT
1 
Protein 
LOC690728  
82.79
5 
732 8 Infinite 
Lpin1 Q5XIM
8 
Lipin 1  101.9 924 5 Infinite 
Lpp F1LSB
9 
Lipoma-pre-
ferred part-
ner homolog  
68.38
9 
633 4 Infinite 
Lsm12 D4A8G
0 
Protein 
Lsm12  
21.70
1 
195 6 Infinite 
Maged2 Q3B7U
1 
Melanoma 
antigen, 
family D, 2  
65.75
3 
618 3 Infinite 
Map1s P0C5W
1 
Microtu-
bule-associ-
ated protein 
1S  
102.8 972 3 Infinite 
Map2k2 F1LMI
4 
Dual-speci-
ficity mito-
gen-acti-
vated protein 
kinase ki-
nase 2  
44.38 401 3 Infinite 
Map3k7 P0C8E
4 
Mitogen-ac-
tivated pro-
tein kinase 
kinase ki-
nase 7  
67.19
9 
606 2 Infinite 
Map3k7ip1 D4A6C
6 
Protein 
Map3k7ip1  
54.6 502 3 Infinite 
Map7 F1MA8
2 
Protein 
Map7 (Frag-
ment)  
80.41 713 5 Infinite 
Mapk1 P63086 Mitogen-ac-
tivated pro-
tein kinase 1  
41.27
5 
358 4 Infinite 
Mapk3 P21708
-2 
Isoform 2 of 
Mitogen-ac-
tivated pro-
tein kinase 3  
45.76
9 
406 4 Infinite 
Mark2 D3ZZQ
3 
Serine/thre-
onine-pro-
tein kinase 
MARK2  
85.77
9 
773 3 Infinite 
Mark3 F1M83
6 
Uncharac-
terized pro-
tein  
88.72 797 2 Infinite 
Mast1 Q810W
7 
Microtu-
bule-associ-
ated ser-
ine/threo-
nine-protein 
kinase 1  
171.0
3 
1570 3 Infinite 
Mat2a P18298 S-adenosyl-
methionine 
43.71
5 
395 6 Infinite 
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synthase iso-
form type-2  
Mb21d2 D4ACS
3 
Protein 
RGD155964
3  
55.76
1 
491 7 Infinite 
Mbnl2 F2Z3T4 Muscle-
blind-like 
protein 2  
40.15
6 
373 6 Infinite 
Mcm7 Q6AY
N8 
Minichro-
mosome 
maintenance 
deficient 7 
(S. cere-
visiae)  
81.06
2 
719 2 Infinite 
Mcmbp B1H26
8 
Mini-chro-
mosome 
maintenance 
complex-
binding pro-
tein  
73.00
6 
642 6 Infinite 
Mdh2 P04636 Malate de-
hydrogen-
ase, mito-
chondrial  
35.68
3 
338 2 Infinite 
Memo1 Q4QQ
R9 
Protein 
MEMO1  
33.67
9 
297 2 Infinite 
Metap1 D3ZE7
2 
Methionine 
aminopepti-
dase  
43.20
5 
386 5 Infinite 
Mettl11a Q5BJX
0 
N-terminal 
Xaa-Pro-Lys 
N-methyl-
transferase 1  
25.46
4 
223 2 Infinite 
Micall2 D3ZEN
0 
Protein Mi-
call2  
107.7
9 
1003 17 Infinite 
Mob4 Q9QY
W3 
MOB-like 
protein pho-
cein  
26.03
2 
225 11 Infinite 
Mobkl1a D4A1V
7 
MOB1, Mps 
One Binder 
kinase acti-
vator-like 
1A (Yeast) 
(Predicted)  
25.09
1 
216 3 Infinite 
Mpo D4A85
6 
Protein Mpo  80.88
2 
718 4 Infinite 
Mrpl35 D3ZE1
0 
Mitochon-
drial riboso-
mal protein 
L35 (Pre-
dicted), iso-
form CRA_a  
21.47
9 
188 2 Infinite 
Msh2 B1WB
Q7 
DNA mis-
match repair 
104.1
5 
933 3 Infinite 
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protein 
Msh2  
Msn F1LP60 Uncharac-
terized pro-
tein (Frag-
ment)  
67.65
1 
576 6 Infinite 
Mt3 P37361 Metallothi-
onein-3  
6.809 66 2 Infinite 
Mtpn P62775 Myotrophin  12.86
1 
118 2 Infinite 
Mvp F1LM4
1 
Uncharac-
terized pro-
tein (Frag-
ment)  
96.69
2 
870 4 Infinite 
Myh10 F1LQ0
2 
Myosin-10  233.6
1 
2013 4 Infinite 
Myh14 F1LMN
2 
Protein 
Myh14  
232.2
4 
2032 6 Infinite 
Myl6 B2GV9
9 
Myl6 protein  17.01
3 
152 6 Infinite 
Myo18a D3ZR0
7 
Protein 
Myo18a  
234.3
6 
2064 2 Infinite 
NA Q66H5
8 
UPF0464 
protein 
C15orf44 
homolog  
57.14
3 
515 3 Infinite 
NA Q5U2Q
3 
Ester hydro-
lase 
C11orf54 
homolog  
34.99
3 
315 2 Infinite 
NA Q5I034 Uncharac-
terized pro-
tein 
C12orf43 
homolog  
30.05
6 
277 6 Infinite 
NA Q497C
3 
UPF0585 
protein 
C16orf13 
homolog  
22.61
2 
204 3 Infinite 
NA P56571 ES1 protein 
homolog, 
mitochon-
drial  
28.17
2 
266 2 Infinite 
NA F1MA
A3 
Uncharac-
terized pro-
tein  
69.31
1 
596 11 Infinite 
NA F1M7S
9 
Uncharac-
terized pro-
tein  
1409 12659 3 Infinite 
NA F1M3H
8 
Uncharac-
terized pro-
tein (Frag-
ment)  
20.32
9 
194 2 Infinite 
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NA F1M2
M4 
Uncharac-
terized pro-
tein (Frag-
ment)  
32.17
9 
285 2 Infinite 
NA F1M1H
0 
Protein Dera 
(Fragment)  
34.05
4 
308 3 Infinite 
NA F1LZD
9 
Uncharac-
terized pro-
tein (Frag-
ment)  
37.66
7 
354 2 Infinite 
NA F1LXS
1 
Uncharac-
terized pro-
tein (Frag-
ment)  
205.0
2 
1849 12 Infinite 
NA F1LTJ4 Uncharac-
terized pro-
tein (Frag-
ment)  
29.42
7 
267 4 Infinite 
NA F1LNQ
9 
Uncharac-
terized pro-
tein  
168.9 1536 5 Infinite 
NA D4AE7
3 
Uncharac-
terized pro-
tein  
116.0
7 
1036 2 Infinite 
NA D4AC
H3 
Uncharac-
terized pro-
tein  
30.62
4 
282 3 Infinite 
NA D4ABC
4 
Uncharac-
terized pro-
tein  
92.43
6 
820 34 Infinite 
NA D3ZKL
0 
Uncharac-
terized pro-
tein  
14.3 133 3 Infinite 
NA D3ZIL8 Uncharac-
terized pro-
tein  
14.72
3 
134 2 Infinite 
NA D3ZFF
2 
Uncharac-
terized pro-
tein  
99.53
1 
883 19 Infinite 
NA B0BNA
9 
UPF0760 
protein 
C2orf29 
homolog  
54.83
5 
504 2 Infinite 
Naa50 F1M8I2 Protein 
Nat13 (Frag-
ment)  
19.46 169 4 Infinite 
Nampt Q80Z2
9 
Nicotina-
mide phos-
phoribosyl-
transferase  
55.43
7 
491 3 Infinite 
Nans B1WC2
6 
N-
acetylneu-
raminic acid 
synthase  
40.05
1 
359 2 Infinite 
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Nap1l4 D3ZE2
3 
Uncharac-
terized pro-
tein  
47.30
3 
421 3 Infinite 
Nav2 F1LR1
2 
Protein 
Nav2 (Frag-
ment)  
252.5
1 
2342 4 Infinite 
Ncbp1 Q56A2
7 
Nuclear cap-
binding pro-
tein subunit 
1  
91.91 790 4 Infinite 
Nccrp1 D3ZQ1
8 
Protein 
Nccrp1  
33.00
4 
291 3 Infinite 
Ncoa1 D4AD
D6 
Protein 
Ncoa1  
156.4
3 
1443 4 15.1 
Ncor1 F1LSA
0 
Nuclear re-
ceptor core-
pressor 1  
271.1
9 
2456 2 Infinite 
Ndel1 Q78PB
6 
Nuclear dis-
tribution 
protein 
nudE-like 1  
38.36
5 
345 2 Infinite 
Nme2 P19804 Nucleoside 
diphosphate 
kinase B  
17.28
3 
152 3 Infinite 
Nploc4 Q9ES5
4 
Nuclear pro-
tein localiza-
tion protein 
4 homolog  
68.05
5 
608 4 Infinite 
Npm3 D3ZYK
9 
Protein 
Npm3  
18.91
7 
173 2 Infinite 
Ntpcr D4A47
8 
Protein 
RGD130619
2  
20.81
3 
192 2 Infinite 
Nudt10 D3ZYH
3 
Protein 
Nudt11  
18.59
3 
164 2 Infinite 
Nudt5 Q6AY6
3 
ADP-sugar 
pyrophos-
phatase  
24.11
7 
219 2 Infinite 
Nup93 Q66HC
5 
Nuclear pore 
complex 
protein 
Nup93  
93.30
1 
819 2 Infinite 
Otud4 F1M7Q
7 
Protein 
Otud4  
122.8
5 
1106 2 Infinite 
P4hb P04785 Protein di-
sulfide-iso-
merase  
56.95
1 
509 4 Infinite 
Pabpc4 G3V9N
0 
Protein 
Pabpc4  
72.41
1 
660 6 20.8 
Patl1 B5DF9
3 
Protein 
PAT1 homo-
log 1  
86.86
8 
770 2 Infinite 
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Pdcd10 Q6NX6
5 
Programmed 
cell death 
protein 10  
24.35
5 
210 2 Infinite 
Pdia6 Q63081 Protein di-
sulfide-iso-
merase A6  
48.17
3 
440 3 Infinite 
Pfkfb2 Q9JJH5 6-phos-
phofructo-2-
kinase/fruc-
tose-2,6-
bisphospha-
tase 2  
64.15
5 
557 5 Infinite 
Pfkl P30835 6-phos-
phofructoki-
nase, liver 
type  
85.33
8 
780 2 Infinite 
Pfkm Q52KS
1 
6-phos-
phofructoki-
nase  
85.34
2 
780 11 Infinite 
Pfkp P47860 6-phos-
phofructoki-
nase type C  
85.71
9 
788 4 Infinite 
Pgk1 P16617 Phospho-
glycerate ki-
nase 1  
44.53
8 
417 4 Infinite 
Phf5a P83871 PHD finger-
like domain-
containing 
protein 5A  
12.40
5 
110 3 Infinite 
Pias1 F1LTZ
9 
Protein 
Pias1 (Frag-
ment)  
71.63
8 
651 2 Infinite 
Pick1 Q6GQ
Q2 
PRKCA-
binding pro-
tein  
46.70
5 
416 3 14.0 
Pklr P12928
-2 
Isoform L-
type of Py-
ruvate ki-
nase iso-
zymes R/L  
58.79
3 
543 17 Infinite 
Pla2g6 P97570
-2 
Isoform 
Short of 
85/88 kDa 
calcium-in-
dependent 
phospho-
lipase A2  
83.56
1 
752 16 Infinite 
Plec D4A32
3 
Uncharac-
terized pro-
tein  
534.3
7 
4692 26 Infinite 
Plekha1 D3Z8M
0 
Protein 
Plekha1  
39.70
5 
357 3 Infinite 
Pola1 F1LRJ6 DNA poly-
merase  
166.8
5 
1464 3 Infinite 
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Pold1 G3V8
M1 
DNA poly-
merase  
123.5
7 
1103 6 Infinite 
Polr2a D4A5A
6 
DNA-di-
rected RNA 
polymerase  
217.2 1970 22 Infinite 
Polr2b G3V8Y
5 
DNA-di-
rected RNA 
polymerase  
133.9 1174 9 Infinite 
Polr2c D4A8A
8 
Protein 
Polr2c  
37.62
2 
330 3 Infinite 
Polr2e B0BNE
2 
DNA-di-
rected RNA 
polymerases 
I, II, and III 
subunit 
RPABC1  
24.57 210 4 Infinite 
Polr2h G3V67
8 
Protein 
Polr2h  
17.14
3 
150 3 Infinite 
Ppat P35433 Amidophos-
phoribosyl-
transferase  
57.43
6 
517 2 Infinite 
Ppfia1 D3ZXH
0 
Protein 
Ppfia1  
142.6
5 
1266 2 Infinite 
Ppm1b Q99ND
8 
Ppm1b pro-
tein  
51.00
9 
465 2 Infinite 
Ppm1h Q5M82
1 
Protein 
phosphatase 
1H  
56.37
9 
513 5 Infinite 
Ppme1 Q4FZT
2 
Protein 
phosphatase 
methylester-
ase 1  
42.31
6 
386 25 Infinite 
Ppp1r12a F1LMS
2 
Protein 
phosphatase 
1 regulatory 
subunit 12A  
114.6
7 
1032 2 Infinite 
Ppp2ca P63331 Serine/thre-
onine-pro-
tein phos-
phatase 2A 
catalytic 
subunit α 
isoform  
35.60
8 
309 6 Infinite 
Ppp2cb P62716 Serine/thre-
onine-pro-
tein phos-
phatase 2A 
catalytic 
subunit β 
isoform  
35.57
5 
309 4 Infinite 
Ppp2r1a Q5XI34 Protein 
Ppp2r1a  
65.32
2 
589 46 176.7 
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Ppp2r1b D4A1Y
3 
Serine/thre-
onine-pro-
tein phos-
phatase 2A 
65 kDa regu-
latory subu-
nit A beta 
isoform 
76.10
4 
694 23 Infinite 
Ppp2r2a P36876 Serine/thre-
onine-pro-
tein phos-
phatase 2A 
55 kDa regu-
latory subu-
nit B alpha 
isoform 
51.67
7 
447 13 Infinite 
Ppp2r2d P56932 Serine/thre-
onine-pro-
tein phos-
phatase 2A 
55 kDa regu-
latory subu-
nit B delta 
isoform 
51.98
2 
453 14 Infinite 
Ppp2r3a D3ZLD
7 
Protein 
Ppp2r3a  
129.9 1150 4 Infinite 
Ppp2r5c D4A1A
5 
Protein 
Ppp2r5c  
59.90
9 
514 5 Infinite 
Ppp3ca F1LR8
5 
Serine/thre-
onine-pro-
tein phos-
phatase  
58.53 521 5 Infinite 
Ppp4c G3V8
M5 
Serine/thre-
onine-pro-
tein phos-
phatase  
35.08 307 22 Infinite 
Ppp4r1 Q8VI02 Serine/thre-
onine-pro-
tein phos-
phatase 4 
regulatory 
subunit 1  
105.6
1 
951 12 Infinite 
Ppp4r2 D4A8H
5 
Protein 
Ppp4r2  
46.27
1 
416 3 Infinite 
Ppp6c Q64620 Serine/thre-
onine-pro-
tein phos-
phatase 6 
catalytic 
subunit  
35.15
9 
305 2 Infinite 
Prkaa1 P54645 5-AMP-acti-
vated protein 
63.97
3 
559 4 Infinite 
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kinase cata-
lytic subunit 
alpha-1  
Prph P21807 Peripherin  53.54
9 
468 5 Infinite 
Prps1 P60892 Ribose-
phosphate 
pyrophos-
phokinase 1  
34.83
4 
318 2 Infinite 
Prrc2a Q6MG
48 
Protein 
PRRC2A  
229.0
4 
2161 16 68.2 
Psma2 P17220 Proteasome 
subunit al-
pha type-2  
25.92
6 
234 3 Infinite 
Psma3 P18422 Proteasome 
subunit al-
pha type-3  
28.41
9 
255 2 Infinite 
Psma4 P21670 Proteasome 
subunit al-
pha type-4  
29.49
7 
261 2 Infinite 
Psmb1 P18421 Proteasome 
subunit beta 
type-1  
26.47
9 
240 4 Infinite 
Psmc2 G3V7L
6 
26S protease 
regulatory 
subunit 7  
48.63
3 
433 5 Infinite 
Psmc3 D3ZF9
4 
26S protease 
regulatory 
subunit 6A  
50.34
1 
451 2 Infinite 
Psmd12 Q5XIC
6 
Proteasome 
(Prosome, 
macropain) 
26S subunit, 
non-
ATPase, 12  
52.93
6 
456 5 29.7 
Psmd13 B0BN9
3 
26S pro-
teasome 
non-ATPase 
regulatory 
subunit 13  
42.81
7 
376 2 Infinite 
Psmd14 F1LM
W6 
Protein 
Psmd14 
(Fragment)  
32.92
4 
294 2 Infinite 
Psmd6 Q6PCT
9 
Proteasome 
(Prosome, 
macropain) 
26S subunit, 
non-
ATPase, 6  
45.59
8 
389 2 Infinite 
Psmg1 D4AA
H6 
Down syn-
drome criti-
cal region 
homolog 2 
(Human) 
33.23
8 
289 3 Infinite 
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(Predicted), 
isoform 
CRA_b  
Psmg2 D3ZAQ
4 
Protein 
Psmg2  
29.65
3 
264 3 Infinite 
Rab10 P35281 Ras-related 
protein Rab-
10  
22.85
8 
200 2 Infinite 
Rab1b G3V6H
0 
RCG48149, 
isoform 
CRA_b  
22.17
7 
201 8 37.0 
Rab22a B0BN1
9 
Protein 
Rab22a  
21.77
5 
194 2 Infinite 
Rab2a F1LP82 Ras-related 
protein Rab-
2A  
23.51
7 
212 4 Infinite 
Rab3c P62824 Ras-related 
protein Rab-
3C  
25.87
2 
227 3 Infinite 
Rab3gap2 F1LMT
8 
Rab3 
GTPase-ac-
tivating pro-
tein non-cat-
alytic subu-
nit  
154.0
8 
1386 3 Infinite 
Rab43 Q53B9
0 
Ras-related 
protein Rab-
43  
23.22
9 
210 2 Infinite 
Rab4a D4ADS
8 
Ras-related 
protein Rab-
4A  
23.96
2 
214 2 Infinite 
Rab5c D4AB
V4 
Protein 
Rab5c  
25.17
8 
232 4 Infinite 
Rac1 D4AD
X3 
Ras-related 
C3 botuli-
num toxin 
substrate 1, 
isoform 
CRA_b  
23.43
6 
211 4 Infinite 
Racgap1 B2GV0
2 
Protein Rac-
gap1  
69.91
9 
626 2 Infinite 
Rassf6 Q4QR8
2 
Ras associa-
tion domain-
containing 
protein 6  
39.79
3 
341 2 Infinite 
Rbbp4 B5DFB
2 
Protein 
Rbbp4  
47.65
5 
425 3 Infinite 
Rbm4 E9PTZ
4 
Protein 
Rbm4  
69.37
3 
667 2 Infinite 
Rem2 Q9WT
Y2 
GTP-bind-
ing protein 
REM 2  
37.27
4 
341 2 13.5 
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RGD1304694 F1LN8
2 
Protein 
RGD130469
4 (Fragment)  
48.67
5 
430 3 Infinite 
RGD1305547_pre-
dicted 
G3V6G
2 
Similar to 
RIKEN 
cDNA 
2810417D0
8 (Predicted)  
133.5
4 
1198 6 Infinite 
RGD1306215 G3V7Z
0 
Protein 
RGD130621
5  
22.08
7 
205 2 Infinite 
RGD1306487 F1LP59 Uncharac-
terized pro-
tein (Frag-
ment)  
95.95
7 
860 3 Infinite 
RGD1310592 D3ZLQ
6 
Protein 
RGD131059
2  
112.4
8 
994 5 Infinite 
RGD1560341 F1LRI8 Methionine 
aminopepti-
dase  
52.97
8 
479 2 Infinite 
RGD1560501 D3ZU8
0 
Ribosomal 
protein L15  
24.17
6 
204 2 Infinite 
RGD1562502 G3V6C
3 
Protein 
RGD156250
2  
22.42
3 
198 2 Infinite 
RGD1562601 D3ZLH
3 
Protein 
RGD156260
1  
18.76
6 
160 2 Infinite 
RGD1564370 F1M2Q
3 
Protein 
RGD156437
0 (Fragment)  
30.23
3 
270 2 Infinite 
Rgl2 Q6MG
C5 
Protein Rgl2  83.72
6 
778 3 Infinite 
Rhoa P61589 Transform-
ing protein 
RhoA  
21.78
2 
193 2 Infinite 
Ric8a B1H24
1 
Resistance 
to inhibitors 
of cholines-
terase 8 
homolog A 
(C. elegans)  
59.82
6 
530 2 Infinite 
Rlc-a P13832 Myosin reg-
ulatory light 
chain RLC-
A  
19.89
5 
172 2 Infinite 
Rnf20 D3ZYQ
9 
Protein 
Rnf20  
113.4
6 
973 6 Infinite 
Rpl10a P62907 60S riboso-
mal protein 
L10a  
24.83
1 
217 8 Infinite 
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Rpl12 F8WF
W0 
Protein 
LOC685320 
(Fragment)  
20.91 191 3 Infinite 
Rpl13a P35427 60S riboso-
mal protein 
L13a  
23.47
6 
203 2 Infinite 
Rpl18a F1LQL
3 
60S riboso-
mal protein 
L18a (Frag-
ment)  
22.31
9 
191 5 Infinite 
Rpl19 P84100 60S riboso-
mal protein 
L19  
23.46
6 
196 8 16.3 
Rpl26 G3V6I9 60S riboso-
mal protein 
L26  
17.25
8 
145 5 Infinite 
Rpl27 P61354 60S riboso-
mal protein 
L27  
15.79
8 
136 3 Infinite 
Rpl30 P62890 60S riboso-
mal protein 
L30  
12.78
4 
115 4 Infinite 
Rpl37a-ps1 F1LNS
9 
60S riboso-
mal protein 
L37a  
10.33
5 
92 2 Infinite 
Rpl38 P63174 60S riboso-
mal protein 
L38  
8.217
8 
70 3 Infinite 
Rpl4 P50878 60S riboso-
mal protein 
L4  
47.25
6 
421 8 Infinite 
Rpl6 F1LQS
3 
60S riboso-
mal protein 
L6  
33.54
5 
298 2 Infinite 
Rpl9 P17077 60S riboso-
mal protein 
L9  
21.89
3 
192 5 Infinite 
Rplp1 P19944 60S acidic 
ribosomal 
protein P1  
11.49
8 
114 2 Infinite 
Rprd1a D4AA
U4 
Protein 
Rprd1a  
35.73 312 3 10.4 
Rps10 P63326 40S riboso-
mal protein 
S10  
18.91
6 
165 6 Infinite 
Rps15 P62845 40S riboso-
mal protein 
S15  
17.04 145 4 Infinite 
Rps15a P62246 40S riboso-
mal protein 
S15a  
14.83
9 
130 9 Infinite 
Rps19 P17074 40S riboso-
mal protein 
S19  
16.08
5 
145 11 Infinite 
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Rps2 P27952 40S riboso-
mal protein 
S2  
31.23
1 
293 6 Infinite 
Rps21 P05765 40S riboso-
mal protein 
S21  
9.127
2 
83 4 Infinite 
Rps25 P62853 40S riboso-
mal protein 
S25  
13.74
2 
125 5 Infinite 
Rps28 P62859 40S riboso-
mal protein 
S28  
7.840
9 
69 4 Infinite 
Rps5 B0BN8
1 
Ribosomal 
protein S5, 
isoform 
CRA_b  
22.90
6 
204 6 Infinite 
Rps6 P62755 40S riboso-
mal protein 
S6  
28.68 249 3 Infinite 
Rps7 P62083 40S riboso-
mal protein 
S7  
22.12
7 
194 6 30.6 
Rps9 P29314 40S riboso-
mal protein 
S9  
22.59
1 
194 5 Infinite 
Rtcd1 Q68FS
8 
Protein 
Rtcd1  
39.31
3 
366 2 Infinite 
Rufy1 F1LR4
2 
Protein 
Rufy1  
80.37
6 
711 6 Infinite 
Ruvbl2 G3V8T
5 
Protein 
Ruvbl2  
51.11
2 
463 5 Infinite 
S100a11 Q6B34
5 
Protein 
S100-A11  
11.06
5 
98 2 Infinite 
Saps3-ps1 F1MA
H5 
Uncharac-
terized pro-
tein  
94.67
7 
844 2 Infinite 
Scg2 G3V7X
2 
Secre-
togranin 2, 
isoform 
CRA_a  
71 619 2 Infinite 
Scyl2 D4A1Y
0 
Protein 
Scyl2  
103.3
6 
930 9 Infinite 
Serpinb13 D3ZKA
0 
Protein Ser-
pinb13  
44.24
9 
389 3 Infinite 
Serpinb6 Q6P9U
0 
Protein Ser-
pinb6a  
43.01
8 
379 2 Infinite 
Sf1 F1LSC
3 
Protein Sf1  70.14
9 
653 3 Infinite 
Sf3a1 D3ZQ
M0 
Protein 
Sf3a1  
88.58
7 
791 5 Infinite 
Sf3b1 G3V7T
6 
Protein 
Sf3b1  
145.8
3 
1304 6 Infinite 
Sf3b2 D3ZJX
7 
Protein 
Sf3b2  
98.35
9 
878 6 Infinite 
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Sf3b3 E9PT66 Protein 
Sf3b3  
102.6
2 
920 6 53.4 
Sh3bp1 D3ZFJ3 Protein 
Sh3bp1  
74.85
1 
689 4 Infinite 
Sh3glb1 D4A8Q
6 
Endophilin-
B1  
43.17 386 2 Infinite 
Sike1 Q5FW
T9 
Suppressor 
of IKBKE 1  
23.57
8 
207 12 Infinite 
Sirt5 Q68FX
9 
NAD-de-
pendent pro-
tein deacyl-
ase sirtuin-5, 
mitochon-
drial  
34.09
8 
310 2 Infinite 
Slc25a5 Q09073 ADP/ATP 
translocase 2  
32.90
1 
298 3 Infinite 
Slc9a3r1 Q9JJ19 Na(+)/H(+) 
exchange 
regulatory 
cofactor 
NHE-RF1  
38.83 356 5 Infinite 
Slmap F1LM8
5 
Sarcolem-
mal mem-
brane-asso-
ciated pro-
tein  
98.23
8 
858 7 Infinite 
Smc2 D4AB5
7 
Structural 
maintenance 
of chromo-
somes pro-
tein  
139.1 1230 4 Infinite 
Smc3 P97690 Structural 
maintenance 
of chromo-
somes pro-
tein 3  
138.4
5 
1191 7 Infinite 
Smek2 D3ZCR
4 
Protein 
Smek2  
93.96
9 
820 27 Infinite 
Sorbs2 F1LPM
3 
Sorbin and 
SH3 do-
main-con-
taining pro-
tein 2  
134.0
7 
1196 5 12.4 
Spast D4A0I3 Uncharac-
terized pro-
tein  
66.77
2 
613 3 Infinite 
Spata5 D4A6T
1 
Protein 
Spata5  
91.16
1 
838 2 Infinite 
Sphkap F1LNS
0 
A-kinase an-
chor protein 
SPHKAP  
187.0
9 
1708 5 Infinite 
Srp72 D4A7R
0 
Protein 
Srp72  
75.00
2 
671 2 Infinite 
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Srr Q76EQ
0 
Serine race-
mase  
35.69
3 
333 4 Infinite 
Stat6 Q1KQ0
7 
Protein Stat6  93.86
8 
841 2 Infinite 
Stmn2 D3ZW7
3 
Stathmin-2  23.33
4 
204 2 Infinite 
Strap Q5XIG
8 
Serine-thre-
onine kinase 
receptor-as-
sociated pro-
tein  
38.45
6 
350 4 Infinite 
Strn G3V6L
8 
RCG61894, 
isoform 
CRA_a  
86.14 780 28 Infinite 
Strn4 F1M6V
8 
Protein 
Strn4  
81.43
6 
759 23 Infinite 
Svil D3ZEZ
9 
Uncharac-
terized pro-
tein  
241.9
4 
2167 3 Infinite 
Synj1 F1LPS0 Synap-
tojanin-1  
172.8
7 
1574 3 Infinite 
Taf9 Q5BKE
0 
Transcrip-
tion initia-
tion factor 
TFIID subu-
nit 9  
28.99
4 
264 4 Infinite 
Taldo1 Q9EQS
0 
Transal-
dolase  
37.46 337 5 Infinite 
Tbc1d1 D4AC1
6 
Protein 
Tbc1d1  
142.3
3 
1257 5 Infinite 
Tbc1d9b F1LRL
4 
Protein 
Tbc1d9b 
(Fragment)  
137.6
2 
1224 4 Infinite 
Tbk1 D4A7D
3 
Protein Tbk1  83.38
7 
729 6 Infinite 
Tbl1x G3V6G
5 
Protein 
Tbl1x  
56.80
2 
527 5 Infinite 
Tceb1 P83941 Transcrip-
tion elonga-
tion factor B 
polypeptide 
1  
12.47
3 
112 9 Infinite 
Tcf25 D3ZC4
6 
Protein 
Tcf25  
76.80
4 
677 3 Infinite 
Tes Q2LAP
6 
Testin  47.63
2 
419 11 Infinite 
Tf F1LMP
2 
Serotrans-
ferrin (Frag-
ment)  
107.4
1 
979 2 Infinite 
Tfip11 Q5U2Y
6 
Tuftelin-in-
teracting 
protein 11  
96.15
1 
837 2 Infinite 
Tgm1 P23606 Protein-glu-
tamine 
90.76
9 
824 4 Infinite 
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gamma-glu-
tamyltrans-
ferase K  
Tgm2 Q9WVJ
6 
Protein 
Tgm2  
76.93
4 
686 8 Infinite 
Thop1 P24155 Thimet oli-
gopeptidase  
78.38
5 
687 3 Infinite 
Tkt G3V82
6 
Transketo-
lase, isoform 
CRA_a  
71.15
8 
655 5 Infinite 
Tmed10 Q63584 Transmem-
brane emp24 
domain-con-
taining pro-
tein 10  
24.85
7 
219 2 Infinite 
Tnpo3 D4AA
M0 
Protein 
Tnpo3  
104.8
6 
929 2 Infinite 
Tpd52l1 Q499Q
2 
Protein 
Tpd52l1  
18.34
8 
163 3 Infinite 
Tpm3 Q63610 Tropomyo-
sin alpha-3 
chain  
29.00
6 
248 7 Infinite 
Tpm4 P09495 Tropomyo-
sin alpha-4 
chain  
28.50
9 
248 3 Infinite 
Trappc3 Q5U1Z
2 
Trafficking 
protein parti-
cle complex 
subunit 3  
20.30
2 
180 3 Infinite 
Trim3 G3V8D
6 
Tripartite 
motif protein 
3, isoform 
CRA_a  
80.76 744 6 51.5 
Trim33 D3ZUK
4 
Protein 
Trim33  
124.1
3 
1144 2 Infinite 
Trip11 D4AB
D7 
Protein 
Trip11  
226.0
6 
1976 3 Infinite 
Tsg101 F1LRB
7 
Tumor sus-
ceptibility 
gene 101 
protein  
44.24
2 
391 3 Infinite 
Tsn E9PT79 Protein Tsn  31.47
3 
278 3 Infinite 
Ttc9c Q6P5P
3 
Tetratrico-
peptide re-
peat protein 
9C  
20.06
7 
171 2 Infinite 
Tubb2a P85108 Tubulin 
beta-2A 
chain  
49.90
6 
445 6 Infinite 
Tubb3 Q4QRB
4 
Tubulin 
beta-3 chain  
50.41
8 
450 8 255.6 
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Tubgcp2 B2RYP
8 
A disintegrin 
and metallo-
protease do-
main 8 (Pre-
dicted), iso-
form CRA_b  
103.0
6 
905 3 Infinite 
Txnrd1 O89049 Thioredoxin 
reductase 1, 
cytoplasmic  
54.68
8 
499 11 Infinite 
Uba5 Q5M7
A4 
Ubiquitin-
like modi-
fier-activat-
ing enzyme 
5  
44.89
5 
403 2 Infinite 
Uba52 P62986 Ubiquitin-
60S riboso-
mal protein 
L40  
14.72
8 
128 4 Infinite 
Ube2c D3ZU
W6 
Protein 
Ube2c  
19.67
9 
179 2 Infinite 
Ubr1 D3ZQC
6 
Protein Ubr1  199.7
6 
1756 4 Infinite 
Ubxn1 Q499N
6 
UBX do-
main-con-
taining pro-
tein 1  
33.58
1 
297 3 Infinite 
Uggt1 Q9JLA
3 
UDP-glu-
cose:glyco-
protein glu-
cosyltrans-
ferase 1  
176.4
3 
1551 2 Infinite 
Umps Q4QQS
7 
Protein 
Umps  
52.37
8 
481 7 Infinite 
Usp14 Q5U2N
2 
Ubiquitin 
carboxyl-
terminal hy-
drolase  
55.97
6 
493 3 Infinite 
Vat1 Q3MIE
4 
Synaptic 
vesicle 
membrane 
protein 
VAT-1 hom-
olog  
43.11
8 
404 4 Infinite 
Vcpip1 Q8CF9
7 
Deubiqui-
tinating pro-
tein 
VCIP135  
134.5
6 
1221 4 Infinite 
Vdac1 Q9Z2L
0 
Voltage-de-
pendent an-
ion-selective 
channel pro-
tein 1  
30.75
5 
283 2 Infinite 
Vgll4 Q5BJP
0 
Protein 
Vgll4  
31.02 287 4 Infinite 
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Vps13a D3Z8N
6 
Protein 
Vps13a  
360.0
5 
3167 19 Infinite 
Vps37a Q4V79
4 
Protein 
Vps37a  
44.48
7 
398 2 Infinite 
Vps52 O55166 Vacuolar 
protein sort-
ing-associ-
ated protein 
52 homolog  
82.10
2 
723 4 Infinite 
Vps53 D3ZPE
5 
Protein 
Vps53  
94.42
8 
832 2 Infinite 
Vwa5b2 D4A7U
5 
Protein 
Vwa5b2  
133.3 1248 4 Infinite 
Wdr37 D3ZLR
5 
Protein 
Wdr37  
53.9 492 2 Infinite 
Wdr5 Q498M
4 
WD repeat-
containing 
protein 5  
36.58
8 
334 3 Infinite 
Wdr81 D4A92
9 
WD repeat-
containing 
protein 81  
212.2
6 
1933 7 Infinite 
Wdr91 B2RYI
0 
WD repeat-
containing 
protein 91  
83.14
5 
747 10 Infinite 
Xpo5 D3ZQE
8 
Protein 
Xpo5  
136.8
8 
1204 2 Infinite 
Xpot D3ZSC
0 
Protein Xpot  109.6
8 
963 2 Infinite 
Yars G3V71
3 
Tyrosine--
tRNA ligase, 
cytoplasmic  
63.02
5 
564 3 Infinite 
Ybx2 D4A3P
0 
Protein 
Ybx2  
38.09
4 
359 4 Infinite 
Zc3h14 Q7TM
D5 
Zinc finger 
CCCH do-
main-con-
taining pro-
tein 14  
82.63
1 
736 2 Infinite 
Zfand5 B5DF1
1 
AN1-type 
zinc finger 
protein 5  
23.08
8 
213 6 Infinite 
Zfp655 Q5RK
G8 
Protein 
Znf655  
63.59
9 
541 2 Infinite 
Zyg11b F1M8P
2 
Protein 
Zyg11b 
(Fragment)  
83.80
4 
743 5 Infinite 
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Table 6. 89 Glucose responsive interaction partners in INS-1 832/13 cells. 
Gene name Protein 
ID 
Protein name MW 
[kDa] 
Se-
quence 
length 
Num-
ber of 
uniqu
e pep-
tides 
de-
tected 
in the 
PP2A
c IP 
Enrich-
ment ra-
tio 
Apip D3ZUI1 APAF1 inter-
acting protein 
(Predicted), 
isoform 
CRA_a  
27.05
3 
241 8 Infinitea 
Appl1 D3ZWA
8 
Protein Appl1  79.36
3 
707 3 Infinite 
Arpc4 B2RZ72 Actin related 
protein 2/3 
complex, sub-
unit 4 (Pre-
dicted), iso-
form CRA_a  
19.66
7 
168 2 Infinite 
Cbr3 B2GV72 Carbonyl re-
ductase 3  
30.84
1 
277 3 Infinite 
Cc2d1a F1LQC6 Coiled-coil 
and C2 do-
main-contain-
ing protein 1A  
103.7
1 
942 3 Infinite 
Ciapin1 Q5XID1 Anamorsin  33.04
1 
309 4 Infinite 
Cnbp P62634 Cellular nu-
cleic acid-
binding pro-
tein  
19.46
3 
177 22 12.6 
Cnot4 F1MAD
6 
Protein Cnot4  78.21
1 
713 3 Infinite 
Csrp1 P47875 Cysteine and 
glycine-rich 
protein 1  
20.61
3 
193 9 Infinite 
Cttnbp2 Q2IBD4 Cortactin 
binding pro-
tein 2  
178.7
7 
1649 7 Infinite 
Dctn2 Q6AYH
5 
Dynactin sub-
unit 2  
44.14
7 
402 4 Infinite 
Ddx17 E9PT29 Protein Ddx17  72.82
7 
651 2 Infinite 
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Eea1 F1LUA1 Protein Eea1 
(Fragment)  
161.1 1411 20 Infinite 
Eif2b1 Q64270 Translation in-
itiation factor 
eIF-2B subunit 
alpha  
33.67
8 
305 2 Infinite 
Eif2c2 Q9QZ81 Protein argo-
naute-2  
97.31
7 
860 5 Infinite 
Fhl2 O35115 Four and a half 
LIM domains 
protein 2  
32.08
6 
279 6 Infinite 
Filip1 Q8K4T4 Filamin-A-in-
teracting pro-
tein 1  
137.7
5 
1212 11 Infinite 
Gfpt1 D3ZZH8 Glucosamine--
fructose-6-
phosphate 
aminotransfer-
ase [isomeriz-
ing] 1  
78.91
8 
699 6 15.4 
Gga2 G3V8F7 Golgi associ-
ated, gamma 
adaptin ear 
containing, 
ARF binding 
protein 2, iso-
form 
66.21
4 
604 5 Infinite 
Gmds Q3MHS
7 
GDP-mannose 
4, 6-dehydra-
tase  
42.09
4 
372 4 Infinite 
Gmps F1LS80 GMP synthase 
[glutamine-hy-
drolyzing]  
77.76
2 
699 3 Infinite 
Gpd1 O35077 Glycerol-3-
phosphate de-
hydrogenase 
[NAD(+)], cy-
toplasmic  
37.45
2 
349 6 Infinite 
Gprasp2 D4A542 Protein 
Gprasp2  
92.93
6 
827 3 Infinite 
Hist1h1c P15865 Histone H1.4  21.98
7 
219 4 Infinite 
Hmmr D4A2M
9 
Hyaluronan 
mediated mo-
tility receptor 
(RHAMM) 
82.93
5 
715 3 Infinite 
Hnrnpf Q794E4 Heterogeneous 
nuclear ribo-
nucleoprotein 
F  
45.72
9 
415 2 Infinite 
119 
 
 
Ilf3 F1LNJ4 Interleukin en-
hancer-bind-
ing factor 3  
98.07
9 
915 4 Infinite 
Ints12 Q68FR3 Integrator 
complex subu-
nit 12  
48.47
7 
461 5 Infinite 
Ints5 D3ZTW
1 
Protein Ints5  108.4 1019 9 Infinite 
Ints7 D4ADS
6 
Protein Ints7  106.9
1 
967 20 Infinite 
Itpk1 D3ZQM
7 
Protein Itpk1  46.20
4 
421 2 Infinite 
Kalrn P97924-
4 
Isoform 4 of 
Kalirin  
337.5
7 
2968 2 Infinite 
Lig1 Q9JHY8 DNA ligase 1  102.4
8 
918 14 48.3 
Limd1 B5DEH
0 
LIM domain-
containing 
protein 1  
71.39
2 
663 3 Infinite 
Limk1 G3V663 LIM motif-
containing 
protein kinase 
1, isoform 
CRA_a  
72.60
7 
647 4 Infinite 
LOC10036424
0 
D4A0X3 Lysophospha-
tidylcholine 
acyltransferase 
2B  
103.5
9 
967 3 Infinite 
LOC10036588
9 
D3ZIT7 Protein 
LOC10036588
9  
83.78
4 
750 14 Infinite 
Lpin1 Q5XIM8 Lipin 1  101.9 924 5 Infinite 
Lsm12 D4A8G0 Protein Lsm12  21.70
1 
195 6 Infinite 
Map7 F1MA82 Protein Map7 
(Fragment)  
80.41 713 5 Infinite 
Mcmbp B1H268 Mini-chromo-
some mainte-
nance com-
plex-binding 
protein  
73.00
6 
642 6 Infinite 
Mettl11a Q5BJX0 N-terminal 
Xaa-Pro-Lys 
N-methyl-
transferase 1  
25.46
4 
223 2 Infinite 
Micall2 D3ZEN0 Protein Mi-
call2  
107.7
9 
1003 17 Infinite 
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Mrpl35 D3ZE10 Mitochondrial 
ribosomal pro-
tein L35 (Pre-
dicted), iso-
form CRA_a  
21.47
9 
188 2 Infinite 
NA D3ZFF2 Uncharacter-
ized protein  
99.53
1 
883 19 Infinite 
NA F1LTJ4 Uncharacter-
ized protein 
(Fragment)  
29.42
7 
267 4 Infinite 
NA F1LZD9 Uncharacter-
ized protein 
(Fragment)  
37.66
7 
354 2 Infinite 
Naa50 F1M8I2 Protein Nat13 
(Fragment)  
19.46 169 4 Infinite 
Nav2 F1LR12 Protein Nav2 
(Fragment)  
252.5
1 
2342 4 Infinite 
Ncor1 F1LSA0 Nuclear recep-
tor corepressor 
1  
271.1
9 
2456 2 Infinite 
Ntpcr D4A478 Protein 
RGD1306192  
20.81
3 
192 2 Infinite 
Nudt10 D3ZYH
3 
Protein 
Nudt11  
18.59
3 
164 2 Infinite 
Pfkfb2 Q9JJH5 6-phos-
phofructo-2-
kinase/fruc-
tose-2,6-
bisphospha-
tase 2  
64.15
5 
557 5 Infinite 
Phf5a P83871 PHD finger-
like domain-
containing 
protein 5A  
12.40
5 
110 3 Infinite 
Pla2g6 P97570-
2 
Isoform Short 
of 85/88 kDa 
calcium-inde-
pendent phos-
pholipase A2  
83.56
1 
752 16 Infinite 
Pold1 G3V8M
1 
DNA poly-
merase  
123.5
7 
1103 6 Infinite 
Ppat P35433 Amidophos-
phoribosyl-
transferase  
57.43
6 
517 2 Infinite 
Ppm1b Q99ND8 Ppm1b protein  51.00
9 
465 2 Infinite 
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Ppp2r1b D4A1Y3 Serine/threo-
nine-protein 
phosphatase 
2A 65 kDa 
regulatory 
subunit A beta 
isoform 
76.10
4 
694 23 Infinite 
Ppp2r2a P36876 Serine/threo-
nine-protein 
phosphatase 
2A 55 kDa 
regulatory 
subunit B al-
pha isoform 
51.67
7 
447 13 Infinite 
Ppp4r1 Q8VI02 Serine/threo-
nine-protein 
phosphatase 4 
regulatory 
subunit 1  
105.6
1 
951 12 Infinite 
Ppp6c Q64620 Serine/threo-
nine-protein 
phosphatase 6 
catalytic subu-
nit  
35.15
9 
305 2 Infinite 
Prph P21807 Peripherin  53.54
9 
468 5 Infinite 
Rab10 P35281 Ras-related 
protein Rab-10  
22.85
8 
200 2 Infinite 
Rab5c D4ABV
4 
Protein Rab5c  25.17
8 
232 4 Infinite 
Rhoa P61589 Transforming 
protein RhoA  
21.78
2 
193 2 Infinite 
Rpl18a F1LQL3 60S ribosomal 
protein L18a 
(Fragment)  
22.31
9 
191 5 Infinite 
Rpl30 P62890 60S ribosomal 
protein L30  
12.78
4 
115 4 Infinite 
Rpl4 P50878 60S ribosomal 
protein L4  
47.25
6 
421 8 Infinite 
Rpl9 P17077 60S ribosomal 
protein L9  
21.89
3 
192 5 Infinite 
Scyl2 D4A1Y0 Protein Scyl2  103.3
6 
930 9 Infinite 
Serpinb6 Q6P9U0 Protein Ser-
pinb6a  
43.01
8 
379 2 Infinite 
Sh3bp1 D3ZFJ3 Protein 
Sh3bp1  
74.85
1 
689 4 Infinite 
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Slmap F1LM85 Sarcolemmal 
membrane-as-
sociated pro-
tein  
98.23
8 
858 7 Infinite 
Sorbs2 F1LPM3 Sorbin and 
SH3 domain-
containing 
protein 2  
134.0
7 
1196 5 12.4 
Srp72 D4A7R0 Protein Srp72  75.00
2 
671 2 Infinite 
Stat6 Q1KQ07 Protein Stat6  93.86
8 
841 2 Infinite 
Tceb1 P83941 Transcription 
elongation fac-
tor B polypep-
tide 1  
12.47
3 
112 9 Infinite 
Trip11 D4ABD
7 
Protein Trip11  226.0
6 
1976 3 Infinite 
Tsg101 F1LRB7 Tumor suscep-
tibility gene 
101 protein  
44.24
2 
391 3 Infinite 
Txnrd1 O89049 Thioredoxin 
reductase 1, 
cytoplasmic  
54.68
8 
499 11 Infinite 
Ube2c D3ZUW
6 
Protein Ube2c  19.67
9 
179 2 Infinite 
Ubr1 D3ZQC
6 
Protein Ubr1  199.7
6 
1756 4 Infinite 
Uggt1 Q9JLA3 UDP-glu-
cose:glycopro-
tein glucosyl-
transferase 1  
176.4
3 
1551 2 Infinite 
Vat1 Q3MIE4 Synaptic vesi-
cle membrane 
protein VAT-1 
homolog  
43.11
8 
404 4 Infinite 
Vgll4 Q5BJP0 Protein Vgll4  31.02 287 4 Infinite 
Vps37a Q4V794 Protein 
Vps37a  
44.48
7 
398 2 Infinite 
Vps52 O55166 Vacuolar pro-
tein sorting-as-
sociated pro-
tein 52 homo-
log  
82.10
2 
723 4 Infinite 
Wdr5 Q498M4 WD repeat-
containing 
protein 5  
36.58
8 
334 3 Infinite 
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Table 7. Thirty-eight previously reported PP2Ac interaction partners were iden-
tified in this study 
Gene name 
Protein 
ID 
Protein name 
MW 
[kDa] 
Enrich-
ment ra-
tio 
Ref-
er-
ence 
Spe-
cies* 
Ankle2 Q7TP65 Ankyrin repeat and LEM do-
main-containing protein 2  
106.4 1000# 94 H 
Arpc4 B2RZ72 Actin related protein 2/3 com-
plex, subunit 4 (Predicted), iso-
form CRA_a 
19.7 1000 187 H 
Cdk2 D3ZJC8 Cyclin-dependent kinase 2  39.0 1000 99,188 H 
Csnk1a1 D3ZRE3 Casein kinase I isoform α 41.9 1000 189 H 
Cttnbp2 Q2IBD4 Cortactin binding protein 2  178.8 1000 95 H 
Cttnbp2nl D4A8X8 CTTNBP2 N-terminal like 
(Predicted), isoform CRA_a 
70.1 1000 95 H 
Fam40a G3V8E2 Protein Fam40a  95.6 1000 95 H 
Fgfr1op Q4V7C1 FGFR1 oncogene partner  43.0 1000 95,190 H, M 
Fgfr1op2 Q6TA25 FGFR1 oncogene partner 2 
homolog  
29.4 1000 94 H 
Gga1 F1LPF4 Protein Gga1  70.0 1000 191 H 
Hnrnpa2b1 A7VJC2 Heterogeneous nuclear ribonu-
cleoproteins A2/B1  
37.5 1000 192 M 
Igbp1 O08836 Immunoglobulin-binding pro-
tein 1  
39.1 1000 94,95,1
06,193-
201 
H, M, 
R 
Ints3 D3ZUT9 Protein Ints3  117.9 1000 98 H 
Ints5 D3ZTW1 Protein Ints5  108.4 1000 98 H 
Map3k7ip1 D4A6C6 Protein Map3k7ip1  54.6 1000 194 H 
Mapk3 P21708-2 Isoform 2 of Mitogen-activated 
protein kinase 3  
45.8 1000 202 H 
Mob4 Q9QYW3 MOB-like protein phocein 26.0 1000 94,95 H 
Myh10 F1LQ02 Myosin-10  233.6 1000 94 H 
Pdcd10 Q6NX65 Programmed cell death protein 
10  
24.4 1000 95 H 
Pola1 F1LRJ6 DNA polymerase  166.9 1000 203 H 
Ppfia1 D3ZXH0 Protein Ppfia1  142.7 1000 94,95 H 
Ppm1b Q99ND8 Ppm1b protein  51.0 1000 99 H 
Ppme1 Q4FZT2 Protein phosphatase methyles-
terase 1  
42.3 1000 94,95 H 
Ppp2r1a Q5XI34 PP2 65 kDa regulatory subunit 
A, α isoform 
65.3 176.7 93-
97,105,
187,190
,204-
210 
H, M 
Ppp2r1b D4A1Y3 PP2 65 kDa regulatory subunit 
A, β isoform 
76.1 1000 93-97 H 
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Ppp2r2a P36876 PP2 55 kDa regulatory subunit 
B, α isoform 
51.7 1000 93-
95,204,
211 
H, M 
Ppp2r2d P56932 PP2 55 kDa regulatory subunit 
B, δ isoform 
52.0 1000 94,95,2
12 
H 
Ppp2r3a D3ZLD7 PP2 72/130 kDa regulatory 
subunit B,  α isoform 
129.9 1000 213,214 H, M 
Ppp4c G3V8M5 PP4 catalitic subunit 35.1 1000 215 H 
Ppp2r5c D4A1A5 PP2 56 kDa regulatory subunit 
B, γ isoform 
59.9 1000 94,95,1
84,216-
218 
H 
Prkaa1 P54645 5-AMP-activated protein ki-
nase catalytic subunit α-1  
64.0 1000 219,220 H 
Rplp1 P19944 60S acidic ribosomal protein 
P1  
11.5 1000 221 H 
Sike1 Q5FWT9 Suppressor of IKBKE 1  23.6 1000 94 H 
Slmap F1LM85 Sarcolemmal membrane-asso-
ciated protein  
98.2 1000 94 H 
Strn G3V6L8 RCG61894, isoform CRA_a 86.1 1000 94,95 H 
Strn4 F1M6V8 Protein Strn4  81.4 1000 94,95 H 
Tnpo3 D4AAM0 Protein Tnpo3  104.9 1000 187 H 
Uba52 P62986 Ubiquitin-60S ribosomal pro-
tein L40  
14.7 1000 195 H 
Ankle2 Q7TP6
5 
Ankyrin repeat and LEM do-
main-containing protein 2  
106.4 1000# 94 H 
Arpc4 B2RZ7
2 
Actin related protein 2/3 
complex, subunit 4 (Pre-
dicted), isoform CRA_a 
19.7 1000 187 H 
Cdk2 D3ZJC
8 
Cyclin-dependent kinase 2  39.0 1000 99,1
88 
H 
Csnk1a1 D3ZRE
3 
Casein kinase I isoform α 41.9 1000 189 H 
Cttnbp2 Q2IBD
4 
Cortactin binding protein 2  178.8 1000 95 H 
Cttnbp2nl D4A8X
8 
CTTNBP2 N-terminal like 
(Predicted), isoform CRA_a 
70.1 1000 95 H 
Fam40a G3V8E
2 
Protein Fam40a  95.6 1000 95 H 
Fgfr1op Q4V7C
1 
FGFR1 oncogene partner  43.0 1000 95,1
90 
H, M 
Fgfr1op2 Q6TA2
5 
FGFR1 oncogene partner 2 
homolog  
29.4 1000 94 H 
Gga1 F1LPF
4 
Protein Gga1  70.0 1000 191 H 
Hnrnpa2b
1 
A7VJC
2 
Heterogeneous nuclear ribo-
nucleoproteins A2/B1  
37.5 1000 192 M 
Igbp1 O08836 Immunoglobulin-binding 
protein 1  
39.1 1000 94,9
5,10
6,19
H, 
M, R 
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3-
201 
Ints3 D3ZUT
9 
Protein Ints3  117.9 1000 98 H 
Ints5 D3ZT
W1 
Protein Ints5  108.4 1000 98 H 
Map3k7ip
1 
D4A6C
6 
Protein Map3k7ip1  54.6 1000 194 H 
Mapk3 P21708
-2 
Isoform 2 of Mitogen-acti-
vated protein kinase 3  
45.8 1000 202 H 
Mob4 Q9QY
W3 
MOB-like protein phocein 26.0 1000 94,9
5 
H 
Myh10 F1LQ0
2 
Myosin-10  233.6 1000 94 H 
Pdcd10 Q6NX6
5 
Programmed cell death pro-
tein 10  
24.4 1000 95 H 
Pola1 F1LRJ6 DNA polymerase  166.9 1000 203 H 
Ppfia1 D3ZX
H0 
Protein Ppfia1  142.7 1000 94,9
5 
H 
Ppm1b Q99ND
8 
Ppm1b protein  51.0 1000 99 H 
Ppme1 Q4FZT
2 
Protein phosphatase meth-
ylesterase 1  
42.3 1000 94,9
5 
H 
Ppp2r1a Q5XI3
4 
PP2 65 kDa regulatory subu-
nit A, α isoform 
65.3 176.7 93-
97,1
05,1
87,1
90,2
04-
210 
H, M 
Ppp2r1b D4A1Y
3 
PP2 65 kDa regulatory subu-
nit A, β isoform 
76.1 1000 93-
97
 
H 
Ppp2r2a P36876 PP2 55 kDa regulatory subu-
nit B, α isoform 
51.7 1000 93-
95,2
04,2
11 
H, M 
Ppp2r2d P56932 PP2 55 kDa regulatory subu-
nit B, δ isoform 
52.0 1000 94,9
5,21
2 
H 
Ppp2r3a D3ZLD
7 
PP2 72/130 kDa regulatory 
subunit B,  α isoform 
129.9 1000 213,
214 
H, M 
Ppp4c G3V8
M5 
PP4 catalitic subunit 35.1 1000 215 H 
Ppp2r5c D4A1A
5 
PP2 56 kDa regulatory subu-
nit B, γ isoform 
59.9 1000 94,9
5,18
4,21
6-
218 
H 
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Prkaa1 P54645 5-AMP-activated protein ki-
nase catalytic subunit α-1  
64.0 1000 219,
220 
H 
Rplp1 P19944 60S acidic ribosomal protein 
P1  
11.5 1000 221 H 
Sike1 Q5FW
T9 
Suppressor of IKBKE 1  23.6 1000 94 H 
Slmap F1LM8
5 
Sarcolemmal membrane-as-
sociated protein  
98.2 1000 94 H 
Strn G3V6L
8 
RCG61894, isoform CRA_a 86.1 1000 94,9
5 
H 
Strn4 F1M6V
8 
Protein Strn4  81.4 1000 94,9
5 
H 
Tnpo3 D4AA
M0 
Protein Tnpo3  104.9 1000 187 H 
Uba52 P62986 Ubiquitin-60S ribosomal 
protein L40  
14.7 1000 195 H 
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Table 8. IPA analysis of the 516 partners showing the 39 enriched pathways 
Ingenuity Ca-
nonical Path-
ways 
P value Glucose re-
sponsive 
PP2Ac part-
ners identified 
in the study 
Glucose nonresponsive PP2Ac 
partners identified in the study 
EIF2 Signaling 1.26E-18 RPL4, 
RPL18A, 
RPL30, 
EIF2B1, RPL9 
EIF2B4, MAPK1, RPL26, 
RPS21, EIF4G1, RPS7, RPL6, 
MAP2K2, EIF3D, MAPK3, 
RPS9, RPL19, RPL12, RPL37A, 
RPL27, RPS2, RPS19, RPL10A, 
EIF3G, RPS6, UBA52, RPS15, 
RPS25, RPS15A, 
LOC100360491, RPL38, 
RPL13A 
Regulation of 
eIF4 and 
p70S6K Signal-
ing 
2.51E-13 PPP2R2A, 
EIF2B1, 
PPP2R1B 
EIF2B4, MAPK1, , RPS2, 
RPS19, RPS21, EIF4G1, EIF3G, 
RPS7, RPS6, , PPP2R1A, 
MAP2K2, PPP2R3A, EIF3D, 
MAPK3, RPS9, RPS15, 
RPS15A, RPS25 
mTOR Signal-
ing 
5.01E-11 PPP2R2A, 
RHOA, 
PPP2R1B 
MAPK1, , RPS2, RPS19, RAC1, 
RPS21, EIF4G1, EIF3G, RPS7, 
RPS6, , PPP2R1A, PPP2R3A, 
EIF3D, MAPK3, RPS9, 
PRKAA1, RPS15, RPS15A, 
RPS25 
AMPK Signal-
ing 
3.63E-07 PPM1B, 
PPP2R2A, 
PPP2R1B, 
PPAT, 
PFKFB2 
TAF9, MAPK1, , PFKP, PFKL, 
PFKM, , PPP2R1A, PPP2R3A, 
PRKAA1 
CDK5 Signal-
ing 
5.89E-07 PPP2R2A, 
PPP2R1B 
PPP2R1A, MAP2K2, CDK5, 
MAPK1, , PPP2R3A, MAPK3, 
CAPN1, PPP1R12A 
ILK Signaling 1.07E-06 PPP2R2A, 
RHOA, 
PPP2R1B 
MYH10, FBLIM1, MYL6, 
MAPK1, CFL1, , MYH14, ILK, , 
PPP2R1A, PPP2R3A, FLNA, 
MAPK3, PPP1R12A 
Actin Cytoskel-
eton Signaling 
1.62E-06 RHOA, 
ARPC4, 
LIMK1 
ACTR2, MYH10, MYL6, CFL1, 
MAPK1, CRKL, MYH14, 
RAC1, GSN, GIT1, ACTR3, 
MAP2K2, FLNA, MAPK3, 
PPP1R12A, MSN 
Salvage Path-
ways of Pyrimi-
dine Ribonucle-
otides 
8.71E-06 LIMK1 MAP2K2, CDK5, MAPK1, 
MAPK3, PRKAA1, NME2, 
CSNK1A1, CMPK1, CDK2, 
DYRK1A 
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Cell Cycle Reg-
ulation by BTG 
Family Proteins 
1.02E-05 PPP2R2A, 
PPP2R1B 
PPP2R1A, , PPP2R3A, CDK2 
Glycolysis I 1.15E-05   PGK1, PKLR, ALDOA, PFKP, 
PFKL, PFKM 
Pyridoxal 5'-
phosphate Sal-
vage Pathway 
1.51E-05 LIMK1 MAP2K2, CDK5, MAPK1, 
MAPK3, PRKAA1, CSNK1A1, 
CDK2, DYRK1A 
Mitotic Roles of 
Polo-Like Ki-
nase 
1.74E-05 PPP2R2A, 
PPP2R1B 
SMC3, PPP2R1A, , PPP2R3A, 
CAPN1, CDC16 
Protein Ubiqui-
tination Path-
way 
1.86E-05 UBR1, TCEB1, 
UBE2C 
USP14, PSMA3, HSPH1, 
PSMD13, PSMD6, THOP1, 
DNAJA1, PSMD12, PSMA4, 
PSMB1, PSMD14, PSMA2, 
PSMC2, PSMC3, HSPA4L, 
HSPB1 
Chemokine Sig-
naling 
2.19E-05 RHOA, LIMK1 Calm1 (includes others), 
CAMK1, MAP2K2, MAPK1, 
CFL1, MAPK3, PPP1R12A 
Estrogen Recep-
tor Signaling 
2.82E-05 NCOR1 TAF9, DDX5, POLR2A, 
POLR2C, MAP2K2, MAPK1, 
POLR2E, MAPK3, NCOA1, 
POLR2H, POLR2B 
Tight Junction 
Signaling 
4.07E-05 PPP2R2A, 
RHOA, 
PPP2R1B 
MYH10, MYL6, , MYH14, 
MARK2, RAC1, CTNNA1, , 
PPP2R1A, PPP2R3A 
Glucocorticoid 
Receptor Sig-
naling 
8.51E-05 NCOR1, 
TSG101 
TAF9, MAPK1, RAC1, 
POLR2B, POLR2C, POLR2A, 
MAP2K2, MAP3K7, POLR2E, 
ANXA1, MAPK3, NCOA1, 
PRKAA1, POLR2H, PPP3CA 
ERK/MAPK 
Signaling 
8.71E-05 PLA2G6, 
PPP2R2A, 
PPP2R1B 
MAPK1, , CRKL, RAC1, , 
PPP2R1A, MAP2K2, PPP2R3A, 
MAPK3, PPP1R12A, HSPB1 
Regulation of 
Actin-based 
Motility by Rho 
9.77E-05 RHOA, 
ARPC4, 
LIMK1 
ACTR2, ACTR3, CFL1, MYL6, 
RAC1, PPP1R12A, GSN 
D-myo-inositol 
(1, 4, 5, 6)-
Tetrakisphos-
phate Biosyn-
thesis 
1.00E-04 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
D-myo-inositol 
(3, 4, 5, 6)-
tetrakisphos-
phate Biosyn-
thesis 
1.00E-04 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
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PI3K/AKT Sig-
naling 
1.00E-04 PPP2R2A, 
PPP2R1B 
PPP2R1A, SYNJ1, MAP2K2, 
MAPK1, , PPP2R3A, MAPK3, 
ILK 
Rac Signaling 1.12E-04 RHOA, 
ARPC4, 
LIMK1 
ACTR2, ACTR3, ARFIP2, 
MAP2K2, MAPK1, CFL1, 
MAPK3, RAC1 
Androgen Sig-
naling 
2.09E-04   CALR, POLR2A, Calm1 (in-
cludes others), POLR2C, 
MAPK1, POLR2E, MAPK3, 
NCOA1, POLR2H, POLR2B 
Role of CHK 
Proteins in Cell 
Cycle Check-
point Control 
2.14E-04 PPP2R2A, 
PPP2R1B 
PPP2R1A, , PPP2R3A, CDK2 
Calcium Signal-
ing 
2.14E-04   MYH10, CALR, Calm1 (in-
cludes others), CAMK1, 
MAPK1, MYL6, MYH14, 
Acta2, Camk2b, Tpm4, MAPK3, 
PPP3CA, Tpm3 
3-phosphoinosi-
tide Degrada-
tion 
3.09E-04 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
D-myo-inositol-
5-phosphate 
Metabolism 
3.09E-04 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
p70S6K Signal-
ing 
3.63E-04 PPP2R2A, 
PPP2R1B 
RPS6, , PPP2R1A, MAP2K2, 
MAPK1, , PPP2R3A, MAPK3 
RhoA Signaling 4.47E-04 RHOA, 
ARPC4, 
LIMK1 
ACTR2, ACTR3, CFL1, MYL6, 
PPP1R12A, ARHGEF11, 
ARHGAP1, MSN 
Wnt/Î²-catenin 
Signaling 
4.79E-04 APPL1, 
PPP2R2A, 
PPP2R1B 
PPP2R1A, , MAP3K7, 
PPP2R3A, MARK2, CSNK1A1, 
ILK, RUVBL2 
3-phosphoinosi-
tide Biosynthe-
sis 
6.31E-04 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
PAK Signaling 7.76E-04 LIMK1 MAP2K2, MAPK1, CFL1, 
MYL6, MAPK3, RAC1, GIT1 
Remodeling of 
Epithelial Ad-
herens Junctions 
7.94E-04 RAB5C, 
ARPC4 
DNM1, ACTR2, TUBB3, 
ACTR3, TUBB2A, CTNNA1, 
EXOC2 
Assembly of 
RNA Polymer-
ase II Complex 
8.32E-04   TAF9, POLR2A, POLR2C, 
POLR2E, POLR2H, POLR2B 
Signaling by 
Rho Family 
GTPases 
8.91E-04 RHOA, 
ARPC4, 
LIMK1 
ACTR2, MAPK1, CFL1, MYL6, 
RAC1, ACTR3, ARFIP2, 
MAP2K2, MAPK3, PPP1R12A, 
ARHGEF11, MSN 
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IL-3 Signaling 1.02E-03 STAT6 MAP2K2, MAPK1, CRKL, 
MAPK3, RAC1, PPP3CA 
Nucleotide Ex-
cision Repair 
Pathway 
1.02E-03   POLR2A, POLR2C, POLR2E, 
POLR2H, POLR2B 
Aryl Hydrocar-
bon Receptor 
Signaling 
1.20E-03 TRIP11 TGM2, MAPK1, POLA1, 
MAPK3, BAX, CDK2, HSPB1, 
MCM7, AIP 
Ephrin B Sig-
naling 
1.32E-03 KALRN, 
RHOA, LIMK1 
MAPK1, CFL1, MAPK3, RAC1 
Integrin Signal-
ing 
1.62E-03 RHOA, ARPC4 ACTR2, ACTR3, MAP2K2, 
MAPK1, CRKL, MAPK3, 
CAPN1, RAC1, ILK, 
PPP1R12A, GIT1 
Epithelial Ad-
herens Junction 
Signaling 
1.66E-03 RHOA, ARPC4 MYH10, ACTR2, TUBB3, 
ACTR3, MYL6, MYH14, 
TUBB2A, RAC1, CTNNA1 
RhoGDI Signal-
ing 
1.91E-03 RHOA, 
ARPC4, 
LIMK1 
ACTR2, ACTR3, CFL1, MYL6, 
RAC1, PPP1R12A, ARHGEF11, 
ARHGAP1, MSN 
Ephrin Receptor 
Signaling 
2.00E-03 KALRN, 
RHOA, 
ARPC4, 
LIMK1 
ACTR2, ACTR3, MAP2K2, 
MAPK1, CFL1, CRKL, 
MAPK3, RAC1 
Ceramide Sig-
naling 
2.04E-03 PPP2R2A, 
PPP2R1B 
PPP2R1A, , PPP2R3A, MAPK3 
Cyclins and Cell 
Cycle Regula-
tion 
2.04E-03 PPP2R2A, 
PPP2R1B 
PPP2R1A, PPP2R3A, CDK2 
Clathrin-medi-
ated Endocyto-
sis Signaling 
3.02E-03 RAB5C, 
TSG101, 
ARPC4 
DNM1, ACTR2, ACTR3, 
RAB4A, TF, SYNJ1, CLTB, 
RAC1, SH3GLB1, PPP3CA 
FAK Signaling 3.31E-03 HMMR MAP2K2, MAPK1, MAPK3, 
CAPN1, RAC1, Acta2 
Cdc42 Signal-
ing 
3.39E-03 ARPC4, 
LIMK1 
ACTR2, ACTR3, MAPK1, 
CFL1, MYL6, EXOC2, 
PPP1R12A, EXOC6, EXOC3 
Superpathway 
of Inositol Phos-
phate Com-
pounds 
3.72E-03 ITPK1, 
NUDT11, 
PPP4R1 
PPFIA1, NUDT5, SYNJ1, 
PPP2R3A, PPM1H, PPP1R12A, 
IGBP1, PPP3CA 
Pyrimidine Ri-
bonucleotides 
De Novo Bio-
synthesis 
4.27E-03   NUDT5, NME2, CMPK1, 
UMPS 
PPAR Signaling 5.13E-03 NCOR1 MAP2K2, MAPK1, MAP3K7, 
MAPK3, NCOA1, AIP 
Amyloid Pro-
cessing 
5.50E-03   CDK5, MAPK1, MAPK3, 
CAPN1, CSNK1A1 
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Phospholipase 
C Signaling 
6.61E-03 PLA2G6, 
RHOA 
TGM2, Calm1 (includes others), 
MAP2K2, MAPK1, MYL6, 
MAPK3, RAC1, PPP1R12A, 
ARHGEF11, PPP3CA 
PPARÎ±/RXRÎ± 
Activation 
6.61E-03 GPD1, NCOR1 CAND1, MAP2K2, MAPK1, 
MAP3K7, MAPK3, CKAP5, 
PRKAA1, AIP 
NRF2-mediated 
Oxidative Stress 
Response 
7.41E-03 TXNRD1 USP14, ERP29, MAP2K2, 
MAPK1, MAP3K7, MAPK3, 
CAT, DNAJA2, DNAJA1,  
Actin Nuclea-
tion by ARP-
WASP Com-
plex 
8.13E-03 RHOA, ARPC4 ACTR2, ACTR3, RAC1, 
PPP1R12A 
Insulin Receptor 
Signaling 
9.77E-03 EIF2B1 EIF2B4, SYNJ1, MAP2K2, 
MAPK1, CRKL, MAPK3, 
PPP1R12A 
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Table 9. The 211 proteins/ protein groups met the 2 rigorous criteria (See Methods 
for details) for classification as PP2Ac interaction partners in human skeletal mus-
cle. # indicating previously identified PP2A partners. 
Gene name Protein 
ID 
Protein name enrichme
nt ratio 
PPP2R1A B3KQV6 Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A alpha 
isoform 
213.3 
PPP2R2A E5RFR9 Serine/threonine-protein 
phosphatase 2A 55 kDa 
regulatory subunit B alpha 
isoform 
155.7 
PPP2R3A F6URX5 Serine/threonine-protein 
phosphatase 2A regulatory 
subunit B subunit alpha 
10435.3 
PPP2R5D E9PFR3 Serine/threonine-protein 
phosphatase 2A 56 kDa 
regulatory subunit delta 
isoform 
Infinite 
AASDHPPT B4DDW7 L-aminoadipate-semialdehyde 
dehydrogenase-
phosphopantetheinyl 
transferase 
Infinite 
ACAD8 B7Z5W4 Isobutyryl-CoA 
dehydrogenase, mitochondrial 
715.6 
ACADM B4DJE7 Medium-chain specific acyl-
CoA dehydrogenase, 
mitochondrial 
20.0 
ACADS E9PE82 Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
58.5 
ACADSB B4DQ51 Short/branched chain specific 
acyl-CoA dehydrogenase, 
mitochondrial 
28.9 
ACO1,IRP1 P21399 Cytoplasmic aconitate 
hydratase 
Infinite 
ACOT9 C9J7L8 Acyl-coenzyme A thioesterase 
9, mitochondrial 
11.0 
ACTR1A B4DXP9 Alpha-centractin Infinite 
ACTR1B P42025 Beta-centractin Infinite 
ADSSL1 G3V232 Adenylosuccinate synthetase 
isozyme 1 
10.7 
AKR1B1 E9PCX2 Aldose reductase Infinite 
AKR7A2 H3BLU7 Aflatoxin B1 aldehyde 
reductase member 2 
Infinite 
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AKT2 A8MX96 RAC-beta serine/threonine-
protein kinase 
Infinite 
ALDH4A1 P30038 Delta-1-pyrroline-5-
carboxylate dehydrogenase, 
mitochondrial 
Infinite 
ALDH6A1 G3V4Z4 Methylmalonate-
semialdehyde dehydrogenase 
[acylating], mitochondrial 
Infinite 
ANXA5 D6RBE9 Annexin A5;Annexin Infinite 
AP1G1 B3KXW5 AP-1 complex subunit 
gamma-1 
Infinite 
APPL1 C9JAB0 DCC-interacting protein 13-
alpha 
Infinite 
APRT H3BQB1 Adenine 
phosphoribosyltransferase 
Infinite 
ARCN1 B0YIW6 Coatomer subunit delta Infinite 
ARHGDIA J3KRE2 Rho GDP-dissociation 
inhibitor 1 
23.1 
ART3 E7ER42 Ecto-ADP-ribosyltransferase 3 18.6 
ASNA1 K7ERW9 ATPase ASNA1 Infinite 
ATP1B1 A6NGH2 Sodium/potassium-
transporting ATPase subunit 
beta-1 
Infinite 
ATP5J2,PTCD1 C9JJT5 ATP synthase subunit f, 
mitochondrial 
10.6 
ATP5S Q8WXQ4 ATP synthase subunit s, 
mitochondrial 
Infinite 
ATP6V1B2 C9J5E3 V-type proton ATPase subunit 
B, brain isoform 
Infinite 
ATP6V1E1 C9J8H1 V-type proton ATPase subunit 
E 1 
22.0 
BLVRB M0QZL1 Flavin reductase (NADPH) 10.1 
BPNT1 A6NF51 3(2),5-bisphosphate 
nucleotidase 1 
Infinite 
BZW2 B5MCE7 Basic leucine zipper and W2 
domain-containing protein 2 
112.6 
C1ORF57,NTPCR Q5TDF0 Cancer-related nucleoside-
triphosphatase 
50.4 
C21ORF33 F2Z2Q0 ES1 protein homolog, 
mitochondrial 
Infinite 
CA1 E5RFE7 Carbonic anhydrase 1 Infinite 
CAB39 B7ZBJ4 Calcium-binding protein 39 34.3 
CAMK2G B4DVQ3 Calcium/calmodulin-
dependent protein kinase type 
II subunit gamma 
46.8 
CAND1 H0YH27 Cullin-associated NEDD8-
dissociated protein 1 
96.8 
CAPN2 P17655 Calpain-2 catalytic subunit 11.1 
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CARM1 K7EK20 Histone-arginine 
methyltransferase CARM1 
13.3 
CARNS1 A5YM72 Carnosine synthase 1 12.7 
CAV1 E9PCT5 Caveolin-1;Caveolin Infinite 
CBR1 A8MTM1 Carbonyl reductase [NADPH] 
1 
Infinite 
CCDC6 Q16204 Coiled-coil domain-containing 
protein 6 
Infinite 
CCT2 F5GWF6 T-complex protein 1 subunit 
beta 
97.7 
CCT6A B4DPJ8 T-complex protein 1 subunit 
zeta 
11.6 
CDC37 K7EIU0 Hsp90 co-chaperone Cdc37 27.3 
CECR5 A8MYZ9 Cat eye syndrome critical 
region protein 5 
Infinite 
CLPX 
  
Infinite 
COPA P53621 Coatomer subunit 
alpha;Xenin;Proxenin 
16.9 
COPS2 B4DIH5 COP9 signalosome complex 
subunit 2 
115.6 
COPS3 C9JLV5 COP9 signalosome complex 
subunit 3 
17.9 
COPS6 E7EM64 COP9 signalosome complex 
subunit 6 
18.2 
COPS7A F5GXT7 COP9 signalosome complex 
subunit 7a 
14.5 
COQ3 Q5T063 Hexaprenyldihydroxybenzoat
e methyltransferase, 
mitochondrial 
14.1 
CTBP1 D6RAX2 C-terminal-binding protein 1 Infinite 
CUL1 Q13616 Cullin-1 13.9 
DARS,DKFZP781B112
02 
C9J7S3 Aspartate--tRNA ligase, 
cytoplasmic 
10.6 
DDX19A,DDX19B B4DRZ7 ATP-dependent RNA helicase 
DDX19A;ATP-dependent 
RNA helicase DDX19B 
15.5 
DNAJA4 C9JDE6 DnaJ homolog subfamily A 
member 4 
12.3 
DPP9 M0QXA6 Dipeptidyl peptidase 9 Infinite 
ECI2 C9J000 Enoyl-CoA delta isomerase 2, 
mitochondrial 
14.9 
EHD1 C9J2Z4 EH domain-containing protein 
1 
Infinite 
EIF2B1 B4DGX0 Translation initiation factor 
eIF-2B subunit alpha 
240.6 
EIF3F B3KSH1 Eukaryotic translation 
initiation factor 3 subunit F 
56.5 
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EIF3I Q13347 Eukaryotic translation 
initiation factor 3 subunit I 
Infinite 
EIF3M B4E2Q4 Eukaryotic translation 
initiation factor 3 subunit M 
586.7 
EIF4A1 B4E102 Eukaryotic initiation factor 
4A-I 
Infinite 
EIF4A2 E7EQG2 Eukaryotic initiation factor 
4A-II 
Infinite 
ENDOG Q14249 Endonuclease G, 
mitochondrial 
35.2 
FAF1 B1ANM7 FAS-associated factor 1 Infinite 
FAHD1 Q6P587 Acylpyruvase FAHD1, 
mitochondrial 
Infinite 
FAM49B E5RFS4 Protein FAM49B Infinite 
FBP2 O00757 Fructose-1,6-bisphosphatase 
isozyme 2 
166.1 
FERMT2 G3V1L6 Fermitin family homolog 2 7502.3 
FH P07954 Fumarate hydratase, 
mitochondrial 
12.3 
FLNA E9PHF0 Filamin-A 19.6 
FLNB E7EN95 Filamin-B 32.9 
GALK1 B4E1G6 Galactokinase Infinite 
GARS H7C443 Glycine--tRNA ligase Infinite 
GCDH B4DK85 Glutaryl-CoA dehydrogenase, 
mitochondrial 
32.0 
GDI2 E7EU23 Rab GDP dissociation 
inhibitor beta 
12.5 
GFPT1 E5RJP4 Glucosamine--fructose-6-
phosphate aminotransferase 
[isomerizing] 1 
Infinite 
GGH Q92820 Gamma-glutamyl hydrolase Infinite 
GMPPA C9J255 Mannose-1-phosphate 
guanyltransferase alpha 
Infinite 
GMPPB Q9Y5P6 Mannose-1-phosphate 
guanyltransferase beta 
Infinite 
GPD1L C9JFA7 Glycerol-3-phosphate 
dehydrogenase 1-like protein 
17.2 
GPS1 C9JFE4 COP9 signalosome complex 
subunit 1 
692.0 
GSN P06396 Gelsolin;Isoform 4 of Gelsolin 22.1 
GSTM3 P21266 Glutathione S-transferase Mu 
3 
63.2 
HAGH E7EN93 Hydroxyacylglutathione 
hydrolase, mitochondrial 
26.5 
HDDC2 Q7Z4H3 HD domain-containing protein 
2 
Infinite 
HMGCL B1AK13 Hydroxymethylglutaryl-CoA 
lyase, mitochondrial 
17.9 
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HMGCS2 P54868 Hydroxymethylglutaryl-CoA 
synthase, mitochondrial 
Infinite 
HSD17B8 Q92506 Estradiol 17-beta-
dehydrogenase 8 
101.7 
IDH3B O43837 Isocitrate dehydrogenase 
[NAD] subunit beta, 
mitochondrial 
23.9 
IDH3G E7EQB8 Isocitrate dehydrogenase 
[NAD] subunit gamma, 
mitochondrial 
17.7 
IFIT2 P09913 Interferon-induced protein 
with tetratricopeptide repeats 2 
Infinite 
IGBP1 P78318 Immunoglobulin-binding 
protein 1 
61343.7 
IMPDH2 C9J381 Inosine-5-monophosphate 
dehydrogenase 2 
Infinite 
IQGAP1 E9PDT6 Ras GTPase-activating-like 
protein IQGAP1 
64.3 
IVD H0YKV0 Isovaleryl-CoA 
dehydrogenase, mitochondrial 
Infinite 
KIF5B C9JWB9 Kinesin-1 heavy chain Infinite 
KPNA3 H0Y4S9 Importin subunit alpha-3 Infinite 
KPNA4 H7C4F6 Importin subunit alpha-4 56.9 
LAMP1 B4DWL3 Lysosome-associated 
membrane glycoprotein 1 
Infinite 
LAP3 H0Y983 Cytosol aminopeptidase Infinite 
LARS B4DER1 Leucine--tRNA ligase, 
cytoplasmic 
98.0 
LUM P51884 Lumican 72.8 
LYPLAL1 Q5VWZ2 Lysophospholipase-like 
protein 1 
11.8 
MAML3 E7EVW8 Mastermind-like protein 3 Infinite 
MAOB B7Z242 Amine oxidase [flavin-
containing] B 
13.8 
MAP2K1 G5E9C7 Dual specificity mitogen-
activated protein kinase kinase 
1 
87.8 
MAP2K6 K7EIW3 Dual specificity mitogen-
activated protein kinase kinase 
6 
118.7 
MARCKS P29966 Myristoylated alanine-rich C-
kinase substrate 
Infinite 
MPST B1AH49 3-mercaptopyruvate 
sulfurtransferase;Sulfurtransfe
rase 
14.5 
MUSTN1,TMEM110 
  
Infinite 
MYH11 E7ERA5 Myosin-11 Infinite 
MYH14 F2Z2U8 Myosin-14 72.7 
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MYL12A,MYL12B,M
YL9 
J3KTJ1 Myosin regulatory light chain 
12B;Myosin regulatory light 
chain 12A;Myosin regulatory 
light polypeptide 9 
Infinite 
NAP1L4 A8MXH2 Nucleosome assembly protein 
1-like 4 
14.4 
NEK7 C9J1H8 Serine/threonine-protein 
kinase Nek7 
357.1 
NT5C3 B9A035 Cytosolic 5-nucleotidase 3 Infinite 
OTUB1 F5GYJ8 Ubiquitin thioesterase OTUB1 27.4 
PACSIN3 E9PIY1 Protein kinase C and casein 
kinase substrate in neurons 
protein 3 
26.5 
PCTP I3L2M9 Phosphatidylcholine transfer 
protein 
Infinite 
PCYOX1 B7Z3Y2 Prenylcysteine oxidase 1 12.2 
PDE4D D6RHE0 cAMP-specific 3,5-cyclic 
phosphodiesterase 4D 
Infinite 
PDIA3 G5EA52 Protein disulfide-isomerase 
A3;Thioredoxin 
39.9 
PDIA6 B5MCQ5 Protein disulfide-isomerase 
A6 
59.1 
PDK2 D6R983 [Pyruvate dehydrogenase 
[lipoamide]] kinase isozyme 2, 
mitochondrial 
181.5 
PGAM2 P15259 Phosphoglycerate mutase 2 36.1 
PLCD4 C9JAE4 1-phosphatidylinositol 4,5-
bisphosphate 
phosphodiesterase delta-4 
2677.5 
PLIN5 K7EIX1 Perilipin-5 15.3 
PPME1 F5H2D4 Protein phosphatase 
methylesterase 1 
Infinite 
PPP1R7 B5MBZ8 Protein phosphatase 1 
regulatory subunit 7 
Infinite 
PPP4C H3BTA2 Serine/threonine-protein 
phosphatase 4 catalytic 
subunit;Serine/threonine-
protein phosphatase 
Infinite 
PPP4R2 C9IZ04 Serine/threonine-protein 
phosphatase 4 regulatory 
subunit 2 
Infinite 
PRELP P51888 Prolargin Infinite 
PRKAB2 B4DH06 5-AMP-activated protein 
kinase subunit beta-2 
17.4 
PRKAG1 E9PGP6 5-AMP-activated protein 
kinase subunit gamma-1 
27.0 
PRKG1 B1ALS0 cGMP-dependent protein 
kinase 1 
49.1 
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PSMA7,PSMA8 H0Y586 Proteasome subunit alpha 
type-7;Proteasome subunit 
alpha type-7-like 
Infinite 
PSMC1 B4DR63 26S protease regulatory 
subunit 4 
17.6 
PSMC2 B7Z5E2 26S protease regulatory 
subunit 7 
33.9 
PSMC3 E9PKD5 26S protease regulatory 
subunit 6A 
13.7 
PSMC5 J3KRP2 26S protease regulatory 
subunit 8 
12.1 
PSMC6 H0YJC0 26S protease regulatory 
subunit 10B 
19.5 
PSMD1 C9J9M4 26S proteasome non-ATPase 
regulatory subunit 1 
13.9 
PSMD11 J3KSW3 26S proteasome non-ATPase 
regulatory subunit 11 
28.2 
PSMD12 J3KSK1 26S proteasome non-ATPase 
regulatory subunit 12 
24.5 
PSMD13 E9PL38 26S proteasome non-ATPase 
regulatory subunit 13 
40.0 
PSMD14 C9JW37 26S proteasome non-ATPase 
regulatory subunit 14 
11.9 
PSME2 H0YKU2 Proteasome activator complex 
subunit 2 
27.9 
PTGR1 F2Z3J9 Prostaglandin reductase 1 Infinite 
PTPN11 H0YF12 Tyrosine-protein phosphatase 
non-receptor type 11 
Infinite 
RAB12 Q6IQ22 Ras-related protein Rab-12 12.7 
RAB1B,RAB1C E9PLD0 Ras-related protein Rab-
1B;Putative Ras-related 
protein Rab-1C 
32.3 
RAC1 
  
11.0 
RALA,RALB B4E040 Ras-related protein Ral-
A;Ras-related protein Ral-B 
61.9 
RBX1 P62877 E3 ubiquitin-protein ligase 
RBX1 
40.0 
RNF114 Q9Y508 RING finger protein 114 10.2 
RNF123 C9J266 E3 ubiquitin-protein ligase 
RNF123 
20.4 
RPLP0,RPLP0P6 F8VPE8 60S acidic ribosomal protein 
P0;60S acidic ribosomal 
protein P0-like 
13.2 
RPS15A H3BN98 40S ribosomal protein S15a Infinite 
RPS20 E5RIP1 40S ribosomal protein S20 91.4 
RPS25 P62851 40S ribosomal protein S25 328.0 
RPS6KA3 B1AXG1 Ribosomal protein S6 kinase 
alpha-3 
10.3 
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RRAS2 B7Z5Z2 Ras-related protein R-Ras2 134.5 
S100A11 P31949 Protein S100-A11 13.9 
S100A7 P31151 Protein S100-A7 Infinite 
SAMHD1 A6NDZ3 SAM domain and HD domain-
containing protein 1 
Infinite 
SCFD1 B7Z5N7 Sec1 family domain-
containing protein 1 
164.5 
SCPEP1 Q9HB40 Retinoid-inducible serine 
carboxypeptidase 
Infinite 
SEMA6C Q9H3T2 Semaphorin-6C Infinite 
SESN1 P58005 Sestrin-1 148.6 
SLK Q9H2G2 STE20-like serine/threonine-
protein kinase 
Infinite 
SNX1 A6NKH4 Sorting nexin-1 575.2 
SNX2 D6RC15 Sorting nexin-2 Infinite 
SOD1 H7BYH4 Superoxide dismutase [Cu-Zn] 21.5 
SPR P35270 Sepiapterin reductase 11.2 
SPRR3 B1AN48 Small proline-rich protein 3 11.2 
SPTAN1 A6NG51 Spectrin alpha chain, brain 249.0 
STARD7 C9JTD3 StAR-related lipid transfer 
protein 7, mitochondrial 
94.3 
STAT3 G8JLH9 Signal transducer and activator 
of transcription 3 
11.3 
STAT5A,STAT5B C9J4I3 Signal transducer and activator 
of transcription 5B;Signal 
transducer and activator of 
transcription 5A 
32.0 
STRN O43815 Striatin;Isoform 2 of Striatin Infinite 
STRN3 G3V340 Striatin-3 Infinite 
SUGT1 F5H5A9 Suppressor of G2 allele of 
SKP1 homolog 
Infinite 
SYCP1 Q15431 Synaptonemal complex 
protein 1 
Infinite 
TALDO1 E9PKI8 Transaldolase Infinite 
TIMM44 M0QXU7 Mitochondrial import inner 
membrane translocase subunit 
TIM44 
11.3 
TIPRL O75663 TIP41-like protein Infinite 
TLN2 H0YMT1 Talin-2 635.0 
TPD52L2 O43399 Tumor protein D54 13.7 
TRIM28 M0R0K9 Transcription intermediary 
factor 1-beta 
81.2 
TRIM54 Q969Q1 Tripartite motif-containing 
protein 54 
17.7 
TSN E9PGT1 Translin 82.0 
TUBB2A,TUBB2B 
  
15.2 
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UBA2 B3KWB9 SUMO-activating enzyme 
subunit 2 
Infinite 
UQCRFS1,UQCRFS1P
1 
P0C7P4 Cytochrome b-c1 complex 
subunit Rieske, 
mitochondrial;Cytochrome b-
c1 complex subunit 
11;Putative cytochrome b-c1 
complex subunit Rieske-like 
protein 1 
17.5 
USP7 F5H2X1 Ubiquitin carboxyl-terminal 
hydrolase 7;Ubiquitin 
carboxyl-terminal hydrolase 
61.1 
USP9X O00507 Probable ubiquitin carboxyl-
terminal hydrolase FAF-X 
Infinite 
VARS A2ABF4 Valine--tRNA ligase 42.8 
VPS28 E9PI55 Vacuolar protein sorting-
associated protein 28 homolog 
68.0 
VPS4A I3L4J1 Vacuolar protein sorting-
associated protein 4A 
Infinite 
WARS G3V227 Tryptophan--tRNA ligase, 
cytoplasmic;T1-TrpRS;T2-
TrpRS 
Infinite 
XRCC5 C9JZ81 X-ray repair cross-
complementing protein 5 
199.5 
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Table 10. 69 proteins PP2Ac partners in human skeletal muscle with significant 
change among different groups  
Gene name Protein 
ID 
Protein name enrich-
ment ratio 
PPP2R1A B3KQV6 Serine/threonine-protein phospha-
tase 2A 65 kDa regulatory subunit 
A alpha isoform 
213.3 
ACADM B4DJE7 Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
20.0 
ACADS E9PE82 Short-chain specific acyl-CoA de-
hydrogenase, mitochondrial 
58.5 
ACO1, IRP1 P21399 Cytoplasmic aconitate hydratase Infinite 
ACOT9 C9J7L8 Acyl-coenzyme A thioesterase 9, 
mitochondrial 
11.0 
AKR1B1 E9PCX2 Aldose reductase Infinite 
AKR7A2 H3BLU7 Aflatoxin B1 aldehyde reductase 
member 2 
Infinite 
AKT2 A8MX96 RAC-beta serine/threonine-protein 
kinase 
Infinite 
ART3 E7ER42 Ecto-ADP-ribosyltransferase 3 18.6 
ATP5S Q8WXQ4 ATP synthase subunit s, mitochon-
drial 
Infinite 
ATP6V1B2 C9J5E3 V-type proton ATPase subunit B, 
brain isoform 
Infinite 
BLVRB M0QZL1 Flavin reductase (NADPH) 10.1 
CA1 E5RFE7 Carbonic anhydrase 1 Infinite 
CAMK2G B4DVQ3 Calcium/calmodulin-dependent 
protein kinase type II subunit 
gamma 
46.8 
CAV1 E9PCT5 Caveolin-1;Caveolin Infinite 
CCDC6 Q16204 Coiled-coil domain-containing pro-
tein 6 
Infinite 
CCT2 F5GWF6 T-complex protein 1 subunit beta 97.7 
CCT6A B4DPJ8 T-complex protein 1 subunit zeta 11.6 
CLPX 
  
Infinite 
COPS2 B4DIH5 COP9 signalosome complex subu-
nit 2 
115.6 
CTBP1 D6RAX2 C-terminal-binding protein 1 Infinite 
DPP9 M0QXA6 Dipeptidyl peptidase 9 Infinite 
EIF2B1 B4DGX0 Translation initiation factor eIF-2B 
subunit alpha 
240.6 
EIF3M B4E2Q4 Eukaryotic translation initiation fac-
tor 3 subunit M 
586.7 
FERMT2 G3V1L6 Fermitin family homolog 2 7502.3 
FLNA E9PHF0 Filamin-A 19.6 
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FLNB E7EN95 Filamin-B 32.9 
GARS H7C443 Glycine--tRNA ligase Infinite 
GFPT1 E5RJP4 Glucosamine--fructose-6-phos-
phate aminotransferase [isomeriz-
ing] 1 
Infinite 
GGH Q92820 Gamma-glutamyl hydrolase Infinite 
GMPPA C9J255 Mannose-1-phosphate guanyltrans-
ferase alpha 
Infinite 
GPS1 C9JFE4 COP9 signalosome complex subu-
nit 1 
692.0 
GSTM3 P21266 Glutathione S-transferase Mu 3 63.2 
HSD17B8 Q92506 Estradiol 17-beta-dehydrogenase 8 101.7 
IFIT2 P09913 Interferon-induced protein with tet-
ratricopeptide repeats 2 
Infinite 
IQGAP1 E9PDT6 Ras GTPase-activating-like protein 
IQGAP1 
64.3 
KIF5B C9JWB9 Kinesin-1 heavy chain Infinite 
LAP3 H0Y983 Cytosol aminopeptidase Infinite 
LUM P51884 Lumican 72.8 
MPST B1AH49 3-mercaptopyruvate sulfurtransfer-
ase;Sulfurtransferase 
14.5 
PDE4D D6RHE0 cAMP-specific 3,5-cyclic phos-
phodiesterase 4D 
Infinite 
PGAM2 P15259 Phosphoglycerate mutase 2 36.1 
PPME1 F5H2D4 Protein phosphatase methylesterase 
1 
Infinite 
PPP1R7 B5MBZ8 Protein phosphatase 1 regulatory 
subunit 7 
Infinite 
PPP4R2 C9IZ04 Serine/threonine-protein phospha-
tase 4 regulatory subunit 2 
Infinite 
PRELP P51888 Prolargin Infinite 
PSMC2 B7Z5E2 26S protease regulatory subunit 7 33.9 
PSMC3 E9PKD5 26S protease regulatory subunit 6A 13.7 
PSMD1 C9J9M4 26S proteasome non-ATPase regu-
latory subunit 1 
13.9 
PSMD11 J3KSW3 26S proteasome non-ATPase regu-
latory subunit 11 
28.2 
PSMD12 J3KSK1 26S proteasome non-ATPase regu-
latory subunit 12 
24.5 
PSMD13 E9PL38 26S proteasome non-ATPase regu-
latory subunit 13 
40.0 
PSMD14 C9JW37 26S proteasome non-ATPase regu-
latory subunit 14 
11.9 
PSME2 H0YKU2 Proteasome activator complex sub-
unit 2 
27.9 
PTPN11 H0YF12 Tyrosine-protein phosphatase non-
receptor type 11 
Infinite 
RPS25 P62851 40S ribosomal protein S25 328.0 
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S100A11 P31949 Protein S100-A11 13.9 
SAMHD1 A6NDZ3 SAM domain and HD domain-con-
taining protein 1 
Infinite 
SCPEP1 Q9HB40 Retinoid-inducible serine carboxy-
peptidase 
Infinite 
SESN1 P58005 Sestrin-1 148.6 
SLK Q9H2G2 STE20-like serine/threonine-pro-
tein kinase 
Infinite 
SOD1 H7BYH4 Superoxide dismutase [Cu-Zn] 21.5 
SPRR3 B1AN48 Small proline-rich protein 3 11.2 
STAT3 G8JLH9 Signal transducer and activator of 
transcription 3 
11.3 
STAT5A,STAT5B C9J4I3 Signal transducer and activator of 
transcription 5B;Signal transducer 
and activator of transcription 5A 
32.0 
TALDO1 E9PKI8 Transaldolase Infinite 
UBA2 B3KWB9 SUMO-activating enzyme subunit 2 Infinite 
VARS A2ABF4 Valine--tRNA ligase 42.8 
XRCC5 C9JZ81 X-ray repair cross-complementing 
protein 5 
199.5 
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Table 11. Known partners from databases  
Gene 
name 
Protein name 
PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A 
alpha isoform 
PPP2R2A Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B 
alpha isoform 
PPP2R3A Serine/threonine-protein phosphatase 2A regulatory subunit B subunit 
alpha 
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit 
delta isoform 
STRN Striatin;Isoform 2 of Striatin 
STRN3 Striatin-3 
CCDC6 Coiled-coil domain-containing protein 6 
CCT2 T-complex protein 1 subunit beta 
CCT6A T-complex protein 1 subunit zeta 
CUL1 Cullin-1 
IGBP1 Immunoglobulin-binding protein 1 
PPME1 Protein phosphatase methylesterase 1 
PSMC6 26S protease regulatory subunit 10B 
PSMD1 26S proteasome non-ATPase regulatory subunit 1 
RAC1 
 
SOD1 Superoxide dismutase [Cu-Zn] 
TIPRL TIP41-like protein 
USP7 Ubiquitin carboxyl-terminal hydrolase 7;Ubiquitin carboxyl-terminal 
hydrolase 
PPP4C Serine/threonine-protein phosphatase 4 catalytic subunit;Serine/threo-
nine-protein phosphatase 
CAV1 Caveolin-1;Caveolin 
AMPK AMP-activated protein kinase 
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Table 12. 38 proteins; Comparing partners from both INS-1 cells and human skel-
etal muscle biopsies (bold italics are in common with the database proteins) 
Gene name Protein name 
PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A al-
pha isoform 
PPP2R2A Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B al-
pha isoform 
PPP2R3A Protein phosphatase 2A regulatory subunit B subunit alpha 
STRN Striatin;Isoform 2 of Striatin 
CCDC6 Coiled-coil domain-containing protein 6 
IGBP1 Immunoglobulin-binding protein 1 
PPME1 Protein phosphatase methylesterase 1 
RAC1 
 
AKR1B1 Aldose reductase 
APPL1 DCC-interacting protein 13-alpha 
ARCN1 Coatomer subunit delta 
ASNA1 ATPase ASNA1 
NTPCR Cancer-related nucleoside-triphosphatase 
CAND1 Cullin-associated NEDD8-dissociated protein 1 
DARS Aspartate--tRNA ligase, cytoplasmic 
EIF2B1 Translation initiation factor eIF-2B subunit alpha 
FAHD1 Acylpyruvase FAHD1, mitochondrial 
FLNA Filamin-A 
GFPT1 Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1 
GSN Gelsolin;Isoform 4 of Gelsolin 
IDH3B Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial 
MYH14 Myosin-14 
NAP1L4 Nucleosome assembly protein 1-like 4 
PDIA6 Protein disulfide-isomerase A6 
PPP4C Serine/threonine-protein phosphatase 4 catalytic subunit; 
PPP4R2 Serine/threonine-protein phosphatase 4 regulatory subunit 2 
PSMC2 26S protease regulatory subunit 7 
PSMC3 26S protease regulatory subunit 6A 
PSMD12 26S proteasome non-ATPase regulatory subunit 12 
PSMD13 26S proteasome non-ATPase regulatory subunit 13 
PSMD14 26S proteasome non-ATPase regulatory subunit 14 
RAB1B Ras-related protein Rab-1B;Putative Ras-related protein Rab-1C 
RPS15A 40S ribosomal protein S15a 
RPS25 40S ribosomal protein S25 
S100A11 Protein S100-A11 
TALDO1 Transaldolase 
TSN Translin 
TUBB2A 
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PROTEIN PHOSPHATASE 2A INTERACTIONS IN ISLET AND HUMAN SKELE-
TAL MUSCLE IN DIABETES 
by 
DIVYASRI DAMACHARLA 
August 2017 
Advisor: Dr. Zhengping Yi  
Major: Pharmaceutical Sciences (Pharmacology and Toxicology) 
Degree: Doctor of Philosophy 
Type 2 Diabetes is a metabolic disorder associated with insulin resistance and 
consequent high blood glucose levels. Under normal conditions, in response to high 
blood glucose levels, pancreatic beta cells produce insulin. The secreted insulin is dis-
tributed to tissues thereby stimulating insulin stimulated glucose uptake. However, 
maximum glucose disposal takes place in skeletal muscle. Thus, studying beta cells  
and skeletal muscle in respect to diabetes is crucial. Protein Phosphatase 2A (PP2A) is 
one of the major serine/threonine phosphatases belonging to PhosphoProteinPhospha-
tase (PPP) family. It constitutes about 80% of all serine/threonine phosphatases. It is 
regulated by numerous regulatory subunits as well as other substrate molecules and post 
translational modifications. This alters their localization, activity and its target mole-
cules. Many evidences show the effect of insulin on PP2Ac and its abnormal regulation 
in conditions of glucolipotoxicity. Thus, studying PP2Ac interaction partners in respect 
to type 2 diabetes will give insight into its role in insulin resistance. 
Here, we studied interaction partners of PP2Ac in both beta cells and human 
skeletal muscle. INS-1 832/13 insulin secreting cells are used to study beta cell which 
are treated with basal and high glucose for 48hrs which are then harvested and analyzed. 
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Skeletal muscle biopsies are collected from human subjects. Two biopsies are collected 
from each individual, basal and insulin stimulated using hyperinsulenemic euglycemic 
clamp technique. We collected biopsies from individuals characterized in three differ-
ent groups, lean controls, obese/overweight insulin resistant, and type 2 diabetics. Both 
beta cells and human skeletal muscle biopsies are analyzed using a similar proteomics 
approach using ESI-HPLC-MS/MS. Using this technique, we identified 514 partners in 
INS-1 832/13 cells with 89 partners classified as glucose responsive. Similarly, 211 
interaction partners are identified in human skeletal muscle biopsies and 69 proteins 
presented a significant difference among three gropus. Several important PP2Ac inter-
action partners were identified which included some known partners (identified in other 
cell types) as well. Many proteins involved in insulin secretion are found as PP2Ac 
partners in beta cells whereas several vital molecules involved in insulin signaling path-
way are identified in skeletal muscle biopsies. Some important molecules like Rac1, 
Limk1, Akt2, MAPK are identified among others. Proteins that effect PP2Ac post trans-
lational modification, such as PPME-1, are also identified and presented with a signif-
icant change. Further validation of these partners will help with a better understanding 
of the role and regulation of PP2Ac in diabetes.   
  
175 
 
 
AUTOBIOGRAPHICAL STATEMENT 
DIVYASRI DAMACHARLA 
EDUCATION 
2017 PhD in Pharmaceutical Sciences, Wayne State University, Detroit, Michigan, 
U.S.A. 
2015 Masters in Pharmaceutical Sciences, Wayne State University, Detroit, Michigan, 
U.S.A. 
2012 Bachelors in Pharmacy, Rajiv Gandhi University of Health sciences, India 
 
PROFESSIONAL ASSOCIATIONS 
American Society for Mass Spectrometry (ASMS) 
American Association for Pharmaceutical Scientists (AAPS) 
PRESENTATIONS 
Divyasri Damacharla., et al. Identification of Protein Interaction Partners of Protein 
Phosphatase 2A Catalytic Subunit Using Quantitative Mass Spectrometry, the 62nd 
American Society for Mass Spectrometry Conference on Mass Spectrometry, June 15-
19, 2014, Baltimore Convention Center, Baltimore, MD. 
 
Divyasri Damacharla., et al. Protein Interaction Partners of Protein Phosphatase 2A 
Catalytic Subunit in Rat β-Islet cells Using Quantitative Mass Spectrometry, the 63rd 
ASMS Conference on Mass Spectrometry and Allied Topics, May 31 - June 4, 2015 - 
America's Center, St. Louis, Missouri 
 
Divyasri Damacharla., et al. Identification of Interaction Partners of Protein Phospha-
tase 2A Catalytic Subunit in human skeletal muscle using Label free Mass Spectrome-
try, the 65th American Society for Mass Spectrometry Conference on Mass Spectrom-
etry, June 4-8, 2017, Indianapolis Convention Center, Indianapolis, Indiana. 
 
PUBLICATION 
 
Zhang, X., et al. Quantitative proteomics reveals novel protein interaction partners of 
PP2A catalytic subunit in pancreatic beta-cells. Molecular and cellular endocrinology 
424, 1-11 (2016). 
 
 
 
 
